IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 1 of 111  23 June  2017  
 TITLE:  An Open -Label Trial of  Venetoclax with Ibrutinib in Relapsed or Refractory 
Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia  
      [STUDY_ID_REMOVED]  
Coordinating Center of a Multi -Center Study  
Stanford Cancer Institute  (SCI)  
[ADDRESS_234860],  CA  [ZIP_CODE]  
Protocol Director  / Principal Investigator :  
[INVESTIGATOR_197701],  MD 
[ADDRESS_234861],  CA  [ZIP_CODE]   
Phone 650 -498-6000 / Fax 650 -724-5203  
[EMAIL_3899]   
Investigators  at other Sites : 
Steven  Rosen,  MD 
City of Hope National Medical Center  
[ADDRESS_234862] 
Duarte,  CA  [ZIP_CODE]  
 
[EMAIL_3900]  Tanya  Siddiqi,  MD 
City of Hope National Medical Center  
[ADDRESS_234863] 
Duarte,  CA  [ZIP_CODE]  
[EMAIL_3901]   
SCI Biostatistician : SCI Study Coordinator:  
Alex McMillan,  PhD  
Senior Research Scientist  
Stanford  University  
[EMAIL_3902]  Pamela Clay, CRC  
[ADDRESS_234864]; FC2C51  
Stanford, CA  
 
[EMAIL_3903]   
Regulatory Information  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 2 of 111  23 June  2017  
 Table of Contents  
1 OBJECTIVES, ENDPOINT S, AND OUTCOMES  ................................ .........................  17 
1.1 Objectives  ................................ ................................ ................................ ..................  17 
1.1.1  Primary Objectives  ................................ ................................ ................................  17 
1.1.2  Secondary Objectives  ................................ ................................ ...........................  17 
1.1.3  Exploratory Objectives  ................................ ................................ ..........................  17 
1.2 Endpoints (summary)  ................................ ................................ ................................  17 
1.2.1  Primary Endpoint(s)  ................................ ................................ ...............................  17 
1.2.2  Secondary Endpoint(s)  ................................ ................................ ..........................  17 
1.3 Study Design  ................................ ................................ ................................ .............  18 
1.3.1  Overview  ................................ ................................ ................................ ...............  18 
1.3.2  Randomization  ................................ ................................ ................................ ...... 18 
1.3.3  Number of Participants  ................................ ................................ ..........................  18 
1.4 ClinicalTrials.gov Registration, Outcomes, and Results  ................................ ............  18 
1.4.1  Interventional model  ................................ ................................ ..............................  18 
1.4.2  Masking  ................................ ................................ ................................ .................  18 
1.4.3  Type of Primary Objective / Outcome  ................................ ................................ ... 18 
1.4.4  Outcomes Measures for ClinicalTrials.gov Results Reporting  ..............................  18 
1.5 Regulatory Status of Study Agents  ................................ ................................ ...........  19 
1.5.1  Vene toclax  ................................ ................................ ................................ .............  19 
1.5.2  Ibrutinib  ................................ ................................ ................................ ..................  19 
2 BACKGROUND  ................................ ................................ ................................ ............  20 
2.1 Study Disease  ................................ ................................ ................................ ...........  20 
2.1.1  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma  ...........................  20 
2.1.2  Treatment Options  ................................ ................................ ................................ . 20 
2.1.3  Role of BTK and Bcl -2 Family Proteins in CLL/SLL  ................................ ..............  [ADDRESS_234865] -completion  ................................ ................................ ..........  28 
4 TREATMENT PLAN  ................................ ................................ ................................ ...... 29 
4.1 Study Drug Administration  ................................ ................................ .........................  29 
4.2 Toxicity Management  ................................ ................................ ................................  29 
4.3 General Concomitant Medication and Supportive Care Guidelines  ..........................  29 
4.3.1  Prophylaxis and Management of Tumor Lysis Syndrome  ................................ ..... 29 
4.3.2  Permitted Concomitant Medications  ................................ ................................ ...... 36 
4.3.3  Concomitant Medications to be Used with Caution  ................................ ...............  36 
4.3.4  Prohibited Concomitant Medications  ................................ ................................ ..... 38 
4.3.5  Guidelines for Ibrutinib Management with Surgeries or Procedures  .....................  39 
4.4 Duration of Therapy  ................................ .....................  Error! Bookmark not defined.  
4.5 Duration of Follow -up ................................ ................................ ................................  39 
4.6 Criteria for Removal from Study  ................................ ................................ ................  40 
4.6.1  Removal from Study Treatment  ................................ ................................ ............  40 
4.6.2  Removal from Study  ................................ ................................ ..............................  40 
4.7 Study Risk Information  ................................ ................................ ..............................  40 
4.8 Risk Mitigation  ................................ ................................ ................................ ...........  40 
5 STUDY DRUG INFORMATI ON ................................ ................................ .....................  41 
5.1 Study Drug Venetoclax  ................................ ................................ ..............................  41 
5.1.1  Name  ................................ ................................ ................................ .....................  41 
5.1.2  Formulation  ................................ ................................ ................................ ...........  41 
5.1.3 Study Cohorts / Arms / Groups  ................................ ................................ .............  41 
5.1.4  Mechanism of Action  ................................ ................................ .............................  41 
5.1.5  Non-clinical and Clinical Pharmacokinetics  ................................ ...........................  41 
5.1.6  Summaries of Non -Clinical Pharmacology and Toxicology Studies  ......................  42 
5.1.7  Summaries of Clinical Studies  ................................ ................................ ...............  43 
5.1.8  Major Route of Elimination  ................................ ................................ ....................  44 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 4 of 111  23 June  2017  
 5.1.9  Safety Profile  ................................ ................................ ................................ .........  45 
5.1.10  Rationale for the Starting Dose and Re gimen Selected  ................................ ........  47 
5.1.11  Maximum Allowable Dose/ Overdose  ................................ ................................ ... 47 
5.1.12  Treatment Duration  ................................ ................................ ...............................  47 
5.2 Study Drug Ibrutinib  ................................ ................................ ................................ ... 48 
5.2.1  Names  ................................ ................................ ................................ ...................  48 
5.2.2  Formulation  ................................ ................................ ................................ ...........  48 
5.2.3  Study Cohorts  ................................ ................................ ................................ ........  48 
5.2.4  Mechanism of Action  ................................ ................................ .............................  48 
5.2.5  Non-Clinical and Clinical Pharmacokinetics  ................................ ..........................  48 
5.2.6  Summaries of Non -Clinical Pharmacology and Toxicology Studies  ......................  49 
5.2.7  Summaries of Clinical Studies  ................................ ................................ ...............  49 
5.2.8  Major Route of Elimination  ................................ ................................ ....................  50 
5.2.9  Safety Profile  ................................ ................................ ................................ .........  50 
[IP_ADDRESS]  Hypertension  ................................ ................................ ................................ .........  53 
[IP_ADDRESS]  Rationale for the Starting Dose and Regimen Selected  ................................ ....... 54 
[IP_ADDRESS]  Maximum Allowable Dose / Overdose  ................................ ................................ .. 54 
[IP_ADDRESS]  Treatment Duration  ................................ ................................ ...............................  54 
5.3 Study Drug Supply  ................................ ................................ ................................ .... 55 
5.3.1  Venetoclax Drug Supply  ................................ ................................ ........................  55 
5.3.2  Ibrutinib Drug Supply  ................................ ................................ .............................  55 
5.4 Venetoclax and Ibrutinib Accountability  ................................ ................................ ..... 55 
6 DOSE MODIF ICATIONS AND DISCONT INUATION  ................................ ...................  55 
6.1 Venetoclax Dose Modification  ................................ ................................ ...................  55 
6.2 Ibrutinib Dose Modification  ................................ ................................ ........................  56 
6.3 Dose Modification for Both Venetoclax and Ibrutinib  ................................ .................  57 
6.4 Treatment Discontinuation  ................................ ................................ ........................  58 
7 ADVER SE EVENTS AND REPORT ING PROCEDURES  ................................ ............  59 
7.1 Adverse Events Definition  ................................ ................................ .........................  59 
7.1.1  Serious Adverse Events Definition  ................................ ................................ ........  60 
7.2 Adverse Event Reporting  ................................ ................................ ..........................  60 
7.3 Safety Monitoring  ................................ ................................ ................................ ...... 62 
7.4 Adverse Events of Special Co nsideration  ................................ ................................ . 62 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 5 of 111  23 June  2017  
 7.4.1  Second Malignancy vs Secondary Malignancy  ................................ .....................  62 
7.4.2  Other Adverse Events of Special Considerations  ................................ .................  63 
7.5 Case Report Forms  (CRFs) for Adverse Event Reporting  ................................ ........  64 
8 CORRELATIVE / SPECIA L STUDIES  ................................ ................................ ..........  65 
8.1 Pharmacokinetics Assessments: Collected at Stanford Cancer Institute Site ONLY  65 
8.2 Biomarker Assessments  ................................ ................................ ............................  65 
9 TREATMENT ASSESSMENT S AND STUDY CALENDAR  ................................ .........  66 
9.1 Study Treatment Schedule  ................................ ................................ ........................  66 
9.1.1  Screening Phase  ................................ ................................ ................................ ... 66 
9.1.2  Treatment Phase  ................................ ................................ ................................ ... 66 
9.2 Study Procedures and Assessments  ................................ ................................ ........  67 
9.2.1  Study Assessments  ................................ ................................ ...............................  67 
9.2.2  Efficacy Evaluations  ................................ ................................ ..............................  68 
9.2.3  Study Diagnostics / Procedures  ................................ ................................ ............  69 
9.3 Table  of Assessments / Study Calendar  ................................ ................................ ... [ADDRESS_234866] (IRB) Approval of Protocol  ................................ ..............  [ADDRESS_234867] Health Information Authorizatio n ................................ ..............  77 
10.3  Data and Safety Monitoring Plan  ................................ ................................ ...............  78 
10.3.1  Data Management Plan  ................................ ................................ .........................  78 
10.4  Investigator Responsibilities  ................................ ................................ ......................  79 
10.5  Protocol Amendments  ................................ ................................ ...............................  79 
10.6  Publication of Study Results  ................................ ................................ ......................  79 
11 STATISTICAL CONSIDER ATIONS  ................................ ................................ ..............  80 
11.1  Statistical Design  ................................ ................................ ................................ ....... 80 
11.1.1  Treatment Assignment  ................................ ................................ ..........................  80 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 6 of 111  23 June  2017  
 11.2  Endpoints  ................................ ................................ ................................ ..................  80 
11.2.1  Primary Endpoint  ................................ ................................ ................................ ... 80 
11.2.2  Secondary Endpoint(s ) ................................ ................................ ..........................  80 
11.2.3  Exploratory Endpoint(s)  ................................ ................................ .........................  [ADDRESS_234868]  ................................ .............................  86 
13.2  Appendix B.  ECOG Status Scores  ................................ ................................ ...........  91 
13.3  Appendix C.  Inhibitors and Inducers of CYP3A  ................................ ........................  91 
13.4  Appendix D.  Modified 2008 IWCLL Criteria for Tumor Response  ............................  94 
13.5  Appendix E.  Recommendations for Initial Management of Electrolyte Abnormalities 
and Prevention of Tumor Lysis Syndrome  (TLS)  ................................ ......................  95 
13.6  Appendix F.  Clinical and Laboratory Definition of Tumor Lysis Syndrome  ..............  99 
13.7  Appendix G.  Template for Pro tocol Amendments  ................................ ..................  100 
13.8  Appendix H.  Drug Order Form for Venetoclax  ................................ .......................  101 
13.9  Appendix I.  Drug Order Form for Ibrutinib  ................................ ..............................  103 
13.10  Appendix J.  Drug Diary for Ibrutinib  ................................ ................................ ....... 105 
13.11  Appendix K.  Drug Diary for Venetoclax  ................................ ................................ .. 107 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 7 of 111  23 June  2017  
 Protocol S ynopsis  
Study Title  An Open -Label Trial of Venetoclax with Ibrutinib in Relapsed or 
Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic 
Leukemia  
Study Design  This is an open -label non -randomized two -center phase  2 study 
evaluating the safety and  efficacy of concurrent therapy with ibrutinib and 
venetoclax in subjects with relapsed or refractory CLL/SLL.   
Screening, including CT scans and bone marrow aspi[INVESTIGATOR_12752], 
must be performed within 28  days of study drug initiation.  Ibrutinib 
420 mg PO daily will be initiated on Week  1.  Intra -patient dose ramp -up 
of venetoclax will be initiated at Week  9 at 20  mg PO daily with the dose 
increasing weekly to 50  mg; 100  mg; 200 mg; and 400  mg as per 
FDA-approved dosing guidelines . Upon completion of ib rutinib + 
venetoclax combination treatment at Week 117, participants will have 
completed the trial and may transition off -study to receive commercial 
ibrutinib at the discretion of the investigator . 
Restaging CT/MRI imaging must be performed at Week  9, Wee k 38, 
Week  62, and within 1 month of completion of therapy at Week 117 .  
Study visits will be conducted on Day  1 of each of the following  weeks:  
Week  1; Week  5; Week  9 through Week  14; Week  18;  Week  22;  
Week  26; Week  30; Week  38; and every [ADDRESS_234869] is discontinued from 
the study due to toxicities attributable to either study drug , additional 
Follow -Up Visits will be conducted as clinically appropriate until 
satisfactory clinical resolution of the adverse event . 
Study Phase  Phase  2  
Study Duration  117 weeks of treatment a nd up to 1 month of follow up to complete final 
assessment . 
Primary Objective(s)  The primary objective of this study is to evaluate the efficacy of 
concurrent therapy with ibrutinib and venetoclax in patients with relapsed 
and refractory chronic lymphocyt ic leukemia (CLL) and small lymphocytic 
leukemia (SLL).  
Primary Endpoint(s)  Complete response rate  (CR)  
Secondary Objectives  To define the safety  and tolerability  of combination therapy with ibrutinib 
and venetoclax.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 8 of 111  23 June  2017  
 Secondary 
Endpoint(s)  For the combi nation of venetoclax and ibrutinib:  
• Overall response rate  (ORR)  
• Duration of response  (DOR)  
• Time -to-progression  (TTP)  
• Progression -free survival  (PFS)  
• Overall survival  (OS)  
• Rate of minimal residual disease  (MRD) negativity in the bone 
marrow  
• Safety :  
o Frequ ency, severity, and relatedness of AEs  
o Frequency, severity and management of TLS  
o Frequency of AEs requiring discontinuation of study drug or dose 
reductions, or leading to death  
Exploratory 
Objectives  • Time to next CLL treatment (TNT)  
• Change in mutation la ndscape at time of progression  
• Pharmacokinetics of ibrutinib and venetoclax when administered in 
combination  
Indication  Relapsed or refractory CLL/SLL patients  
Investigational Drug  Venetoclax in combination with ibrutinib  
Dose  Venetoclax will be admin istered PO with single daily doses QD starting at 
Week  9.  Venetoclax dose increments will proceed weekly from  
20 mg → 50  mg → 100  mg → 200  mg → [ADDRESS_234870] gelatin capsules for oral (PO) 
administration.  Subjects wi ll receive 420  mg ibrutinib PO daily.  
Sample Size  22 subjects  
Summary of 
Eligibility Criteria  Inclusion Criteria  
• Voluntarily sign and date an informed consent form  (ICF) with 
authorization to use protected health information (in accordance with 
nationa l and local subject privacy regulations) and approved by [CONTACT_5030]  (IRB) prior to initiation of any study specific 
procedures  
• Diagnosis of chronic lymphocytic leukemia  CLL) or small lymphocytic 
leukemia  (SLL) meeting IWCLL criteria, an d relapsed  after or 
refractory  to at least 1  prior treatment  
• Measurable nodal disease by [CONTACT_20420]  (CT) 
Laboratory  
• Adequate hematologic function independent of transfusion and 
IRB-[ADDRESS_234871] 7  days prior to screening, (except  for 
pegylated G -CSF (pegfilgrastim) and darbepoetin which require at 
least 14  days prior to screening ) defined as the following.  
o Absolute neutrophil count >  750 cells/mm3 (0.75  x 109/L)  
o Platelet count >  30,000 cells/mm3 (30 x 109/L) without transfusion 
support ; evidence of mucosal bleeding ; a known bleeding 
epi[INVESTIGATOR_5319] 3  months of screening ; or a history of a 
bleeding  disorder  
o Hemoglobin >  8.0 g/dL 
If the bone marrow evaluation shows heavy infiltration with 
underlying disease, growth factor support m ay be administered to 
achieve the eligibility criteria.  
• Adequate hepatic and renal function defined as:  
o Serum aspartate transaminase (AST) or alanine transaminase 
(ALT ) ≤ 2.5 x upper limit of normal  (ULN)  
o Estimated Creatinine Clearance ≥  30 mL/min (24 -hour measured 
GFR or modified Cockcroft -Gault)  
o Bilirubin ≤  1.[ADDRESS_234872] (unless bil irubin rise is due to 
Gilbert’s  syndrome or of non -hepatic origin)  
• PT/INR <  1.[ADDRESS_234873] an d PTT (aPTT) <  1.[ADDRESS_234874]  
Demographic  
• Men and women ≥  18 years of age  
• Eastern Cooperative Oncology Group (ECOG) performance status of 
0, 1, or 2  
Ethical/Other  
• Female subjects who are of non -reproductive potential 
(ie, post-menopausal by [CONTACT_969] - no me nses for ≥  1 year; OR history 
of hysterectomy;  OR history of bilateral tubal ligation; OR history of 
bilateral oophorectomy).  
OR 
• Female subjects of childbearing potential must have a negative 
serum pregnancy test upon study entry  
• Male and female subjects m ust agree to use highly effective 
methods of birth control (eg,  condoms, implants, injectables, 
combined oral contraceptives, some intrauterine devices [IUDs], 
sexual abstinence, or sterilized partner) during the period of therapy 
and for [ADDRESS_234875] dose of study drug  
Exclusion Criteria  
• Prior treatment with either ibrutinib or venetoclax  
• Vaccinated with live, attenuated vaccine(s) within [ADDRESS_234876] dose of study  drug 
• Received an a llogeneic stem cell transplant within the past 1  year  
(if over  [ADDRESS_234877] 
active  cGVHD ) 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 10 of 111  23 June  2017  
 • Richter’s transformation confirmed by [CONTACT_9256]  
• Active uncontrolled autoimmune cytopenias  
Concurrent Conditions  
• Chemotherapy ≤  [ADDRESS_234878] administration of study 
treatment  and/or monoclonal antibody ≤  [ADDRESS_234879] 
administration of study treatment.  
• History of other malignancies, except:  
o Malignancy treated with curative intent and with no known active 
disease present for ≥  [ADDRESS_234880] dose of study d rug, 
and felt to be at low  risk for recurrence by [CONTACT_35425]  
o Adequately treated non -melanoma skin cancer or lentigo  maligna 
without evidence of disease  
o Adequately treated carcinoma in situ without evidence of disease  
• Concurrent systemic immunosu ppressant therapy 
[eg, cyclosporine  A, tacrolimus, etc, or chronic administration  
(> 14 days ) of > 20 mg/day of prednisone ] within [ADDRESS_234881] dose of study  drug  
• Recent infection re quiring systemic treatment that was completed 
≤ [ADDRESS_234882] dose of study  drug  
• Unresolved toxicities from prior anti -cancer  therapy, defined as 
having not  resolved to Common Terminology Cri teria for Adverse 
Event (CTCAE,  v4.03), Grade  ≤ 1, or to the levels dictated in the 
inclusion/exclu sion criteria except for  alopecia  
• Known bleeding disorders (eg,  von Willebrand’s  disease ) or 
hemophilia  
• History of stroke or intracranial  hemorrhage within [ADDRESS_234883] dose of study  drug 
• Known history of human immunodeficiency virus  (HIV) or active with 
hepatitis  C virus  (HCV) or hepatitis  B virus  (HBV).   
Subjects who are positive for hepatitis  B core antibody or hepatitis  B 
surface antigen must have a negative polymerase chain 
reaction  (PCR) result before enrollment  in order to meet eligibil ity for 
this criterion .  Those who are PCR -positive will be excluded . 
• Any uncontrolled active systemic infection  
• Major surgery within [ADDRESS_234884]  dose of study  drug  
• Any life -threatening illness, medical condition, or organ system 
dysfunction that, i n the investigator’s opi[INVESTIGATOR_1649], could compromise the 
subject’s safety or put the study outcomes at undue risk  
• Currently active, clinically significant cardiovascular disease, such as 
uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as 
define d by [CONTACT_197759]; 
or a history of myocardial infarction, unstable angina, or acute 
coronary syndrome within 6  months prior to screening   
• Unable to swallow capsules ; malabsorption syndrome;  disease 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 11 of 111  23 June  2017  
 significantly  affecting gastrointestinal function; resection of the 
stomach or entire small bowel; symptomatic inflammatory bowel 
disease or ulcerative colitis; or partial or complete bowel obstruction  
• Concomitant use of warfarin or other Vitamin  K antagonists  
• Subjec ts who received a strong cytochrome P450  (CYP)  3A inhibitor 
or inducer within [ADDRESS_234885] dose of ibrutinib or subjects 
who require continuous treatment with a strong cytochrome  P450 
CYP3A  inhibitor  or inducer  (see Appendix  C)  
• Lactating or p regnant  
• Unwilling or unable to participate in all required study evaluations 
and procedures  
• Unable to understand the purpose and risks of the study  
• Subjects with chronic liver disease with hepatic impairment 
Child -Pugh class  B or C 
Treatment and 
Proced ural Summary  Ibrutinib 420  mg PO daily will be initiated on Week  1 Day 1.  Venetoclax 
will be initiated at 20  mg PO daily on Week  9 Day 1 and increased every 
7 days to 50  mg; 100  mg; 200  mg; and 400  mg. Upon completion of 
ibrutinib + venetoclax combination  treatment at Week 117, participants 
will have completed the trial and may transition off -study to receive 
commercial ibrutinib at the discretion of the investigator . 
Ibrutinib and Venetoclax Dose and Schedule  
Week  Ibrutinib  Venetoclax  
1 420 0 
9 420 20 
10 420 50 
11 420 100 
12 420 200 
13 to 117 420 400 
 
Safety Plan  Adverse event (AE) monitoring; vital signs; physical examination; ECG; 
and laboratory values will be assessed.  Guidelines for tumor lysis 
syndrome (TLS) management are provided.  Chemist ry labs (including 
potassium; calcium; uric acid; phosphorus; and creatinine) will be 
performed pre -dose;  8  hours;  and [ADDRESS_234886] and 
each escalated venetoclax dose and additionally as deemed necessary 
to monitor TLS.  
Statistical 
Considerations  All efficacy analyses will be performed using the intent -to-treat (ITT)  
population.   
Primary Efficacy Analysis:   
Complete Response Rate  
The proportion of subjects with a complete response (per investigator 
assessment) will be calculated for  all subjects based on IWCLL criteria. A 
95% confidence interval based on binomial distribution will be 
constructed for the calculated CR rate.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 12 of 111  23 June  2017  
 Secondary Efficacy Analysis:  
Overall Response Rate  
The proportion of subjects with an overall response (per inve stigator 
assessment) will be calculated for all subjects based on IWCLL criteria.  
A 95% confidence interval based on binomial distribution will be 
constructed for the calculated ORR.  
Duration of Response  
Duration of response will be defined as the number of days from the date 
of first response per investigator assessment to the earliest recurrence or 
PD per investigator assessment.  If a subject is still responding, then the 
subject's data will be censored at the date of the subject's last available  
clinic al disease assessment.  For subjects who never experienced 
response, the subject's data will be censored on the date of enrollment.  
Duration of response will be analyzed by [CONTACT_5263] -Meier methodology 
using data for all enrolled subjects who receive study tr eatment.  Median 
duration of response will be calculated and the corresponding 95% 
confidence interval will be presented.  
Time -to-progression  
Time -to-progression will be defined as the number of days from the date 
of first dose to the date of earliest dise ase progression (per the 
investigator assessment).  All disease progression will be included 
regardless whether the event occurred while the subject was taking study 
drug or had previously discontinued study drug.  If the subject does not 
experience diseas e progression, then the data will be censored at the 
date of the last available disease assessment.  TTP will be analyzed by 
[CONTACT_5263] -Meier methodology using data for all enrolled subjects.  Median 
time TTP will be calculated and 95% confidence interval for median time 
TTP will be presented.  
Progression -Free Survival  
Progression -Free Survival will be defined as the number of days from the 
date of first dose to the date of earliest disease progression (per the 
investigator assessment) or death.  All disease pr ogression will be 
included regardless whether the event occurred while the subject was 
taking study drug or had previously discontinued study drug.  If the 
subject does not experience disease progression or death, then the data 
will be censored at the date  of the last disease assessment.  PFS will be 
analyzed by [CONTACT_197760].  
Median PFS time will be calculated and 95% confidence interval for 
median PFS time will be presented.  
Overall Survival  
Overall survival w ill be defined as the number of days from the date of 
first dose to the date of death for all dosed subjects.  The data for 
subjects who did not die will be censored at the date of last study visit or 
the last known date to be alive, whichever is later.  O S will be analyzed 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 13 of 111  23 June  2017  
 by [CONTACT_5263] -Meier methodology using data from all dosed subjects.  
Median time survival will be calculated and 95% confidence interval for 
the median time survival will be presented.  
Rate of Minimal Residual Disease (MRD) Negativity in the  Bone Marrow  
MRD negativity will be defined as less than one CLL cell per 10,000 
leukocytes (or below 10-4) on bone marrow -based flow cytometry.  Rate 
of MRD negativity will be defined as the proportion of subjects who have 
MRD negativity on bone marrow as sessment.  Ninety -five percent (95%) 
confidence intervals based on the binomial distribution will be provided.  
Safety Endpoints and Analysis   
A safety analysis will be performed for all dosed subjects unless 
otherwise indicated.  For the entire study, AEs will be evaluated and 
summarized.  Laboratory test results and vital signs will be explored for 
trends and summarized as appropriate.   
Endpoints :  
• Frequency, severity, and relatedness of AEs  
• Frequency, severity and management of TLS  
• Frequency of AEs requi ring discontinuation of study drug or dose 
reductions, or leading to death   
Exploratory Efficacy Analysis:  
Pharmacokinetics  
Pharmacokinetic samples for ibrutinib will be collected on the first day of 
ibrutinib dose administration (Week  1 Day1) and each da y when dosed in 
combination with a newly escalated dose of venetoclax in all subjects 
enrolled in the study at Stanford University.  
Pharmacokinetic samples for venetoclax will be collected at [ADDRESS_234887] 
University .  Pharmacokinetic samples will be collected for the dose 
ramp -up stage.   
Values for the pharmacokinetic parameters for ibrutinib and venetoclax 
including  the maximum observed plasma concentration (C max), the time 
to C max (peak time, T max), the area under the plasma concentration -time 
curve (AUC) from [ADDRESS_234888] measurable concentration 
(AUC t) and AUC over a 24 -hour dose interval (AUC 0-24) will be 
determined.  Additional analyses may be performed if useful in the 
interpretation of the data.  
Time to Next Anti -CLL Treatment  
Time to next anti -CLL treatment will be defined as the number of days 
from the date of the first dose of ibrutinib to the d ate of first dose of new 
non-protocol anti -leukemia therapy (NPT) or death from any cause.  For 
IRB-[ADDRESS_234889] 
known date to be free of NPT.  TTNT will be analyzed by [CONTACT_5263] -Meier 
methodology using data  for all dosed subjects.  Median TTNT time will be 
calculated.  
Change in mutation landscape at time of progression  
BTK mutation analysis (NeoGenomics) will be performed at baseline and 
at time of progression.  
Interim Analysis  No interim analysis for effic acy is planned.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 15 of 111  23 June  2017  
 Protocol Schema  
Figure 1.  Administration of Ibrutinib and Venetoclax  
8 weeks ibrutinib alone:  
Week  1 Day 1  Week  8 Day 7 
 
5 weeks venetoclax dose -escalation:  
Week  9 Day 1  Week  13 Day 7 
 
2 years combined therapy:  
Week  14 Day 1  Week  [ADDRESS_234890]  
ALC Absolute lymphocyte count  IV Intravenous  
AML Acute myeloid leukemia  IVRS  Interactive -voice response system  
ANC  Absolute neutrophil count  IWRS  Interactive web response system  
AUC  Area under curve (exposure)  IWCLL 
NCI-WG International Workshop on Chronic 
Lymphocytic Leukemia National Cancer 
Institute -Working Group  
BCR  B-cell receptor  LTLS  Laboratory Tumor Lysis Syndrome  
BTK Bruton’s tyrosine kinase  MCL  mantle cell lymphomas  
CBC  Complete blood count  MRD  Minima l residual disease  
CLL Chronic lymphocytic leukemia  NCI National Cancer Institut e  
Cmax Maximum concentration of drug  NHL non-Hodgkin's Lymp homa  
CRF Case report form (paper or electronic)  ORR  Overall response rate   
CR Complete response  OS Overall survi val 
CT Computed tomography  PD Pharmacodynamics   
CTCAE  Common Terminology Criteria for 
Adverse Events  PFS Progression -free survival  
CTEP  Cancer Therapy Evaluation Program  pK Pharmacokinet ics  
CTLS  Clinical tumor lysis syndrome  PO Oral 
DCF Data Clarific ation Form  PR Partial Response  
DLBCL  Diffuse large B -cell lymphoma  SAE Serious adverse event  
DLT Dose -limiting Toxicity  SCI Stanford Cancer Institute  
DMC  Data monitoring committee  SLL  Small lymphocytic lymphoma  
DSM -IV Diagnostic and Statistical Manual  of 
Mental Disorders (4th edition)  SRC  Scientific Review Committee  
ECG  Electrocardiogram  TLS Tumor lysis syndrome  
eDC Electronic data capture  Tmax Median time to maximum plasma 
concentration   
FL Follicular lymphomas  TPN Total parenteral nutrition  
GCP  Good Clinical Practice  Tmax Median time to maximum plasma 
concentration  
HBsAg  Hepatitis  B surface antigen  TTNT  Time to Next anti -cancer Treatment   
HIV Human immunodeficiency virus  TTP Time -to-progression   
ICF Informed Consent Form  ULN Upper limit of nor mal  
ICH International Conference on 
Harmonization  USP [LOCATION_002] Pharmacopeia  
 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 17 of 111  23 June  2017  
 1 OBJECTIVES, ENDPOINT S, AND OUTCOMES  
1.1 Objectives   
1.1.1  Primary Objectives  
The primary objective of this trial is to evaluate the efficacy  of orally -administered venetoclax 
comb ined with ibrutinib in patients with CLL/SLL who have been previously treated with at least 
one agent but who are naïve to ibrutinib and venetoclax.   
1.1.2  Secondary Objectives   
The secondary objectives of this trial are to define the safety  and tolerability  of combination 
therapy with venetoclax and ibrutinib  in relapsed and refractory CLL/SLL patients who have not 
been previously treated with either venetoclax or ibrutinib . 
1.1.3  Exploratory Objectives   
• To determine the time to next treatment.   
• To perform BTK muta tion analysis (Neo Genomnics)  to identify potential mechanisms of 
resistance.   
• To evaluate the pharmacokinetics of ibrutinib and venetoclax when administered in 
combination.  
1.2 Endpoints (summary)  
Endpoints for this study are presented in greater detail in Se ction  11.2 Endpoints.   
1.2.1  Primary Endpoint(s)  
Complete response rate  (CR)  
1.2.2  Secondary Endpoint(s)  
Secondary Endpoints include:  
• Overall response rate (ORR)  
• Duration of response  (DOR)  
• Time -to-progression  (TTP)  
• Progression -free survival  (PFS)  
• Overall survival  (OS)  
• Rate of minimal residual disease (MRD) negativity in the bone marrow  
• Safety  
o Frequency, severity, and relatedness of AEs  
o Frequency, severity and management of TLS  
o Frequency of AEs requiring discontinuation of study drug or dose reductions, or 
leading t o death  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 18 of 111  23 June  2017  
 1.3 Study Design  
1.3.1  Overview  
This is a Phase  2, open -label, non -randomized 2 -center study that will evaluate the safety and 
efficacy of orally administered venetoclax combined with ibrutinib in patients with relapsed or 
refractory CLL/SLL and no prior tre atment with either ibrutinib or venetoclax.  
Table  1.  Planned intra -patient dose ramp -up of venetoclax  
Week  Venetoclax 
(mg/day)  Ibrutinib 
(mg/day)  
1 0 420 
9 20 420 
10 50 420 
11 100 420 
12 200 420 
13-117 400 420 
1.3.2  Randomization  
This is an open -label s tudy.  Participants will not be blinded or randomized to study treatment.  
1.3.3  Number of Participants  
A total of twenty -two (22) participants will be enrolled in this study.  
1.4 ClinicalTrials.gov Registration, Outcomes, and Results  
1.4.1  Interventional model  
The inte rvention model of this study is a single group study.   
1.4.2  Masking  
This is an open -label, non -randomized study.   
1.4.3  Type of Primary Objective / Outcome  
The primary outcome of this study is to evaluate the efficacy of concurrent therapy with ibrutinib 
and vene toclax in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and 
small lymphocytic leukemia  (SLL).   
1.4.4  Outcomes Measures for ClinicalTrials.gov Results Reporting  
[IP_ADDRESS]  Primary Outcome(s)  
• Primary Outcome Measure :  The primary outcome for this study, for the purposes of 
Clinical  Trials.gov registration and results reporting, is the complete response rate.  
• Primary Outcome Measure Title:  Complete response rate  when  venetoclax is used 
in combination with 420  mg/day ibrutinib to treat c hronic lymp hocytic leukemia  (CLL) and 
small lymphocytic leukemia  (SLL) .  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 19 of 111  23 June  2017  
 • Time Frame :  The time  frame for assessment of the primary outcome / primary endpoint 
is 62 weeks .  
• Safety Issue :  Does not assess  a safety  issue.   
[IP_ADDRESS]  Secondary Outcome(s)  
• Overall response rate (OR R) based on IWCLL NCI -WG criteria  
• Duration of response  (DOR)  defined as the number of days from the date of first 
response per investigator assessment to the earliest recurrence or progressive disease 
per investigator assessment  
• Time -to-progression (TTP) defined as the number of days from the date of first dose 
(date of enrollment if not dosed) to the date of earliest disease progression (per the 
investigator assessment)  
• Progression -free survival (PFS)  
• Overall survival (OS)  
• Rate of minimal residual disease (MRD) negativity in the bone marrow  
• Safety  
o Frequency, severity, and relatedness of AEs  
o Frequency, severity and management of TLS  
o Frequency of AEs requiring discontinuation of study drug or dose reductions, or 
leading to death  
1.[ADDRESS_234891] this study is pursuant to IND  131,600 
submitted by [CONTACT_1525]  E Coutre,  MD. 
1.5.1  Venetoclax  
Venetoclax is approved for marketing in the United  States, as Venclexta for the indication of 
treatment of chronic lymphocytic leukemia  (CLL) with 17p  deletion, after at least one prior 
therapy.  
Venetoclax manufacturer  [COMPANY_013] Inc has submitted to FDA a Letter of Authorization o f 
Cross -reference to their IND  110,159 on behalf  of this study.  
1.5.2  Ibrutinib  
Ibrutinib is approved for marketing in the United  States, as Imbruvica for the indication of 
treatment of FDA for the treatment of CLL regardless of the presence or absence of the 
17p deletion, and also to treat mantle cell lymphoma (MCL) after one  prior therapy;  relapsed or 
refractory marginal zone lymphoma  (MZL);  chronic graft -vs-host disease  (GvHD ) after failure of 
1 or more systemic lines of therapy ;  or Waldenström’s macroglob ulinemia  (WM).  .  
Ibrutinib manufacturer Pharmacyclics  LLC has submitted to FDA a Letter of Authorization of 
Cross -reference to their ibrutinib IND  102,688 on behalf  of this study.  Ibrutinib continues to be 
studied in other disease settings.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 20 of 111  23 June  2017  
 2 BACKGROUND  
2.1 Study Disease  
2.1.1  Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma  
Chronic lymphocytic leukemia (CLL), and its analogous disease small lymphocytic leukemia 
(SLL), is a lymphoproliferative disorder characterized by [CONTACT_197761],  small, mature -appearing CD5+ B -cells in peripheral blood, bone marrow, and 
secondary lymphoid organs.  It is the most common form of leukemia in adults in the Western 
World, accounting for approximately 30% of all leukemias .1  Chronic lymphocytic leukemia  
primarily affects elderly individuals; however, approximately one third of patients are less than 
[ADDRESS_234892] 4,500 individuals will die 
of the disease .3  In Europe, CLL accounts for approximately 30% of all leukemias in adults with 
a reported age -standardized incidence rate of 3.79 per 100,000 individuals (for CLL/SLL) in the 
years 2000  to 2002.4  The app roximate 5 -year survival rate for patients with CLL is 73%.[ADDRESS_234893] compromised bone marrow reserve due to their underlying disease.  The principal 
complication of CLL is immunodeficiency related to myelosuppression and as a result, infection 
is the major cause of death in patients with CLL .  
2.1.2  Treat ment Options  
The current practice for early stage CLL patients is to take an expectant approach, while those 
with advanced stage disease who require treatment receive combination regimens.  
Chlorambucil, in use for several decades, can induce partial remis sions in advanced CLL, but 
does not improve survival when used in asymptomatic early -stage CLL.6 Fludarabine, approved 
as a second -line agent, improves response rates, progression -free survival (PFS), and in 
combination with cyclophosphamide and rituximab (FCR), overall survival (OS) compared to 
fludarabine and cyclophosphamide alone.7-[ADDRESS_234894] line therapy for CLL, based on improvement in PFS versus chlorambucil.  
For patients over the age of 65 -70, FCR is not tolerated; other therapi[INVESTIGATOR_014], such as chlorambucil ± 
rituximab, or bendamustine ± rituximab are commonly used in the up -front setting.  For patients 
with del(17p13.1) none of these traditional approaches work effectively.  
Standard chemotherapeutic options for CLL cause significant immune suppression and 
myelosuppression are not well tolerated by [CONTACT_197762].  Treatment decisions for patients with CLL are made based on 
considerations such as age, clinical stage, expected survival, and anticipated toxicities.  With 
the notable exception of allogeneic stem cell transplantation, CLL is currently a n incurable 
disease, despi[INVESTIGATOR_197702].  Nonetheless, globally access 
to allogeneic stem cell transplant and/or clinical trials is limited, and treatment options for 
relapsed disease tend to have increased toxicity and re duced antitumor activity.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 21 of 111  23 June  2017  
 2.1.3  Role of BTK and Bcl -2 Family Proteins in CLL/SLL  
B-cells are lymphocytes with multiple functions in the immune response, including antigen 
presentation, antibody production, and cytokine release.  B -cells express cell surface 
immu noglobulins comprising the B -cell receptor (BCR), which is activated by [CONTACT_14178].  
Antigen binding induces receptor aggregation and the clustering and activation of multiple 
tyrosine kinases, which in turn activate further downstream signaling pa thways.[ADDRESS_234895] that signaling through the BCR is necessary to sustain the viability of B -cell 
malignancies.   
The protein Bruton’s tyrosine kinase  (BTK) is a Tec -family kinase that is exclusively expressed 
in B-cells and partic ipates in the BCR signaling pathway.  The upstream Src -family kinases Blk, 
Lyn and Fyn13,14 activate BTK which in turn phosphorylates and activates phospholipase -Cγ 
(PLCγ); this leads to Ca2+ mobilization and activation of NFκB, MAP kinase and Akt pathways.15 
There is strong evidence that lymphomas require BCR signaling.  A functional B -cell receptor is 
maintained, even as the non -expressed immunoglobulin heavy cha in (IgH) is involved in 
oncogenic translocations.[ADDRESS_234896] identified in follicular lymphoma where the t(14;18) chromosomal 
translocation results in significant over -expression of the protein in B -cells.  The Bcl -2 family of 
genes encodes a family of closely related proteins that possess either pro -apoptotic or  
anti-apoptotic activity and share up to four Bcl -2 Homology domains.20-23  Bcl-2 overexpression 
is a major contributor to the pathogenesis of some types of lymphoid malignancies.  Bcl -2 is 
also overexpressed in acute and chronic leukemias. Chronic lymphoc ytic leukemia (CLL) is a 
genetic disease where the microRNAs miR15a and miR16 -1 that negatively regulate the 
transcription of Bcl -2 are deleted or down regulated, resulting in uncontrolled expression of 
Bcl-2.24,25  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 22 of 111  23 June  2017  
 2.2 Study Drugs  
2.2.1  Venetoclax  
Venetoclax is a n ovel, orally available small molecule Bcl -2 family protein inhibitor that binds 
with >  500-fold higher affinity (Ki <  0.010  nM) to Bcl -2 and with lower affinity to other Bcl -2 family 
proteins Bcl -XL (Ki – 48 nM) and Bcl -w (Ki – 245 nM).[ADDRESS_234897] a panel of lymphoma and 
leukemia cells including B -cell follicula r lymphomas (FLs), mantle cell lymphomas (MCLs), 
diffuse large B -cell lymphomas (DLBCLs), and acute myeloid leukemias (AMLs).  Venetoclax 
was especially potent against cell lines expressing high levels of Bcl -2.  Leukemia and 
lymphoma cell lines bearing th e t(14;18) translocation were significantly more sensitive to 
venetoclax than non -mutated cell lines.  
Venetoclax inhibited subcutaneous murine xenograft growth of human tumor cell lines derived 
from acute lymphoblastic leukemia (ALL) and non -Hodgkin's Lymp homa (NHL).  The drug was 
also active in a model of disseminated ALL.  
Venetoclax is approved by [CONTACT_3133] (FDA) for the treatment of  
1) Chronic lymphocytic leukemia (CLL) in patients with 17p deletion who have received at 
least one prior therapy, and  
2) CLL in patients with 17p deletion  
More information on the nonclinical, pharmacology, and clinical data for venetoclax can be 
found in Section  5 of this protocol and in the current version of the venetoclax package insert 
and Investigato r’s Brochure.  
2.2.[ADDRESS_234898] -in-class, orally -administered covalently -binding inhibitor of Bruton’s 
tyrosine kinase  (BTK).  Inhibition of BTK blocks downstream BCR signaling pathways and thus 
prevents B -cell proliferation.  In vitro, ibrutinib inhibits purified BTK and selected members of the 
kinase family with 10 -fold specificity compared with non -BTK kinases.   
Ibrutinib (Imbruvica) is approved by [CONTACT_3133] (FDA) for the 
treatment of  
1) Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy 
based on overall response rate,  
2) Chronic lymphocytic leukemia (CLL),  
3) CLL in patients with 17p deletion ,  
4) Waldenström’s macroglobulinemia ,  
5) Marginal zone lymphoma  (MZL) in patients who have rec eived at least one prior 
anti-CD20 -based therapy, and  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 23 of 111  23 June  2017  
 6) Chronic graft -vs-host disease  (GVHD) after failure of one or more lines of systemic 
therapy.  
Ibrutinib is currently under investigation in various indications.   
This study uses the FDA —approved dose o f ibrutinib for patients with CLL/SLL 
(420 mg/day  oral).  More information on the nonclinical, pharmacology, and clinical data for 
ibrutinib can be found in Section  5 of this protocol and in the current version of the ibrutinib 
package insert and Investiga tor’s Brochure.  
2.3 Rationale  
The optimal approach to CLL/SLL treatment with the multiple agents that are available and in 
development remains an open question.  While the default approach continues to be serial 
treatment with different agents at the time of d isease progression, concurrent treatment offers 
the possibility of deeper and more durable responses.  Targeting multiple mediators of 
malignancy simultaneously with highly -active; well -tolerated therapi[INVESTIGATOR_197703] a particular therapy and prevent the emergence of 
resistance through single escape mutations.  
The combination of ibrutinib and venetoclax is compelling for multiple reasons.  Both are well 
tolerated with high response rates as single agent s.  Multiple lines of evidence show activation 
of apoptosis in CLL cells in response to ibrutinib and the effect of venetoclax have the potential 
to dramatically enhance this response.  Combination therapy with traditional 
chemoimmunotherapy has achieved h igher rates of complete response than monotherapy with 
either antibodies or alkylators alone and a combination of targeted agents has the potential to 
achieve this goal, particularly in bone marrow response and in prolonging the duration of 
response.  
The r egimen is designed to start therapy with ibrutinib, and then ramp -up the dose of venetoclax  
as per FDA -approved dosing guidelines , followed by  [CONTACT_197763]/SLL dose of ibrutinib.  
2.3.1  Primary Purpose of the Study  
Treatment:  The clinical trial described in this protocol is designed to determine whether CR 
rates can be improved in patients with relapsed or refractory CLL/SLL when venetoclax is used 
concurrently with ibrutinib . 
IRB-[ADDRESS_234899] satisfy all the following inclusion criteria.  
1. Voluntarily sign and date an informed consent form  (ICF) with authorization to use 
protected health inform ation (in accordance with national and local subject privacy 
regulations) and approved by [CONTACT_4707]  (IRB) prior to initiation of 
any study specific procedures.  
2. Diagnosis of chronic lymphocytic leukemia  CLL) or small lymphocytic leukemi a (SLL) 
meeting IWCLL/NCI -WG criteria, and relapsed  after or refractory  to at least 
1 prior treatment.  
3. Measurable nodal disease by [CONTACT_20420] (CT).  
Laboratory  
4. Adequate hematologic function independent of transfusion and growth factor support for 
at least 7  days prior to screening [except for  pegylated G -CSF (pegfilgrastim) and 
darbepoetin which require at least 14  days prior to screening defined as  the following.   
o Absolute neutrophil count >  750 cells/mm3 (0.75  x 109/L).  
o Platelet count >  30,000 c ells/mm3 (30 x 109/L) without transfusion support; 
evidence of mucosal bleeding; a known bleeding epi[INVESTIGATOR_5319] 3  months of 
screening; or a history of a bleeding  disorder .   
o Hemoglobin >  8.0 g/dL.  
If the bone marrow evaluation shows heavy infiltration wit h underlying disease, growth 
factor support may be administered after screening and prior to the first dose of therapy.  
5. Adequate hepatic and renal function defined as:  
o Serum aspartate transaminas e (AST) or alanine transaminase  (ALT ) 
≤ 2.5 x upper limit of normal  (ULN).  
o Estimated Creatinine Clearance ≥  30 mL/min ( 24-hour measured GFR or 
modified Cockcroft -Gault)  
o Bilirubin ≤  1.[ADDRESS_234900] (unless bilirubin rise is due to Gil bert’s  syndrome or of 
non-hepatic origin)  
6. PT/INR <  1.[ADDRESS_234901] and PTT (aPTT) <  1.[ADDRESS_234902].  
Demographic  
7. Men and women ≥  18 years of age.  
8. Eastern Cooperative Oncology Group  (ECOG) performance status of 0,  1, or 2. 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 25 of 111  23 June  2017  
 Ethical/Other  
9. Female s:  
o Female subjects who are of non -reproductive potential (ie,  post-menopausal by 
[CONTACT_969] - no menses for ≥  1 year; OR history of hysterectomy; OR history of 
bilateral tubal ligation; OR history of bilateral oophorectomy).   
OR 
o Female subjects of childbearing potential must have a negative serum pregnancy 
test upon study entry.  
10. Male and female subjects  must  agree to use highly effective methods of birth control 
(eg, condoms, implants, injectables, combined oral contraceptives, some intrauterine 
devices [IUDs], sexual abstinence, or sterilized partner) during the period of therapy and 
for [ADDRESS_234903] meet NONE of the following exclusion 
criteria:  
1. Prior treatment with either venetoclax or ibrutinib.  
2. Vaccinated with live, attenuated vaccine (s) within [ADDRESS_234904] 1  year (if over [ADDRESS_234905] active  cGVHD) . 
4. Richter’s transformation confirmed by [CONTACT_9256].  
5. Active uncontrolled autoimmun e cytopenias  
Concurrent Conditions  
6. Chemotherapy ≤  [ADDRESS_234906] administration of study treatment and/or 
monoclonal antibody ≤  [ADDRESS_234907] administration of study treatment.  
7. History of other malignancies, except:   
• Malignancy treated with curative intent and with no know n active disease present 
for ≥ [ADDRESS_234908] dose of study drug , and felt to be at low  risk for 
recurrence by [CONTACT_35425].  
• Adequately treated non -melanoma skin cancer or lentigo  maligna without 
evidence of disease.  
• Adequately treated carc inom a in situ without evidence of disease.   
8. Concurrent systemic immunosuppressant therapy [eg, cyclosporine  A, tacrolimus, etc, or 
chronic administration  (> 14 days ) of > 20 mg/day of prednisone ] within [ADDRESS_234909] dose of study  drug.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 26 of 111  23 June  2017  
 9. Recent infe ction requiring systemic treatment that was complete d ≤ [ADDRESS_234910] dose of study  drug.  
10. Unresolved toxicities from prior anti -cancer  therapy, defined as having not  resolved to 
Common Terminology Cri teria for Adverse Event (CTCAE,  v4.03), Grade  ≤ 1, or to the 
levels dictated in the inclusion/ex clusion criteria except for  alopecia.  
11. Known bleeding disorders (eg,  von Willebrand’s  disease) or hemophilia.  
12. History of stroke or intracranial  hemorrhage within [ADDRESS_234911] dose of 
study  drug. 
13. Known history of human immunodeficiency virus  (HIV)  or active with hepatitis  C 
virus  (HCV) or hepatitis  B virus  (HBV).   
Subjects who are positive for hepatitis  B core antibody or hepatitis  B surface antigen 
must have a neg ative polymerase chain reaction  (PCR) result before enrollment  in order 
to meet elig ibility for this criterion .  Those who are PCR -positive will be excluded.  
14. Any uncontrolled active systemic infection.  
15. Major surgery within [ADDRESS_234912]  dose of study  drug. 
16. Any life -threatening illness, medical condition, or organ system dysfunction tha t, in the 
investigator’s opi[INVESTIGATOR_1649], could compromise the subject’s safety or put the study outcomes 
at undue risk.  
17. Currently active, clinically significant cardiovascular disease, such as uncontrolled 
arrhythmia or Class  3 or 4 congestive heart failure as de fined by [CONTACT_197764]; or a history of myocardial infarction, unstable 
angina, or acute coronary syndrome within 6  months prior to screening . 
18. Unable to swallow capsules ; malabsorption syndrome ; disease significan tly affecting 
gastrointestinal function ; resection of the stomach or small bowel ; symptomatic 
inflammatory bowel disease or ulcerative colitis ; or partial or complete bowel obstruction.  
19. Concomitant use of warfarin or other Vitamin  K antagonists.  
20. Received a  strong cytochrome P450  (CYP)  3A inhibitor  or inducer  within [ADDRESS_234913] dose of ibrutinib , OR subjects who require continuous treatment with  a strong 
cytochrome  P450 CYP3A  inhibitor  or inducer  (see Appendix  C)  
21. Lactating or pregnant.  
22. Unwilli ng or unable to participate in all required study evaluations and procedures.  
23. Unable to understand the purpose and risks of the study.  
24. Subjects with chronic liver disease with hepatic impairment Child -Pugh class  B or C 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 27 of 111  23 June  2017  
 3.3 Informed Consent Process  
Prior to par ticipation in any study -specific procedure, including any invasive screening 
procedures, all candidates for participation will be provided a consent form describing the study.  
This consent form will provide sufficient information to make an informed decis ion regarding 
participation.   
• If the person providing consent is fluent in English, the prospective subject must sign the 
IRB-approved informed consent.  
• If the subject is considered “non -English  speaking,” and the “Short  Form” consent 
process will be used , the IRB -approved English consent form (aka, the 
“Summary  Form”) will be signed by [CONTACT_102730]  (POC) and the witness; 
and a Short  Form in the language of the person providing consent will be signed by [CONTACT_197765].   
The pa rticipant will be provided with a copy of the signed and dated consent document prior to 
any study procedure.  The original and any amended signed and dated consent forms must 
remain in each subject’s study file at the study site and be available for verif ication by [CONTACT_33483].  
The informed consent form (ICF) and consent process must comply with the US regulations 
(§ 21 CFR Part 50) as well as country specific national regulations and/or local laws.  The 
Investigator or designee (designee mu st be listed on the Delegation of Authority log), must 
explain in terms understandable to the subject the purpose and nature of the study, study 
procedures, anticipated benefits, potential risks, possible AEs, and any discomfort participation 
in the study may entail.  This process must be documented in the subject’s source record.   
3.4 Eligibility Verification Procedures  
To verify patient eligibility, the following documents should be completed by [CONTACT_197766] e -mailed (secure) to the Stanford C ancer Institute  (SCI) Study Coordinator:   
• Copy of required laboratory tests/procedures  
• Signed patient consent form  
• HIPAA authorization form  
• Eligibility screening worksheet  
The SCI Study Coordinator will have the Principal Investigator  [INVESTIGATOR_197704] y packet and if 
eligible, will : 
• Assign a patient study number  
• Fax or e -mail the patient study number to the participating site  
3.[ADDRESS_234914] -completion  
This study will not follow patients after completion of therapy. Upon completion  of ibrutinib + 
venetoclax combination treatment at Week 117, participants will have completed the trial and 
may transition off -study to receive commercial ibrutinib at  the discretion  of the investigator . 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 29 of 111  23 June  2017  
 4 TREATMENT PLAN  
4.1 Study Drug Administration  
Study participants will start treatment in the outpatient setting with ibrutinib 420  mg PO daily on 
Week  1 Day 1 of treatment.  After completion o f 8 weeks of treatment with ibrutinib, they will 
subsequently begin co -administration of venetoclax once daily with the daily dose increased 
every 7  days through 5 dose levels (20  mg; 50  mg; 100  mg; 200  mg; 400  mg).  The dosing 
schedule is depi[INVESTIGATOR_197705] e 1 in Section  1.3.1.  
Venetoclax will be administered  orally once daily continuously from the time of treatment 
initiation with venetoclax.  Each dose should be taken with approximately 240  mL of water 
(8 ounces) within [ADDRESS_234915]’s first meal of the 
day with an effort to take venetoclax at the same time of day daily.  Venetoclax should be taken 
at the same time as ibrutinib.  
Ibrutinib 420  mg (3  x 140-mg capsules) will be administered  orally once daily.  The capsules are 
to be taken around the same time each day with 8  ounces (approximately 240  mL) of water.  
The capsules should be swallowed intact and subjects should not attempt to open capsules or 
dissolve them in water.  The use of strong CYP3A inhibitors/i nducers, and grapefruit and Seville 
oranges should be avoided for the duration of the study (see Appendix  C). 
If a dose of either study drug is not taken at the scheduled time, it can be taken as soon as 
possible on the same day with a return to the normal  schedule the following day.  The subject 
should not take extra capsules to make up the missed dose.  
4.2 Toxicity Management  
Adverse event management and dose modifications are outlined in Section  6 
Dose  Modifications.   
4.3 General Concomitant Medication and Supp ortive Care Guidelines  
4.3.1  Prophylaxis and Management of Tumor Lysis Syndrome  
There is a potential for tumor lysis syndrome  (TLS) in subjects affected by [CONTACT_197767], especially in those with bulky disease; elevated pretreatment lactate 
dehydrogen ase (LDH) levels; elevated leukocyte count; renal dysfunction; and dehydration.  
In response to the events of TLS reported in the Phase [ADDRESS_234916] that size of baseline lymph nodes is a risk 
factor for TLS, with larger lymph nodes resulting in increas ed risk.  In addition, creatinine 
clearance of ≤  80 mL/min at Screening was identified as a risk factor for TLS.  Data analyses 
have resulted in development of three risk categories, listed below.   
• Risk category for an individual patient is determined upo n study entry.   
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 30 of 111  23 June  2017  
 o A detailed description of risk factors for developi[INVESTIGATOR_197706]'s Brochure.  
Refer to Appendix  F for laboratory and clinical definitions of TLS.  
• TLS Prophylaxis  and Monitoring Checklist will be completed throughout the lead -in 
period to ensure proper TLS prophylaxis measures.  
o The section below describes the management of patients throughout dosing 
based on their risk factors for developi[INVESTIGATOR_197707].   
For tumor lysis syndrome prophylaxis, all subjects enrolling into the study will be classified into 
[ADDRESS_234917] diameter <  5 cm  
AND  ALC < 25 × 109/L 
Medium  Any measurable lymph node with the largest diameter ≥  5 cm and <  10 cm,  
OR ALC ≥  25 × 109/L 
High Any measurable lymph node with the largest diameter ≥  10 cm,  
OR ALC ≥  25 × 109/L AND  any measurable lymph node with the 
largest  diameter ≥  5 cm but <  10 cm  
[IP_ADDRESS]  First Dose of Venetoclax at [ADDRESS_234918] dose of venetoclax at 20  mg and at 50  mg.  Tumor lysis syndrome 
prophylaxis includes:  
• An oral agent to reduce the uric acid level (eg,  allopurinol) to be initiated at least 
[ADDRESS_234919] use 
another uric acid reducer.  
• Oral hydration consisting of fluid intake of 1.[ADDRESS_234920].  
• Serum chemistry and hematology laboratory samples must be drawn anytime within 
[ADDRESS_234921] be 
delayed until resolution and initiate management per Appendix  E, (Recommendations for 
Initial Management of Electrolyte Abnormalities and Prevention of Tumor Lysis 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 31 of 111  23 June  2017  
 Syndrome [TLS]), and if needed, patient should receive additional prophylactic treatment 
prior to the initiation dosing.  
Additional TLS prophylaxis and monitoring procedures are tailored to the individual TLS risk 
category as follows:  
I.  Low Risk Category  
Subjects in Low Risk category can begin venetoclax lead -in period in the outpa tient setting if 
there is no indication to hospi[INVESTIGATOR_18552].  
• For subjects who are unable to maintain adequate oral hydration, IV hydration of 1.5 to 
2 L is recommended in the outpatient setting on D1 of 20  mg and 50  mg dose to assure 
this full amount of hydrati on is achieved.  For subjects in patients for whom volume 
overload is considered a significant risk, hospi[INVESTIGATOR_26596].  
• Chemistry and hematology laboratory tests are to be performed within [ADDRESS_234922] review these laboratory values.  The 
investigator's decision to proceed with venetoclax treatment initiation may be based on 
these laboratory values.   
• Chemistry laboratory tests must be performed STAT at 0  hour (pre -dose), 8, and 
24* hours post -dose after the first dose of venetoclax at [ADDRESS_234923] remain at the hospi[INVESTIGATOR_307], or clinic, until the investigator has reviewed the 
8-hour laboratory values.  
• Day [ADDRESS_234924]-dose chemistry laboratory values.  
• If no significant findings suggestive of clinical or lab TLS occur within 24  hours, the same 
dose will be continued until Day  7 in the outpatient setting.  
• If any significant laboratory c hanges are observed within the first 24  hours after initiation 
of dosing, see Appendix  E (Recommendations for Initial Management of Electrolyte 
Abnormalities and Prevention of Tumor Lysis Syndrome [TLS]) for procedures to follow.  
These laboratory values m ust be reviewed in real time by [CONTACT_093].  
• Additional laboratory assessments may be performed per investigator discretion.  
• Hematology laboratory tests must be performed 24*  hours post -dose after the first dose 
of venetoclax at 20  mg and at 50  mg. 
* All [ADDRESS_234925] creatinine clearance ≥  80 mL/min will receive their 
initial doses of venetoclax at [ADDRESS_234926] creatinine clearance of <  80 mL/min and/or 
higher tumor burden may be handled as high -risk subjects per investigator discretion for the first 
dose of venetoclax at 20  mg and 50  mg (Refer to section for high -risk subjects below).  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 32 of 111  23 June  2017  
 • Subjects will receive IV hydration of 1.5 to 2  L in the outpatient setting on D1 of  20 mg 
and 50  mg dose in addition to oral hydration as stated above.  For subjects in whom 
volume overload is considered a significant risk, hospi[INVESTIGATOR_26596].  
• Chemistry and hematology laboratory tests are to be performed within [ADDRESS_234927] review these laboratory values.  The 
investigator's decision to proceed with venetoclax treatment initiation may be based on 
these laboratory values.  
• Chemistry laboratory tests must be performed STAT at 0  hour (pre -dose), 8, and 
24* hours after the first dose of venetoclax at [ADDRESS_234928] venetoclax administration.  
• Results from pre -dose laboratory values are not required to be available prior to initiating 
venetoclax treatment.  Subjects must remain at the hospi[INVESTIGATOR_307], or clinic, until the 
investigator has reviewed the 8 -hour laboratory values.  
• Day [ADDRESS_234929]-dose chemistry laboratory values.  
• If no significant findings suggestive of clinical or lab TLS occur within 24  hours, the same 
dose will be continued until Day  7 in the outpatient setting.  
• If any significant laboratory changes are observed within the first 24  hours after initiation 
of dosing, see Appendix  E, (Recommendations for Initial Management of Electrolyte 
Abnormalities and Prevention of Tumor Lysis Syndrome [TLS]) for procedures to follow . 
• Additional laboratory assessments may be performed per investigator discretion.  
• Hematology laboratory tests must be performed 24*  hours post -dose after the first dose 
of venetoclax at 20  mg and at 50  mg. 
* All [ADDRESS_234930] -dose chemistry labo ratory 
values are reviewed by [CONTACT_093].  
• Chemistry and hematology laboratory tests to be performed upon admission the night 
before first dose of venetoclax.  The investigator's decision to proceed with venetoclax 
treatment initiation will be based o n these laboratory values.  
• Nephrology (or other acute dialysis service) consultation should be considered upon 
admission per institutional standards at investigators' discretion to ensure emergency 
dialysis is available and the appropriate staff is aware a nd prepared to handle any 
necessary intervention for TLS.  Telemetry should also be considered.  IV hydration 
must be started the night before dosing and continued for 24  hours after dose.  
• Rasburicase must be administered per regional standards or institut ional guidelines for 
subjects with elevated uric acid level at baseline (>  ULN) or rapi[INVESTIGATOR_197708].).  For patients with a 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 33 of 111  23 June  2017  
 contraindication to rasburicase (ie,  glucose -6-phosphate dehydr ogenase [G6PD] 
deficiency), the TLS risk -mitigation plan must be reviewed with the Principal Investigator.  
• Chemistry laboratory tests must be performed STAT at 0 (pre -dose, within 4  hours 
before venetoclax administration), 4, 8, 12 and 24*  hours after the first dose of 
venetoclax at [ADDRESS_234931] venetoc lax administration.  
• Prophylactic reductions for potassium, inorganic phosphorus and/or uric acid above of 
normal range prior to dosing are recommended.  
• If any significant laboratory changes are observed within the first 24  hours after initiation 
of dosing,  see Appendix  E, (Recommendations for Initial Management of Electrolyte 
Abnormalities and Prevention of Tumor Lysis Syndrome [TLS]), for additional laboratory 
assessments and management guidelines.  
• Hematology laboratory tests performed pre -dose (within 4  hours before venetoclax 
administration) and 24*  hours post -dose after the first dose of venetoclax at 20  mg and 
50 mg. 
• Day [ADDRESS_234932]-dose laboratory values.  
• If no significant findings suggestive of clinical or lab TLS occur within 24  hours, the same 
dose will be continued until Day  7 in the outpatient setting.  
* All [ADDRESS_234933]’s next dose.  Based upon the laboratory values, the subject may continue dosing, 
may need to hold dose until resolution of laboratory abnormalities, may require additional 
post-dose laboratory c hecks or may require hospi[INVESTIGATOR_197709].  Please see 
Appendix E, (Recommendations for Initial Management of Electrolyte Abnormalities and 
Prevention of Tumor Lysis Syndrome [TLS]) for appropriate procedures to follow.  
[IP_ADDRESS]  Dose Esca lation of Venetoclax to [ADDRESS_234934] receive the following TLS prophylaxis 
measures prior to subsequent dose increases of venetoclax:  
• Continue administration of an oral uric acid reducer  as indicated above.  
• Oral hydration consisting of fluid intake of approximately 1.5 to 2 L/day starting at least 
48 hours  days prior to each dose increment.  IV hydration is encouraged at subsequent 
dose increases for subjects who are unable to maintain su ch oral hydration.  IV 
hydration will be in the outpatient setting on the day of dose increment.  For patients in 
whom volume overload is considered a significant risk, hospi[INVESTIGATOR_26595].  
• Chemistry and Hematology laboratory tests must be  performed within [ADDRESS_234935] review results prior to each dose escalation.  For subjects 
demonstrating any clinically significant laboratory abnormalities, additional prophylactic 
treatment should be administered prior to dosing ( see Appendix  E, Recommendations 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 34 of 111  23 June  2017  
 for Initial Management of Electrolyte Abnormalities and Prevention of Tumor Lysis 
Syndrome [TLS]).  
Additional TLS prophylaxis and monitoring procedures are tailored to the individual TLS risk 
category as follows:  
I.  Low Risk Category  
Subjects in Low Risk category will receive the subsequent dose escalations (100, 200 and 
400 mg) as outpatients.  
• Chemistry and Hematology laboratory tests will be performed at STAT at 0  hour 
(pre-dose), [ADDRESS_234936] 
venetoclax administration.  
• Subjects must remain at the  hospi[INVESTIGATOR_307], or clinic, until the investigator has reviewed the 
8-hour laboratory values.  
• Day [ADDRESS_234937]-dose chemistry laboratory values.  
• If no significant findings suggestive of clinic al or lab TLS occur within 24  hours, the same 
dose will be continued until Day  7 in the outpatient setting.  
• Additional laboratory assessments may be performed per investigator discretion.  
II.  Medium Risk Category  
Subjects in Medium Risk category may recei ve their subsequent dose escalations in the 
outpatient setting.  Subjects with creatinine clearance <  80 mL/min and/or higher tumor burden 
may be hospi[INVESTIGATOR_197710]'s discretion.  
For subjects who receive their subsequent dose escalations in the outpatient setting,  
• Chemistry and Hematology laboratory tests will be performed 0 (pre -dose), [ADDRESS_234938] venetoclax 
administration.  
• Subjects must remain at the hospi[INVESTIGATOR_307], or clinic, until the investigator has reviewed the 
8-hour laboratory values.  
• Day [ADDRESS_234939]-dose chemistry laboratory values.  
• If no significant findings suggestive of clinical or lab TLS occur within 24  hours, the same 
dose will be continued until Day  7 in the outpatient setting.  
• Additional laboratory assessments may be performed per investigator discretion.  
For subjects who are hospi[INVESTIGATOR_197711],  
• Chemistry and Hematology laboratory tests will be performed upon admission.  
Chemistry tests will be performed STAT at 0 hour (pre -dose), 4, 8, [ADDRESS_234940] venetoclax administration.  
• IV hydration should be started with a target of approximately 2  L per day or as clinically 
appropriate for patients who are hospi[INVESTIGATOR_057].  
• Hematology laboratory tests will be performed [ADDRESS_234941] -dose.  
• The [ADDRESS_234942] leaving the hospi[INVESTIGATOR_197712].  
III.  High -risk Category  
High-risk subjects may receive the subsequent dose increases as outpatients.  Su bjects with 
creatinine clearance <  80 mL/min may be hospi[INVESTIGATOR_197713].  
Hospi[INVESTIGATOR_197714] 24  hours 
after dose administration.  
For subjects who are hospi[INVESTIGATOR_197715],  
• Chemistry and Hematology laboratory tests will be performed upon admission.  
Chemistry tests will be performed STAT at 0  hour (pre -dose); 4; 8; 12; and [ADDRESS_234943] venetoclax administration.  
• IV hydration should be started with a target of approximately 2 L per day o r as clinically 
appropriate for patients who are hospi[INVESTIGATOR_057].  
• Hematology laboratory tests will be performed [ADDRESS_234944] -dose.  
• The [ADDRESS_234945] leaving the hospi[INVESTIGATOR_197716].  
For subjects who are not hospi[INVESTIGATOR_057],  
• Chemistry and Hematology laboratory tests will be performed pre -dose (within 72  hours), 
and at [ADDRESS_234946] 
venetoclax administration.  
• Intravenous hydration (1.5  to 2 L) will be given in the out patient setting w ith a target of 
approximately 2  L per day or as clinically appropriate.  
• Subjects must remain at the hospi[INVESTIGATOR_307], or clinic, until the investigator has reviewed the 
8-hour laboratory values.  
• Day [ADDRESS_234947]-dose chemistry laboratory values.  
• If no significant findings suggestive of clinical or lab TLS occur within 24  hours, the same 
dose will be continued until Day  7 in the outpatient setting.  
• Additional laboratory assessment s may be performed per investigator discretion.  
IRB-[ADDRESS_234948] their subsequent venetoclax dose held until the electrolyte abnormalities resolve.  
Electrolyte changes s hould undergo aggressive management and further monitoring as per 
Appendix  E, (Recommendations for Initial Management of Electrolyte Abnormalities and 
Prevention of Tumor Lysis Syndrome [TLS]).  The subject may resume dosing based on a risk 
assessment (inc luding tumor burden status), as determined by [CONTACT_093].  All subjects 
must receive the intended dose for at least 7  days before increasing to the next higher dose.  
4.3.2  Permitted Concomitant Medications  
Supportive medications in accordance with standar d practice (such as for emesis, diarrhea, etc) 
are permitted.  Use of neutrophil growth factors (filgrastim and pegfilgrastim) or red blood cell 
growth factors (erythropoietin) is permitted per institutional policy and in accordance with the 
ASCO guideline s.27 Transfusions may be given in accordance with institutional policy.  
Short courses (≤  14 days) of steroid treatment for non -cancer related medical reasons (eg,  joint 
inflammation, asthma exacerbation, rash, antiemetic use and infusion reactions) at dos es that 
do not exceed 100  mg per day of prednisone or equivalent are permitted.  
The following may be considered:  localized hormonal or bone sparing treatment for non -B-cell 
malignancies, and localized radiotherapy for medical conditions other than the un derlying B -cell 
malignancies.  
Treatment for autoimmune cytopenias are permitted for <  14 days at doses that do not exceed 
100 mg per day of prednisone or equivalent.  
4.3.3  Concomitant Medications to be Used with Caution  
[IP_ADDRESS]  CYP3A Inhibitors  / Inducers  
Ibrutinib is metabolized primarily by [CONTACT_097]3A4.  Concomitant use of ibrutinib and drugs that 
strongly or moderately inhibit CYP3A can increase ibrutinib exposure , and therefore strong 
CYP3A inhibitors should be avoided.  
IRB-[ADDRESS_234949] ment 
required.  
Moderate CYP3A  inhibitors  280 mg once daily . 
Voriconazole 200 mg twice 
daily 
Posaconazole  suspension 
100mg once daily, 100 mg 
twice daily, or 200 mg twice 
daily  140 mg once daily . 
Other s trong CY P3A inhibitors  
Posaconazole at higher 
dosesb  Avoid concomitant use and 
consider alternative with less 
CYP3A inhibitory potential.  
If these inhibitors will be used 
short -term (such as anti -infectives 
for seven days or less), interrupt 
ibrutinib.  
If the benefit outweighs the risk, 
and long -term dosing with a 
CYP3A inhibitor is required (more 
than seven days), reduce ibrutinib  
dose to 140 mg once daily for the 
duration of the inhibitor use . 
a.  Monitor for adverse reactions to IMBRUVICA and interrupt or modify dose as recommended (see Dosage and 
Administration).  
b. Posaconazole at higher doses (posaconazole suspension 200 mg three times daily or 400 mg twice daily, 
posaconazole IV injection 300 mg once daily, posaconazole delayed -release tablets 300 mg once daily) . 
• No dose adjustment is required in comb ination with mild inhibitors.  
• Avoid grapefruit and Seville oranges during ibrutinib treatment as these contain 
moderate inhibitors of CYP3A.  
Avoid concomitant use of systemic strong CYP3A inducers (eg, carbamazepi[INVESTIGATOR_050], rifampin, 
phenytoin, and St  John’s  Wort).  Consider alternative agents with less CYP3A induction.  
A list of common CYP3A inhibitors and inducers is provided in Appendix  C.  For further 
information, please refer to the current version of the ibrutinib Investigator Brochure  and the 
examples  of inhibitors, inducers, and substrates found at  
http://medicine.iupui.edu/clinpharm/ddis/main -table/ .  This website is continually revised and 
should be checked frequently for up dates.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 38 of 111  23 June  2017  
 [IP_ADDRESS]  Drugs That May Have Their Plasma Concentrations Altered by [CONTACT_197768] a substrate of P -glycoprotein (P -gp), but is a mild 
inhibitor (with an IC 50 of 2.15  μg/mL).  Ibrutinib is not expected to have systemic drug -drug 
interactions with P -gp substrates.  However, it cannot be excluded that ibrutinib could inhibit 
intestinal P -gp after a therapeutic dose.  There is no clinical data available; therefore , to avoid a 
potential interaction in the GI tract, narrow therapeutic range P -gp substrates such as digoxin, 
should be taken at least [ADDRESS_234950] 6  hours before venetoclax.  
[IP_ADDRESS]  QT -Prolonging Agents  
Any medications known to cause QT prolongation should be used with caution; periodic ECG 
and electrolyte monitoring should be considered.  
[IP_ADDRESS]  Antiplatelet A gents and Anticoagulants  
Use ibrutinib with caution in subjects requiring anticoagulants or medications that inhibit platelet 
function.  Supplements such as fish  oil and vitamin  E preparations should be avoided during 
treatment with ibrutinib.  In an in vitro platelet function study, inhibitory effects of ibrutinib on 
collagen -induced platelet aggregation were observed.  Bleeding events of any grade, including 
bruising and petechiae, occurred in subjects treated with ibrutinib.  Subjects with congenital 
bleeding diathesis have not been studied.  Ibrutinib should be held at least [ADDRESS_234951]-surgery, depending upon the type of surgery and the risk of bleeding .  For guidance on 
ibrutinib and the use of anticoagulants during procedures/surgeries, see Section  4.3.5.  
Subjects requiring the initiation of therapeutic anticoagulation  therapy (eg,  atrial fibrillation), 
should be monitored closely for signs and symptoms of bleeding and the risks and benefits of 
continuing ibrutinib treatment should be co nsidered.  
4.3.[ADDRESS_234952] is receiving ibrutinib treatment.   
Corticosteroids for the treatment of the underlying disease are prohibited.  Corticosteroids for 
the treatment of non -cancer related reasons for longer than 14  days and/or at doses >  100 mg 
of prednisone or its equivalent are prohibited.  
Use of strong CYP3A inhibitors is contraindicated during venetoclax initiation  and dose 
ramp -up.  Subjects may not consume grapefruit or grapefruit products, Seville  oranges 
(including marmalade containing Seville  oranges) or star fruit within the [ADDRESS_234953] day of tr eatment is completed due to possible 
CYP3A mediated metabolic interaction.   
Erythropoietic growth factors (eg,  erythropoietin) and neutrophil growth factors (eg,  filgrastim 
and peg -filgrastim) may be administered per standard practice.   
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 39 of 111  23 June  2017  
 4.3.5  Guidelines for Ibru tinib Management with Surgeries or Procedures  
Ibrutinib may increase risk of bleeding with invasive procedures or surgery.  The following 
guidance should be applied to the use of ibrutinib in the perioperative period for subjects who 
require surgical inter vention or an invasive procedure while receiving ibrutinib:   
[IP_ADDRESS]  Minor Surgical Procedures  
For minor procedures (such as a central line placement, needle biopsy, thoracentesis, or 
paracentesis) ibrutinib should be held for at least [ADDRESS_234954] is on ibrutinib, it is not necessary to hold i brutinib for these 
procedures.  
[IP_ADDRESS]  Major Surgical Procedures  
For any surgery or invasive procedure requiring sutures or staples for closure, ibrutinib should 
be held at least 7  days prior to the intervention  (except for emergency procedures)  and should 
be held at least 7  days after the procedure and restarted at the  discretion of the investigator 
when the surgical site is reasonably healed without serosanguinous drainage or the need for 
drainage tubes.  
4.4 Duration of Therapy  
Upon completion of ibrutinib + venetoclax combination treatment at Week 117, participants will 
have completed the trial and may transition off -study to receive commercial ibrutinib at the 
discretion of the investigator . In the absence of treatment delays due to adverse e vent(s), 
combination treatment may continue through Week 117, or until one of the  following criteria 
applies:  
• Disease progression or relapse  
• Unacceptable drug -related adverse event(s)  
• Patient decides to withdraw from the study  
• Investigator decision that discontinuation is in the best interests of the patient  
• General or specific chang es in the patient's condition render the patient unacceptable for 
further treatment in the judgment of the investigator  
• Pregnancy  
4.5 Duration of Follow -up 
Patients will be followed until end of treatment ; withdrawal of consent; or death, whichever 
occurs firs t.  Patients removed from study for unacceptable adverse event(s)  will be followed 
until resolution or stabilization of the adverse event.   
IRB-[ADDRESS_234955] be 
documented in the Case Report Form  (CRF).   
4.6.2  Removal from Study  
Withdrawal from the study including termination of all follow -up will occur if:  
• The subject is lost to follow -up following reasonable effort from study staff to contact [CONTACT_1560]  
• The subject withdraws consent for follow -up observation  
• The subject dies  
• The study is terminated  
Documentation of the reason for withdraw al and withdrawal of full (treatment and all further 
contact) or partial (withdrawal of consent to treatment but not to follow -up visits) consent will be 
must be documented in the Case Report Form  (CRF).  
4.7 Study Risk Information  
Risks of the study drugs are described within the venetoclax and ibrutinib  
Investigator’s  Brochures and FDA -approved labeling for each.  
4.8 Risk Mitigation  
Risk mitigation will include safety assessments during clinic  visits at weeks  1; 5; and  9 (ibrutinib 
treatment only); then weekly fo r 4 weeks during the venetoclax dose  ramp -up; then, during the 
venetoclax + ibrutinib stage, every 4  weeks through Week  30; then at Week  38, Week  62, and 
every 12  weeks thereafter .  Safety assessments will include hematology; serum chemistry; 
physical exam  with vital signs, weight, and ECOG  performance status; and subject interviews 
for adverse events and concomitant medications.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 41 of 111  23 June  2017  
 5 STUDY DRUG INFORMATI ON 
5.1 Study Drug Venetoclax  
5.1.1  Name  
[CONTACT_197786] [CONTACT_197769] (FDA) as 
Venclexta.   The approved use s of venetoclax are described at Section  2.2.1 Venetoclax.  
5.1.2  Formulation  
The venetoclax tablets will be packaged in high -density polyethylene (HDPE) plastic bottles or 
blister packs to accommodate the study design.  Each conta iner will be labeled per local 
regulatory requirements.  Tablets are formulated with 10  mg, 50  mg and 100  mg doses.  
Blister Packs will contain study drug for one week plus one extra day.  Subjects will be 
instructed to take the extra day's dose (noted with  an "X" on the Blister  Pack) only if directed by 
[CONTACT_093].  
5.1.3  Study Cohorts / Arms / Groups  
This is a single -arm, open label study.  All participants will receive ibrutinib for 8  weeks, then 
begin dose -escalation with venetoclax as described elsewher e in the protocol.  
5.1.4  Mechanism of Action  
Venetoclax is a novel, orally available small molecule Bcl -2 family protein inhibitor that binds 
with >  500-fold higher affinity (Ki <  0.010  nM) to Bcl -2 and with lower affinity to other Bcl -2 family 
proteins Bcl -XL (Ki – 48 nM) and Bcl -w (Ki – 245 nM).  Overexpression of anti -apoptotic Bcl -[ADDRESS_234956] a panel of  lymphoma and 
leukemia cells including B -cell follicular lymphomas (FLs), mantle cell lymphomas (MCLs), 
diffuse large B -cell lymphomas (DLBCLs), and acute myeloid leukemias (AMLs).  Venetoclax 
was especially potent against cell lines expressing high levels  of Bcl -2.  Leukemia and 
lymphoma cell lines bearing the t(14;18) translocation were significantly more sensitive to 
venetoclax than non -mutated cell lines.  
5.1.[ADDRESS_234957] shown that venetoclax is metaboli zed primarily by [CONTACT_097]3A4; thus, 
co-administration of venetoclax with drugs that inhibit CYP3A4 (such as ketoconazole) is 
predicted to cause a significant increase in the exposure of venetoclax and will be undertaken 
with caution.  In a phase -I dose -escalati on trial in patients with relapsed/refractory NHL, after a 
single dose administration with a high -fat meal, venetoclax reached C max at approximately 
7 hours with a terminal half -life of about 15  hours.  Food increased venetoclax exposure by 
[CONTACT_3450] 3 -fold.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 42 of 111  23 June  2017  
 5.1.6  Summaries of Non -Clinical Pharmacology and Toxicology Studies  
Venetoclax inhibited subcutaneous murine xenograft growth of human tumor cell lines derived 
from acute lymphoblastic leukemia (ALL) and Non -Hodgkin's Lymphoma (NHL).  The drug was 
also active in a model of disseminated ALL.  
[IP_ADDRESS]  Non -Clinical Toxicology Studies  
The nonclinical toxicology of venetoclax has been evaluated in repeated -dose studies in mice 
and dogs with up to 4  weeks of once daily oral dosing (and with 4 -week recovery per iods) and in 
dogs with 2  weeks of dosing (18 -week recovery period); safety pharmacology studies 
(cardiovascular, neurofunctional, and pulmonary); and in genetic toxicity tests (Ames and in vitro 
chromosome aberrations assays).   
The primary toxicities asso ciated with venetoclax administration included effects on the 
hematologic system (lymphocytes and red blood cell parameters) in mice and dogs and on the 
male dog reproductive system.  There was no evidence of genotoxicity of venetoclax.  
A severely toxic d ose (STD10) was not identified in mice up to and including the top dose of 
600 mg/kg/day (overall mean AUC 0-24 = 91.5 μg•hr/mL and C max = 7.2 μg/mL).  In dogs, the 
highest non -severely toxic dose (HNSTD) was 150  mg/kg/day, but due to overlappi[INVESTIGATOR_197717], the HNSTD was defined as the mid dose of 
50 mg/kg/day (overall mean AUC 0-24 = 472 μg•hr/mL and C max = 27.4 μg/mL).  
Venetoclax causes decreases in circulating lymphocytes and lymphocytes in lymphoid tissue.  
After 4  weeks of dosing, the lymphocyte effects were reversible or partially reversible in the 
mouse but generally were less reversible in the dog at the end of a 4 -week recovery period.  
However, in a 2 -week dog study focused on lymphocyte recovery over an extended (18 -week) 
period, reversibility of lymphocyte effects w as demonstrated.  Immunophenotypi[INVESTIGATOR_197718] (ie,  mature T -cells, helper T -cells, 
cytotoxic T -cells, and mature B -cells).  At the end of the 18 -week r ecovery period, both total and 
lymphocyte subset counts returned to within range of baseline and control values, and all effects 
on lymphoid tissue reversed.  The venetoclax –related decreases in lymphocytes in blood and 
lymphoid tissues are considered phar macologically mediated and non -adverse.  
Additional hematological effects of venetoclax treatment included reversible decreases in red 
blood cell parameters (primarily, hematocrit and hemoglobin concentration) in mice and dogs.  
The decreases in red cell pa rameters were adverse only at the high dose levels in the 4 -week 
studies (ie,  at 600  mg/kg/day in mice and at 150  mg/kg/day in dogs, but all red cell parameters 
were reversible at the end of a 4 -week recovery period.  Effects on both lymphocytes and red 
cell mass are readily monitored in subjects.  
Dogs at the high dose of 150  mg/kg/day in the 4 -week study had clinical signs of itching and 
swelling of the skin on the ears, head (cranial area), and forepaws and/or hindpaws.  Most of 
the animals (8 of 10 dogs)  were affected.  The clinical signs were mild to moderate in severity, 
transient and sporadic in occurrence, and were absent during the recovery period.  The swelling 
reactions were observed after the first dose in 3 dogs, and therefore not consistent with  
drug-induced immediate (IgE -mediated, Type I) hypersensitivity; however, other 
immune -mediated mechanisms could be involved.  Although the basis for the swelling reactions 
was not established, there were no signs of anaphylaxis.  Any occurrences of swelli ng reactions 
in patients can be monitored and treated.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 43 of 111  23 June  2017  
 In an ongoing 9 -month chronic toxicity study of dogs with venetoclax, hypopi[INVESTIGATOR_49194] (white) 
facial hair was observed after approximately 3 months of dosing (ongoing study Abbvie 
R&D/12/384).  The findi ng was limited to the mid and high doses (6 and 20  mg/kg/day), and was 
observed in both males and females.  Evidence from Bcl -2 knockout mouse (bcl -2-/-) studies 
indicates that hair hypopi[INVESTIGATOR_26609] -2 
functional loss, and occurs due to loss of hair follicle melanocytes dependent on Bcl -2 for 
survival .28 A dedicated physical examination of the skin and extensive ophthalmic examinations 
determined that pi[INVESTIGATOR_26610] (particularly i n the iris and fundus) 
appears unaffected.  The potential for development of white (hypopi[INVESTIGATOR_49194]) hair in humans is 
unknown.  
Venetoclax was tested in a battery of safety pharmacology assays and produced no effects in 
central nervous system/neurobehavioral , or respi[INVESTIGATOR_26614] 
600 mg/kg.  In an anesthetized dog cardiovascular model given intravenous doses of 
venetoclax, mild reductions in myocardial contractility (maximum rate of rise of left ventricular 
pressure [dP/dtmax]:  –6% to –13%) and cardiac output ( –11% to –19%) were observed at 
plasma concentrations of ≥  16 μg/mL and ≥  32 μg/mL, respectively.  However, no effect on 
blood pressure, heart rate, or electrocardiogram (ECG) parameters were observed relative to 
baseline or controls in either the anesthetized dog study or in the conscious dog cardiovascular 
study using telemeterized animals at maximum drug concentrations of 46  μg/mL and 16  μg/mL, 
respectively.  
Nonclinical safety pharmacology and toxicology evaluations of venetoclax, as well as  nonclinical 
and human  studies of related anti -apoptotic Bcl -[ADDRESS_234958] potential 
mechanism -based toxicities may include lymphopenia and neutropenia,29 signs of tumor lysis, 
reduction in red cell mass, decreased spermatogenesis, skin swelling, and hair  
hypopi[INVESTIGATOR_371].  Thrombocytopenia has not been observed in toxicology studies in mice and 
dogs.  These findings are consistent with venetoclax as a Bcl -2 specific (Bcl -XL sparing) 
inhibitor.  Consequently, thrombocytopenia is not expected to be a dose -limiting toxicity  (DLT) 
clinically.  
A detailed discussion of the preclinical toxicology, metabolism, and pharmacology can be found 
in the current version of the Investigator's Brochure.  
[IP_ADDRESS]  Carcinogenesis, Mutagenesis, Impairment of Fertility  
Male dog reproductive effects consisted of markedly reduced numbers of spermatogonia in the 
testes at all venetoclax dose levels after [ADDRESS_234959] the treatment of subjects with advanced hematologic 
malignancies .  
5.1.7  Summaries of Clinical Stu dies  
As of 28  November  2015, data available in the [COMPANY_013] and Genentech/[COMPANY_002] clinical databases  
include  a total of [ADDRESS_234960] 1 dose of venetoclax in the 
oncology and immunology development programs.  A total of 1498 oncology subjects ha ve data 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 44 of 111  23 June  2017  
 available in [COMPANY_013] and Genentech/[COMPANY_002] studies as of 28 November  2015.  Of these 1498, 
935 subjects had CLL/small lymphocytic leukemia (SLL), [ADDRESS_234961] 1 dose of venetoclax in the [COMPANY_013] immunology study, Study M13 -093, as of 
28 November  2015.  
Preliminary efficacy results are available for subjects with CLL/SLL, NHL, MM, and AML as 
listed below.  Preliminary data indicate that venetoclax continues to show promising efficacy in 
oncology subject populations.  
• In venetoclax monotherapy Study M12 -175 (as of [ADDRESS_234962]  2015), the overall remission 
rate (ORR; investigator -assessed) in Arm A (R/ R CLL/SLL) in the Dose -Escalation and 
Safety Expansion Cohorts was 79%.33 The ORR (investigator -assessed) in Arm B (R/R 
NHL) was 38% for FL subjects and 18% for DLBCL subjects (Dose -Escalation and 
Safety Expansion Cohorts).  
• In venetoclax monotherapy Study M13-982 (as of 30  April 2015), the ORR 
(IRC-assessed) for R/R CLL subjects was 74%.  
• In venetoclax monotherapy Study M14 -032 (as of [ADDRESS_234963]  2015 ), the ORR for R/R 
CLL subjects in Arm A (ibrutinib -resistant) was 42% and in Arm B (idelalisib -resistant) 
was 29%.  
• In Study M13 -365 (as of 28  October  2015) the ORR for R/R CLL/SLL subjects treated 
with venetoclax + rituximab was 86%.  
• In Study M12 -630 (as of 17  September  2015), the ORR for R/R NHL subjects treated 
with venetoclax + BR was 67%.  
• In Study M13 -367 (as of 17 September  2015 ), the ORR for R/R MM subjects treated 
with venetoclax was 24% in t(11;14) -positive subjects and 4% in t(11;14) -negative 
subjects.  
• In Study M12 -901 (as of 17 September  2015 ), the ORR for R/R MM subjects treated 
with venetoclax and borte zomib/dexamethasone was 100% in bortezomib -naïve 
subjects, 71% in bortezomib -sensitive subjects, and 17% in bortezomib -refractory 
subjects.  
• In Study M14 -212 (as of 07  October  2014), the ORR for AML subjects treated with 
venetoclax monotherapy was 19%.  
• In Study M14 -358 (as of 19  September  2015), the ORR for AML subjects was 77%.  
• In Study M14 -387 (as of 28  November  2015), the ORR for AML subjects was 44%.  
For the most comprehensive clinical information regarding venetoclax, refer to the current 
version of the  Investigator's Brochure.  
5.1.8  Major Route of Elimination  
Following oral administration in mouse, rat, dog, and human, venetoclax and its metabolites 
were cleared primarily via biliary excretion and fecal elimination, with minimal renal clearance.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 45 of 111  23 June  2017  
 5.1.9  Safety Prof ile  
The preliminary clinical data of venetoclax monotherapy in subjects with CLL/SLL, MCL and 
NHL have shown a favorable benefit  to risk ratio in Study M12 -175.  As of [ADDRESS_234964] been enrolled in Study M12 -175, and had d ata available for the study 
(95 in Arm  A and 58 in Arm  B).  The most common adverse events in Arm  A (CLL/SLL subjects) 
were diarrhea  (38.9%), neutropenia  (37.9%), nausea  (34.7%), upper respi[INVESTIGATOR_4348]  (30.5%), fatigue  (27.4%), and cough  (20.0%) .  The most common adverse events in 
Arm B (NHL subjects) were nausea  (32.8%), diarrhea  (24.1%), and fatigue and upper 
respi[INVESTIGATOR_1092]  (20.7% each).  
The most common adverse events reported for all subjects in the study were nausea  (34.0%), 
diarrhea (33.3%), neutropenia  (29.4%), upper respi[INVESTIGATOR_1092]  (26.8%), and 
fatigue  (24.8%).  The most common events Grade  3 or above reported in Arm A (CLL/SLL 
subjects) were neutropenia  (34.7%) and anemia  (10.5%), and in Arm B (NHL subjects) were 
anemia  (15.5%) and neutropenia  (10.3%).  Overall, Grade  3 or 4 adverse events reported in 
> 5% of patients were anemia, neutropenia, febrile neutropenia, thrombocytopenia, 
hyperglycemia, and tumor lysis syndrome  (TLS).  These adverse events were mostly cons istent 
with complications commonly observed in heavily pretreated patients with R/R CLL/SLL.  Febrile 
neutropenia was the most common serious adverse event observed with venetoclax 
monotherapy treatment  (7.0%); all events resolved on supportive treatment, and none resulted 
in discontinuation from the study.  The only other serious adverse event reported in more than 
2 subjects  was TLS  (11.0%) for venetoclax as a single agent.  A comprehensive safety review 
identified risk factors for developi[INVESTIGATOR_197719] M12 -175 as well as Study M13 -365 
(venetoclax in combination with rituximab), resulting in implementation of a modified 
dose -escalation regimen and revised TLS risk management procedures in ongoing studies in 
various hematologic malignancies.  
[IP_ADDRESS]  Tu mor Lysis Syndrome  (TLS)  
TLS is considered an important identified risk and is predominantly seen in the CLL population 
with high tumor burden.  Primary CLL cells a re essentially dependent on Bcl -[ADDRESS_234965] can cause rapid reduction in size of tumor (debulk) and may pose a risk 
of TLS.  
The management of the risk of TLS with venetoclax has evolved over time. In Study M12 -175 
(June  2011), sub stantial anti -tumor activ ity was observed in the first 3  subjects with CLL 
following a single dose of venetoclax of 100 to 200 mg.  Within 24  hours, reductions in palpable 
lymphad enopathy were observed in all 3  subjects and dramatic reductions in lymphocyt e count 
(> 95%) were observed in the [ADDRESS_234966] also been due to  the radiographic dye in the setting of TLS.  Hospi[INVESTIGATOR_197720]/S LL subjects with the first dose of venetoclax became mandatory following the report of 
this serious adverse event.  
In December  2012, 2 fatal adverse events in the setting of TLS were reported in subjects with 
CLL/SLL.  The first death (in Study M13 -365) oc curred within [ADDRESS_234967] dose of 50 mg venetoclax.  The second death (in Study M12 -175) occurred within 
[ADDRESS_234968] had escalated to the final dose of 1200 mg/daily of venetoclax, the 
highest dose administe red in the venetoclax program to date.  Following the report of 2 fatal 
adverse events in  the setting of TLS in December  2012, the clinical program was halted and a 
comprehensive review of all safety data available from studies with venetoclax revealed:  
• The highest risk period for developi[INVESTIGATOR_197721].  The risk is 
reduced as the tumor burden decreases.  
• Subjects with TLS appeared to have had a higher venetoclax exposure than subjects 
without TLS.  To reduce the initial exposure for all subjects to that of subjects not 
experiencing TLS (Cmax ≤ 0.23  μg/mL), trial simulation data indicated that subjects 
should receive 20 mg as a starting dose.  
• Bulky lymph nodes ≥ 5 cm and elevated screening ALC ≥ 38.9  × 109/L were identified as 
risk fac tors for TLS following administration of venetoclax. Screening CrCl < 80 mL/min 
was also identified as a contributing factor.  These TLS risk factors are not unique to 
venetoclax and have been previously identified in the literature.  
• The 2 subjects who had  fatal CTLS (Subject [ADDRESS_234969] 5503 in 
Study M13 -365) had nodes greater than or approximately equal to 10 cm in size.  
Based on the analyses and discussion with regulatory authorities, the clinical  program was 
reinitiated in May  2013  with a modified venetoclax dosing regimen and enhanced TLS 
prophylaxis and monitoring measures: frequent blood draws, uric acid reducing agents 
≥ [ADDRESS_234970] dose, and site education plan.  Repeat analysis in January 2014 
performed to evaluate  the effectiveness of revised measures indicated a marked reduction in 
severity and frequency of TLS when compared to the previous analysis.  None of the subjects 
experienced any serious (including fatal) or non -serious event of CTLS or laboratory TLS 
(LTLS) or had study treatment discontinued because of TLS.  The revised dosing regimen, 
which includes a more gradual increase in dose, likely led to gradual debulking of the tumor and 
played a key role in mitigating the risk.  Based on the results of this int erim analysis, follo wing 
revisions were made in May  2014:  
• All subjects starting venetoclax treatment at 20  mg QD for 1 week followed by [CONTACT_197770] 400  mg QD dose.  
• More personalized approach for prophylaxis and monitoring measures, w here subjects 
with low and medium risk for TLS could receive venetoclax on an out -patient basis with 
post-dose laboratory monitoring at 8 and 24 hours.  Subjects at high risk for TLS were 
hospi[INVESTIGATOR_197722] 20  mg and 50  mg and then mana ged on an 
out-patient basis.  
• Oral uricosurics starting 72 hours prior and oral hydration starting 48 hours prior to 
starting venetoclax; additional IV fluids for high and medium risk subjects.   Rasburicase 
is recommended for subjects at high risk, especial ly those with high baseline values.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 47 of 111  23 June  2017  
 • Reassessment of tumor burden based on current ALC followed by [CONTACT_197771], based on the investigator's discretion.  
From May  [ADDRESS_234971] r eceived venetoclax following 
the above measures in monotherapy CLL Study M13 -982 (safety expansion cohort) and Study 
M14-032. Adverse events of TLS are reported in 4/105 (3.8%) subjects, with no events of CTLS. 
Hyperkalemia (or blood potassium increased) w as the most common laboratory adverse event 
relevant to TLS, and was reported in 17/105 (16.2%; one Grade  3 event) of subjects. 
Hyperphosphatemia was reported in 15/105 (14.3%, 22 Grade  3 events) subjects; 
hypocalcaemia in 10/105 (9.5%) subjects, and hyper uricemia in 9/105 (8.6%) subjects. All 
adverse events related to clinical chemistries resolved with standard electrolyte management 
without any clinical consequences.  
Current recommendations for TLS prophylaxis and monitoring in CLL are summarized in 
Secti on 4.3.1.  
5.1.10  Rationale for the Starting Dose and Regimen Selected  
Daily oral dosing of venetoclax at 400  mg has been well tolerated in CLL patients previously as 
mono -agent therapy; higher doses have also been tested in other malignancies though without 
significantly increased efficacy in CLL/SLL.  Implementation of intra -patient dose -escalation with 
venetoclax, pre -treatment TLS risk categorization, and enhanced prophylactic guidance and 
monitoring for TLS has eliminated the significant tumor lysis that was previously seen with 
initiation of venetoclax therapy at higher doses.  A similar  use of intra -patient dose -escalation for 
venetoclax in this study will allow rapid identification of the maximal tolerable dose while 
maintaining high sensitivity for adverse  events and dose -limiting toxicities.   
5.1.11  Maximum Allowable Dose/ Overdose  
The maximum allowed dose of venetoclax in this study is [ADDRESS_234972] be 
reported as a Serious Adverse Event in the appropriate time frame and documented as clinical 
sequelae to an overdose.   
There is no specific antidote for venetoclax. In the event of an overdose,  subjects should be 
closely monitored and given appropriate supportive treatment.  
Refer to Section  7 for further information regarding AE reporting.  
5.1.12  Treatment Duration  
Treatment duration of venetoclax for this study is 2 years in  combination with ibrutinib .  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 48 of 111  23 June  2017  
 5.2 Study Drug Ibrutinib  
5.2.1  Names  
Study  drug i brutinib is approved by [CONTACT_197769] (FDA) as Imbruvica .  
The approved use s of ibrutinib are described at Section  2.2.[ADDRESS_234973] gela tin capsule containing 140  mg of ibrutinib.  All 
formulation excipi[INVESTIGATOR_9023].  Refer to the 
ibrutinib Investigator's Brochure for a list of excipi[INVESTIGATOR_840].  
The ibrutinib capsules will be packaged in opaque h igh-density polyethylene plastic bottles with 
labels bearing the appropriate label text as required by [CONTACT_9071].  All study 
drug will be dispensed in child -resistant packaging.  Study drug labels will contain information to 
meet the ap plicable regulatory requirements.  
The first dose of ibrutinib will be delivered in the clinic on Day  1, after which subsequent dosing 
is typi[INVESTIGATOR_183906].  Unused ibrutinib dispensed during previous visits must be 
returned to the site and d rug accountability records updated at each visit.  
Refer to the pharmacy manual/site investigational product manual for additional guidance on 
study drug storage, preparation and handling.  
5.2.[ADDRESS_234974] arting at Week  1 Day 1 at the FDA -approved 
dose for CLL/SLL.  
5.2.4  Mechanism of Action  
Ibrutinib was designed as a selective and covalent inhibitor of Bruton’s tyrosine kinase (BTK).34 
In vitro, ibrutinib is a potent inhibitor of BTK activity (IC 50 = 0.39 nM).  The irreversible binding of 
ibrutinib to cysteine -481 in the active site of BTK results in sustained inhibition of BTK catalytic 
activity and enhanced selectivity over other kinases that do not contain a cysteine at this 
position.  When added directly to h uman whole blood, ibrutinib inhibits signal transduction from 
the B -cell receptor and blocks primary B -cell activation (IC 50 = 80 nM) as assayed by [CONTACT_14181] -IgM 
stimulation followed by [CONTACT_398]69 expression .35 
For more detailed and comprehensive information regardin g pharmacology, refer to the current 
Investigator’s Brochure.  
5.2.5  Non-Clinical and Clinical Pharmacokinetics  
Following oral administration of ibrutinib at doses ranging from 1.25  to 12.5 mg/kg/day as well 
as fixed dose levels of 420, 560, and 840  mg/day, expos ure to ibrutinib increased as doses 
increased, with substantial inter -subject variability.  The mean half -life (t 1/2) of ibrutinib across 
3 clinical studies ranged from 4  to 9 hours, with a median time  to maximum plasma 
concentration (T max) of [ADDRESS_234975] dose at dose levels ≥  2.5 mg/kg.  In Study 
PCYC -[ZIP_CODE], the BTK occupancies for the 2.5  mg/kg/day  to 12.5 mg/kg/day cohorts and for the 
560 mg continuous dosing cohort were all above 90% at either [ADDRESS_234976] comprehensive nonclinical information regarding ibrutinib, refer to the current 
version of the Investigator's Brochure.  
[IP_ADDRESS]  Non -Clinical Toxicology Studi es 
In safety pharmacology assessments, no treatment -related effects were observed in the central 
nervous system or respi[INVESTIGATOR_14128].  Further, no treatment -related 
corrected QT interval (QTc) prolongation effect was observed at  any tested dose in a 
cardiovascular study using telemetry -monitored dogs.  
Based on data from rat and dog including general toxicity studies up to [ADDRESS_234977] potential for human toxicity with ibrutinib is predicted to be in lymphoid ti ssues 
(lymphoid depletion) and the gastrointestinal tract (soft feces/diarrhea with or without 
inflammation).  Additional toxicity findings seen in only one species with no observed human 
correlate in clinical studies to date include pancreatic acinar cell  atrophy (rat), minimally 
decreased trabecular and cortical bone (rat) and corneal dystrophy (dog).  
In vitro and in vivo genetic toxicity studies showed that ibrutinib is not genotoxic.  In a rat 
embryo -fetal toxicity study ibrutinib administration was ass ociated with fetal loss and 
malformations (teratogenicity) at ibrutinib doses that result in approximately 6 times and 
14 times the exposure (AUC) in patients administered the dose of 560  mg daily, respectively.  
[IP_ADDRESS]  Carcinogenesis, Mutagenesis, Impair ment of Fertility  
Carcinogenicity studies have not been conducted with ibrutinib.  
Ibrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay, was not clastogenic in a 
chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in  an in vivo 
bone marrow micronucleus assay in mice at doses up to 2000  mg/kg. 
Fertility studies with ibrutinib have not been conducted in animals.  In the general toxicology 
studies conducted in rats and dogs, orally administered ibrutinib did not result i n adverse effects 
on reproductive organs.  
5.2.7  Summaries of Clinical Studies  
The initial study of ibrutinib in relapsed/refractory CLL patients demonstrated an ORR of 90% 
but only a 7% CR rate with a median treatment duration of [ADDRESS_234978] 
compre hensive clinical information regarding ibrutinib, refer to the current version of the 
Investigator's Brochure.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 50 of 111  23 June  2017  
 5.2.8  Major Route of Elimination  
The results of human mass balance study of [14C]-ibrutinib conducted in 6  healthy male subjects 
demonstrated that less  than 10% of the total dose of [14C]-ibrutinib is renally -excreted, whereas 
approximately 80% is recovered in feces.  Subjects with mild and moderate renal insufficiency 
(creatinine clearance >  30 mL/min) were eligible to enroll in Study PCYC -1102 -CA in wh ich 
pharmacokinetic (PK) assessments were included.  No dose adjustment is needed for mild or 
moderate renal impairment (greater than 30  mL/min creatinine clearance).  There is no data in 
patients with severe renal impairment or patients on dialysis.  In a  hepatic impairment study, 
data showed an increase in ibrutinib exposure.  Following single dose administration, the AUC 
of ibrutinib increased 2.7 -, 8.2- and 9.8 -fold in subjects with mild (Child -Pugh class A), moderate 
(Child -Pugh class B), and severe (C hild-Pugh class C) hepatic impairment compared to 
subjects with normal liver function.  The safety of ibrutinib in patients with hepatic impairment is 
currently in progress.  
5.2.[ADDRESS_234979] completed primary or final analysis included in the CSR 
as of 12 November 2019 are summarized below . Therapi[INVESTIGATOR_197723], included BR (bendamusti ne and rituximab), FCR (fludarabine, 
cyclophosphamide, and rituximab), cytarabine, azacytidine, dexamethasone, durvalumab, 
ofatumumab,  lenalidomide with EPOCH -R (cyclophosphamide, doxorubicin, etoposide, 
vincristine, prednisone +/ - rituximab), nivolumab, O binutuzumab, rituximab, carfilzomib +/ - 
dexamethasone, pomalidomide and dexamethasone  and R -CHOP (rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone).  
IRB-[ADDRESS_234980]  frequently reported TEAEs in subjects receiving ibrutinib in combinatio n 
therapy (N  = 1,971 ) 
Most frequently reported 
TEAEs >  20% Most frequently reported 
Grade  3 or 4 TEAEs >  3% Most frequently reported 
Serious TEAEs >  2% 
Neutropenia  
Diarrhea  
Nausea  
Thrombocytopenia  
Fatigue  
Anemia  
Pyrexia  
Cough  
Upper respi[INVESTIGATOR_197724] , refer to the current version of the IB.  
[IP_ADDRESS]  Bleeding -related Events  
There have been rep orts of hemorrhagic events in subjects treated with ibrutinib both with and 
without thrombocytopenia.  These include minor hemorrhagic events such as contusion, 
epi[INVESTIGATOR_3940], and petechiae; and some major hemorrhagic events , some fatal,  including 
gastrointest inal bleeding, intracranial hemorrhage and hematuria.  Use of ibrutinib in subjects 
requiring other anticoagulants or medications that inhibit platelet function increase s the risk of 
major bleeding.  A higher risk for major bleeding was observed with antic oagulant than with 
antiplatelet agents. Consider the risks and benefits of anticoagulant or antiplatelet therapy when 
co-administered with ibrutinib. Monitor for signs and symptoms of bleeding. Subjects with 
congenital bleeding diathesis have not been stud ied.  See Section  [IP_ADDRESS] for guidance on 
concomitant use of anticoagulants, antiplatelet therapy and/or supplements.  See Section  4.3.5 
for guidance  on ibrutinib management with surgeries or procedures.   In an in vitro platelet 
function study, inhibitory effects of ibrutinib on collagen induced platelet aggregation were 
observed, refer to Section  [IP_ADDRESS]. Supplements such as fish oil and vitamin E preparations 
should be avoided.  
Ibrutinib should be held at least [ADDRESS_234981] -surgery, dependin g upon the type of 
surgery and the risk of bleeding.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 52 of 111  23 June  2017  
 [IP_ADDRESS]  Cardiac Arrhythmias  
Atrial fibrillation , atrial flutter and cases of ventricular tachyarrhythmia including some fatal 
events, have been reported in subjects treated with ibrutinib, particularly in subjects with cardiac 
risk factors, hypertension, acute infections, and a previous history of atrial fibrillation. 
Periodically monitor subjects clinically for cardiac arrhythmia.  Subjects who develop arrhythmic 
symptoms (eg, palpi[INVESTIGATOR_814], lightheadedne ss, syncope, chest discomfort  or new onset of 
dyspnea ) should be evaluated clinically, and if indicated, have an ECG performed.  For cardiac 
arrhythmias  that persists, consider the risks and benefits of ibrutinib treatment and follow the 
protocol dose modi fication guidelines.  
[IP_ADDRESS]  Cytopenias  
Treatment -emergent Grade  3 or 4 cytopenias (neutropenia, thrombocytopenia, and anemia) 
were reported in subjects treated with ibrutinib.   Monitor complete blood counts monthly . 
[IP_ADDRESS]  Diarrhea  
Diarrhea is the most  frequently reported non -hematologic AE with ibrutinib monotherapy and 
combination therapy.  Other frequently reported gastrointestinal events include nausea, 
vomiting, and constipation.  These events are rarely severe  and are generally managed with 
suppor tive therapi[INVESTIGATOR_66809] .  Subjects should be monitored 
carefully for gastrointestinal AEs and cautioned to maintain fluid intake to avoid dehydration. 
Medical evaluation should be made to rule out other etiologies such as Clostridium difficile or 
other infectious agents. Should symptoms be severe or prolonged, follow the protocol dose 
modification guidelines.  
[IP_ADDRESS]  Infections  
Infections (sepsis, bacterial, viral, or fungal infections) were observed in subjects treated  with 
ibrutinib therapy.  Some of these infections have been associated with hospi[INVESTIGATOR_88475].  Consider prophylaxis according to standard of care in subjects who are at risk for 
opportunistic infections.  Although causality has not been established, c ases of progressive 
multifocal leukoencephalopathy  (PML) and hepatitis B reactivation have occurred in subjects 
treated with ibrutinib.  Subjects should be monitored for signs and symptoms (fever, chills, 
weakness, confusion , vomiting and jaundice ) and app ropriate therapy should be instituted as 
indicated.  
[IP_ADDRESS]  Non-melanoma Skin Cancer  
Non-melanoma skin cancers have occurred in subjects treated with ibrutinib.  Monitor subjects 
for the appearance of non -melanoma skin cancer . 
[IP_ADDRESS]  Rash  
Rash has been  commonly reported in subjects treated with either single agent ibrutinib or in 
combination with chemotherapy.  Rash occurred at a higher rate in the ibrutinib arm than in the 
ofatumumab arm in Study 1112. Most rashes were mild  to moderate in severity.   Isolated cases 
of severe cutaneous adverse reactions  (SCARs) including Stevens -Johnson syndrome  (SJS) 
have been reported in subjects treated with ibrutinib.  Subjects should be closely monitored for 
signs and symptoms suggestive of SCAR including SJS.  Subje cts receiving ibrutinib should be 
observed closely for rashes and treated symptomatically, including interruption of the suspected 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 53 of 111  23 June  2017  
 agent as appropriate.  In addition, hypersensitivity -related events including erythema; urticaria; 
and angioedema have been r eported . 
[IP_ADDRESS]  Lymphocytosis and Leukostasis  
[IP_ADDRESS].1  Lymphocytosis  
Upon initiation of treatment, a reversible increase in lymphocyte counts (ie, ≥  50% 
increase from baseline and an absolute count >  5000/µL), often associated with 
reduction of lymphadenopathy, has been observed in most subjects  (66%)  with CLL/ 
small lymphocytic lymphoma (SLL) treated with ibrutinib.  This effect has also been 
observed in some subjects with MCL treated with ibrutinib.  This observed 
lymphocytosis (increase in the number of circul ating lymphocytes eg, >  400,000/µL) is a 
pharmacodynamic effect and should not be considered progressive disease in the 
absence of other clinical findings.  In both disease types, lymphocytosis typi[INVESTIGATOR_197725] (median time 1.1  weeks) and typi[INVESTIGATOR_197726] a median of 8.0  weeks in subjects with MCL and 14 weeks in subjects 
with CLL/SLL  (range 0.1 to 104 weeks) .   
When ibrutinib was administered in combination with BR or with obinutuzumab in 
subjects wi th CLL/SLL, lymphocytosis was infrequent (7% with ibrutinib + BR versus 6% 
with placebo + BR and 7% with ibrutinib + obinutuzumab versus 1% with chlorambucil + 
obinutuzumab).  
Lymphocytosis was not observed with WM treated with ibrutinib.   
[IP_ADDRESS].2  Leukostasis  
There were isolated cases of leukostasis reported in subjects treated with ibrutinib.  A high 
number of circulating lymphocytes (>  400,000/µL) may confer increased risk. Consider 
temporarily withholding ibrutinib. Subjects should be closely monitored. Admini ster supportive 
care including hydration and/or cytoreduction as indicated.  For subject and ibrutinib 
management guidance, refer to Section  [IP_ADDRESS].  
[IP_ADDRESS]  Tumor Lysis Syndrome  
Tumor lysis syndrome has been reported with ibrutinib therapy. Subjects at r isk of tumor lysis 
syndrome are those with high tumor burden prior to treatment . Monitor subjects closely and take 
appropriate precautions . 
[IP_ADDRESS]  Interstitial Lung Disease  
Cases of interstitial lung disease  (ILD) have been reported in subjects treated with ibrutinib.  
Monitor subjects for pulmonary symptoms indicative of ILD.  If symptoms develop, interrupt  
ibrutinib and manage ILD appropriately. If symptoms persist, consider the risks and benefits of 
ibrutinib treatment and  follow the protocol dose modi fication guidelines (see Section  6).  
[IP_ADDRESS]  Hypertension   
Hypertension has occurred in subjects treated with ibrutinib.  Regularly monitor blood pressure 
in subjects treated with ibrutinib and initiate or adjust antihypertensive medication throughout 
treatment with ibrutinib as appropriate .  
IRB-[ADDRESS_234982] -marketing setting, with and without concomitant atrial 
fibrillation and/or hypertension. Regular monitoring and appropriate treatment of 
conditions that can contribute to the occurrence of these events is recommended.  
Long -term safety  
The long-term safety data over 5 years from 1,178 subjects (treatment -naїve CLL/SLL n 
= 162, relapsed/refractory CLL/SLL n=646, and relapsed/refractory MCL n=370) treated 
with ibrutinib were analyzed. The median duration of treatment for CLL/SLL was 51 
months (range, 0.2 to 98 months) with 70% and 52% of subjects receiving treatment for 
more than 2 years and 4 years, respectively. The median duration of treatment for MCL 
was 11 months (range, 0 to 87 months) with 31% and 17% of subjects receiving 
treatment for more than 2 years and 4 years, respectively. The overall known safety 
profile of ibrutinib -exposed subjects remained consistent, other than an increasing 
prevalence of hypertension, with no new safety concerns identified. The prevalence for 
Grade 3 or grea ter hypertension was 4% (year 0 -1), 6% (year 1 -2), 8% (year 2 – 3), 9% 
(year 3 - 4), and 9% (year 4 -5). The incidence for the 5 -year period was 11%.  
[IP_ADDRESS]  Rationale for the Starting Dose and Regimen Selected  
This study uses the FDA approved dose of ib rutinib 420  mg PO daily for CLL/SLL.  Dose 
reduction of ibrutinib is allowed for attributable toxicity as specified in Section  6.2. 
[IP_ADDRESS]  Maximum Allowable Dose  / Overdose  
There are limited data on the effects of ibrutinib overdose.  No  maximum tolerat ed dose  (MTD) 
was reached in the Phase  1 study in which subjects received up to 12.5  mg/kg/day 
(1400  mg/day).  In a separate study, [ADDRESS_234983] who received a dose of 1680  mg 
experienced reversible Grade 4  hepatic enzyme increases (AST and ALT). Ther e is no specific 
antidote to ibrutinib. Subjects who ingest more than the recommended dosage should be closely 
monitored and given appropriate supportive treatment . 
Refer to Section  7 for further information regarding AE reporting.  
[IP_ADDRESS]  Treatment Dura tion 
All study participants will receive ibrutinib daily starting at Week  1 Day 1 and be dosed 
continuously throughout the study until  completion of 2 years combined therapy with venetoclax,  
disease progression, development of intolerable side effects, nee d to initiate prohibited 
therapi[INVESTIGATOR_014], or participant withdrawal.  Upon completion of ibrutinib + venetoclax combination 
treatment at Week 117, participants will have completed the trial and may transition off -study to 
receive commercial ibrutinib at the discr etion of the investigator.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 55 of 111  23 June  2017  
 5.3 Study Drug Supply  
5.3.1  Venetoclax Drug Supply  
Venetoclax will be supplied by [CONTACT_197772] .  
[IP_ADDRESS]  Venetoclax Ordering  
The investigational pharmacist will request drug supply using the form in Appendix H.   
The form should be sent to [EMAIL_3904] .  
5.3.2  Ibrutinib Drug Supply  
Ibrutinib will be supplied by [CONTACT_14190] .   
[IP_ADDRESS]  Ibrutinib Ordering  
The investigational pharmacist will request drug supply using the form in Appendix I.  
The form should b e sent to [EMAIL_3905] .   
5.[ADDRESS_234984] be maintained under adequate security and stored under conditions 
specified on the label.  The venetoclax tablets mus t be stored at 15°  to 25°C (59°  to 77°F).  
Ibrutinib must be kept in a locked limited access room.  The study drug must not be used 
outside the context of the protocol.  Under no circumstances should the Investigator or other site 
personnel supply ibrutinib  or venetoclax to other Investigators, subjects, or clinics or allow 
supplies to be used other than as directed by [CONTACT_3181].  An Investigational Drug 
Accountability Log must be used for drug accountability.  For accurate accountability, the 
following information must be noted when drug supplies are used during the study:  
1. Study identification number  
2. Subject identification number  
3. Lot number(s) of ibrutinib or venetoclax dispensed for that subject  
4. Date and quantity of drug dispensed  
5. Any unused drug ret urned by [CONTACT_423]  
6 DOSE MODIFICATIONS  AND DISCONTINUATION  
6.1 Venetoclax Dose Modification  
If one or more electrolyte changes (from the pre -dose value) suggestive of tumor lysis syndrome 
(TLS) occurs within 24  hours of venetoclax initiation (20  mg dose) or  dose escalation (50, 100, 
200, 400  mg doses) and is confirmed by a repeat laboratory test within 1  to 2 hours, 
no additional venetoclax doses will be administered until resolution  (within normal range)  of 
those laboratory abnormalities.  Upon resolution o f laboratory abnormalities, the subject will 
remain at the current dose level of venetoclax (eg,  if receiving 20  mg, will remain at 20  mg) 
through [ADDRESS_234985] ration of live attenuated vaccines 
prior t o, during, or after venetoclax treatment  (prohibited in this protocol)  and embryo -fetal 
toxicity.   
See also Section  6.3 Dose Modification for Both Venetoclax and Ibrutinib.  
6.2 Ibrutinib Dose Modification  
The dose of ibrutinib should be modified according t o the dose m odification guidelines in 
Table  4 if any of the following toxicities attributable to ibrutinib occur:  
• Grade  3 or greater non -hematological toxicities.  
• Grade  3 or greater neutropenia with infection or fever  
• Grade  3 thrombocytopenia (<  50,000/µL ) in the presence of clinically -significant 
bleeding  events.  
• Grade 4 hematological toxicities, including  thrombocytopenia <  20,000/µL.  
If clinically indicated, the use of anticoagulants or antiplatelet agents may be considered for the 
thromboprophylaxis of  atrial fibrillation ( Section  [IP_ADDRESS]).  
Recommended dose modifications are described in Table  [ADDRESS_234986] Withhold ibrutinib  until recovery to Grade  ≤ 1 or baseline; may restart at  
original dose level  (420 mg/day)  
Second  Withhold ibrutinib until recovery to Grade  ≤ 1 or baseline; restart at 
≤ 280 mg/day  
Third  Withhold ibrutinib until recovery to Grade  ≤ 1 or baseline; restart at 
≤ 140 mg/day  
Fourth  Discontinue ibrutinib  
A high  number of circulating malignant cells (>  400,000/uL) may confer increased risk of 
leukostasis; these subjects should be closely monitored.  Administer supportive care such as 
hydration and/or leukapheresis as indicated.  Ibrutinib may be temporarily held .  
[IP_ADDRESS]  Dose Modification for Hepatic -Impaired Subjects  
Subjects who develop acute hepatic toxicity with liver enzymes Grade [ADDRESS_234987] dose modification guidelines in Section Error! Reference 
source not found. . Ibrutinib is metabolized in the liver. In the population PK analysis (1,202 
subjects), 179 subjects (14.9%) had mild hepatic impairment according to National Cancer 
Institute criteria and 12 subjects (1.0%) had mode rate hepatic impairment. These subjects did 
not show a significantly higher ibrutinib exposure compared with subjects with normal hepatic 
function. In a hepatic impairment study, data showed an increase in ibrutinib exposure. For 
subjects with mild liver i mpairment (Child -Pugh class A), the recommended dose is 280mg 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 57 of 111  23 June  2017  
 daily. For subjects with moderate liver impairment (Child -Pugh class B), the recommended dose 
is 140mg daily. Monitor subjects for signs of ibrutinib toxicity and follow dose modification 
guidan ce as needed. It is not recommended to administer ibrutinib to subjects with severe 
hepatic impairment Subjects with clinically significant chronic hepatic impairment at the time of 
Screening (Child - Pugh class C) are excluded from study participation. Con comitant use of 
strong CYP inhibitors is not permitted in subjects with chronic hepatic impairment. Refer to 
Appendix D for Child -Pugh classification. Please refer to table below  for dose modifications due 
to hepatic impairment.  
Table .   Dose Modification  Guidance for Hepatic Impaired Subjects  
 Child Pugh class A  
(Mild hepatic 
impairment)*  Child Pugh Class B  
(Moderate hepatic 
impairment)**  Child Pugh class 
C 
(Severe hepatic 
impairment)  
 Ongoing at 
time of 
enrollment  Develops 
during 
study  Ongoing at time 
of enrollment  Develops 
during study  Develops during 
study  
Ibrutinib 
Dose 
(daily)  280 mg  280mg  140 mg  140 mg  Hold until 
improves to 
moderate [Class 
B] or better)  
* If further reduction is needed due to non -hepatic toxicity, dose may be reduced to 140 mg. I n 
the event that additional reduction is needed, ibrutinib should be held for non -hepatic toxicity 
until resolution.  
** If further reduction is needed due to non -hepatic toxicity, ibrutinib should be held until 
resolution.  
[IP_ADDRESS]  Leukocytosis / Leukostasis  
There were isolated cases of leukostasis reported in subjects treated with ibrutinib. A high 
number of circulating white blood cells (>400,000/µL) may confer in creased risk of leukostasis;  
these subjects should be closely monitored.  Administer supportive car e such as hydration 
and/or leukapheresis as indicated.  Consider temporarily withholding ibrutinib , and medical 
monitor should be contact[INVESTIGATOR_530].  
6.3 Dose Modification for Both Venetoclax and Ibrutinib  
If the events below occur, no  additional venetoclax doses wil l be administered until resolution of 
those laboratory abnormalities  (≤ Grade  1), and ibrutinib dosing should continue or be 
discontinued per Table  4.   
• Grade  4 ANC (<  500/µL) for more than 7  days.  See Section  4.3.2  for instructions 
regarding the use of g rowth factor support.  
• Any other Grade  [ADDRESS_234988] if 
any of the following occur.  
• Grade  4 treatment -related (ie, possibly -, probably -, or definitely -related) non-hematologic 
toxicity.  
• Grade  4 neutropenia lasting >  21 days  
• Grade  4 thrombocytopenia lasting >  21 days or associated with clinically -significant 
bleeding (requiring >  [ADDRESS_234989] loss 
OR bleeding from a site which in the Investigator’s opi[INVESTIGATOR_197727] a potential life -threatening 
source irrespective of blood loss)  
IRB-[ADDRESS_234990] evaluation time points during the study.  All adverse events (AE) and serious adverse 
events (SAE) whether volunteered by [CONTACT_423], discovered by [CONTACT_168204], detected through physical examination, clinicall y significant laboratory test, or other 
means, will be recorded.  Each recorded adverse event or serious adverse event will be 
described by [CONTACT_13662] (ie,  start and end dates), severity, regulatory seriousness criteria (if 
applicable), suspected relatio nship to the investigational product, and any actions taken.  
The Protocol Director or designee will assess each AE to determine whether it is unexpected 
according to the Investigator’s  Brochure; Protocol; and Informed  Consent, and whether it is 
related to the investigation (eg, study  procedures) and/or the investigational  agent.  All SAEs will 
be tracked until resolution, or until at  least [ADDRESS_234991] a causal relationship with this treatment.  An AE can 
therefore be any unfavorable and unintended sign (including a clinically significant abnormal 
laboratory finding,  for example), symptom, or disease temporally associated with the use of an 
investigational study drug, whether or not considered related to the study drug (ICH -E2A, 1995).  
For the purposes of this clinical study, AE s include events which are either new or  represent 
detectable exacerbations of pre -existing conditions.  
The term “disease progression” should not be reported as an adverse event term.  As an 
example, "worsening of underlying disease" or the  clinical diagnosis that is associated with 
disease prog ression should be reported.  
Adverse events may include, but are not limited to:  
• Subjective or objective symptoms provided by [CONTACT_3184]/or observed by [CONTACT_14204].  
• Any AEs  experienced by [CONTACT_183981].  
• AEs not previously observed in the subject that emerge during the protocol -specified AE 
reporting period, including signs or symptoms associated with the underlying disease 
that were not present before the AE reporting period  
• Complications that occur due to  protocol -mandated interventions (eg,  invasive 
procedures such as biopsies).  
The following are NOT  considered AEs:  
• Pre-existing condition:  A pre -existing condition (documented  on the medical history 
CRF) is not considered an AE unless the severity, frequency, or character of the event 
worsens during the study period.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 60 of 111  23 June  2017  
 • Diagnostic Testing and Procedures:  Testing and procedures should not to be 
reported as AEs or SAEs, but rather the cause for the test or procedure should be 
reported.  
• Asymptomatic Treatment -related Lymphocytosis:  This event should also not be 
considered an AE.  Subjects with treatment -related lymphocytosis should remain on 
study treatment and continue with all stu dy-related procedures.  
An “unexpected” AE is an AE that is not listed in the Investigator's Brochure/package insert or is 
not listed at the specificity or severity that has been observed .  "Unexpected" also refers to AEs 
that are mentioned in the Investiga tor's Brochure as occurring with a class of drugs or as 
anticipated from the pharmacological properties of the drug, but are not specifically mentioned 
as occurring with the study drug under investigation .   
7.1.1  Serious Adverse Events Definition  
For this inves tigational drug study, AEs will be determined to be Serious Adverse Events (SAEs) 
per 21CFR §312.32(a) and ICH  GCP  E6r1 (revision  1).  An adverse event is considered 
"serious" if, in the opi[INVESTIGATOR_197728];  investigator;  or sponsor, it resul ts in any of 
the following.  
• Death  
• Life-threatening, ie, immediate risk of death  
(NOTE:  Life-threatening does NOT include laboratory values that are “ Grade  4 
Life-threatening” per CTCAE v4.03, unless there is an immediate risk of death ) 
• Requires, results in, or prolongs inpatient hospi[INVESTIGATOR_059]  
• Is a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions  
• Is a congenital anomaly/birth defect in the offspring of a study participant  
• Jeopardizes the subj ect, in the opi[INVESTIGATOR_197728];  investigator;  or sponsor  
• Requires medical or surgical intervention to prevent one of the outcomes listed in this 
definition, in the opi[INVESTIGATOR_197728]; investigator; or sponsor  
The following are  NOT  considered SAEs:  
• Pre-planned or elective hospi[INVESTIGATOR_059]:  A hospi[INVESTIGATOR_14147], but rather a therapeutic intervention.  
However, if during the pre -planned hospi[INVESTIGATOR_197729], which prolongs the 
hospi[INVESTIGATOR_14149], the event will be considered an SAE.  
Surgeries or interventions that were under consideration, but not performed before 
enrollment in the study, will not be considered serious if  they are performed after 
enrollment in the study for a condition that has not changed from its baseline level.  
Elective hospi[INVESTIGATOR_14150], solely for the administration of 
chemotherapy, or due to long travel distances are also not SAEs.  
7.2 Adverse Event Reporting  
Adverse events (AEs) will be graded according to CTCAE v4.03, except as noted below.  The 
CTCAE v4.[ADDRESS_234992] experience an y AE not listed in the CTCAE v4.03 the following 
grading system should be used to assess severity:  
• Grade  1 (Mild AE) – experiences which are usually transient, requiring no special 
treatment, and not interfering with the subject’s daily activities  
• Grade  2 (Moderate AE) – experiences which introduce some level of inconvenience or 
concern to the subject, and which may interfere with daily activities, but are usually 
ameliorated by [CONTACT_14212]  
• Grade  3 (Severe AE) – experiences which are unaccep table or intolerable, significantly 
interrupt the subject’s usual daily activity, and require systemic drug therapy or other 
treatment  
• Grade  4 (Life -threatening or disabling AE) – experiences which cause the subject to be 
in imminent danger of death  
• Grade  5 (Death related to AE) – experiences which result in subject death  
All treatment -emergent AEs will be captured from the first dose of study drug.  SAEs will be 
reported to the Sponsor from the time of ICF signing.  Both serious and non -serious AEs will be  
recorded in the eCRF from the first dose of study drug until [ADDRESS_234993] dose of study drug should also 
be reported if considered related to study drug.  Resol ution information after 30  days should be 
provided.  
Progressive disease should NOT be reported as an event term, but instead symptoms/clinical 
signs of disease progression may be reported.  
All adverse events, regardless of seriousness, severity, or presume d relationship to study drug, 
must be recorded using medical terminology in the source document.  All records will need to 
capture the details of the duration and the severity of each epi[INVESTIGATOR_1865], the action taken with 
respect to the study drug, investigator’s  evaluation of its relationship to the study drug, and the 
event outcome.  Whenever possible, diagnoses should be given when signs and symptoms are 
due to a common etiology (eg,  cough, runny nose, sneezing, sore throat, and head congestion 
should be report ed as "upper respi[INVESTIGATOR_4416]").  Investigators must record in the eCRF their 
opi[INVESTIGATOR_197730], as death is 
typi[INVESTIGATOR_197731], not the event itself.  If a death occurs within [ADDRESS_234994] be reported as a serious adverse event.  
All serious adverse events  (SAEs) and AESIs (initial and follow -up information) wil l be reported 
to the FDA Medwatch (Form  3500A) or Suspect Adverse Event Report (CIOMS  Form  1) IRB 
Reporting Form and sent via email ( AEintakeCT@pcyc ) or fax ( [PHONE_4272]) to Pharmacyclics 
Drug Safety, or designee , within [ADDRESS_234995] follow -up 
and other additional information from the Sponsor Investigator.  
All serious adverse events  (SAEs) CTCAE Grade  [ADDRESS_234996] Cancer Institute  (SCI)  Data and Safety Monitoring 
Committee  (DSMC) using the study -specific CRF regardless of the event’s relatedness to the 
investigation.  Following review by [CONTACT_6802], events meeting the IRB definition of 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 62 of 111  23 June  2017  
 “Unanticipated  Problem” will  be reported to the IRB using eProtocol within 10  working  days of 
DSMC review, or within 5  working  days for deaths or life -threatening experiences  
AEs, serious or otherwise, will be attributed to study  treatment as follows:  
• Definite :   The AE is clearly  related to the study treatment.  
• Probable :   The AE is likely  related to the study treatment.  
• Possible :   The AE may  be related to the study treatment.  
• Unlikely :   The AE is doubtfully  related to the study treatment.  
• Unrelated :   The AE is clearly NOT  related  to the study treatment.  
All serious adverse events  (SAEs) will be followed until the SAE(s) is(are) resolved, stabilized, 
returned to baseline, attributed to agents other than the study drugs or to factors unrelated to 
study conduct, or until additional i nformation cannot be obtained (subject or health care 
practitioner refusal to provide additional information, lost  to follow -up after demonstration of due 
diligence with follow -up efforts), whichever is longer.   
Adverse events that are serious and unexpec ted suspected adverse reactions, ie,  are possibly, 
probably, or definitely related to the study drugs venetoclax and ibrutinib, will be reported to the 
FDA via IND  Safety  Report [ 21CFR §312.32 ] within [ADDRESS_234997] Data and Safety Monitoring Committee  (DSMC).  SAEs 
will be reported by [CONTACT_197773].  SAEs that 
meet the definition of an “Unanticipated  Problem” per the Stanford  DSMC will be reported to the 
Stanford  IRB using eProtocol within [ADDRESS_234998] DSMC’s report to the 
Protocol  Director regarding the event (within 5  working days for deaths or life -threatening 
events).  See also Section  10.3 Data and Safety Monitoring Plan.  
All serious adverse events  (SAEs) that are CTCAE Grade  [ADDRESS_234999] itute Data and Safety Monitoring 
Committee (DSMC) using the study specific CRF regardless of the event’s relatedness to the 
investigation.   
All SAEs will be reported will be reporting to the IRB in the annual Continuing  Review, or the 
Final Report, that i s submitted to the IRB.  
7.4 Adverse Events of Special Consideration  
7.4.1  Second Malignancy vs Secondary Malignancy  
[IP_ADDRESS]    Second Malignancy  
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a 
metastasis from the initial malignancy).   All new malignant tumors including solid tumors, skin 
malignancies and hematologic malignancies will be reported as SAEs per the current Stanford 
SOP, for the duration of study treatment and during any protocol -specified follow -up periods 
including post -progression follow -up for overall survival.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 63 of 111  23 June  2017  
 [IP_ADDRESS]    Secondary Malignancy  
In the context of a clinical study, a secondary malignancy is a cancer caused by [CONTACT_197774]/intervention, radiation, or chemotherapy.  A secondary malignancy is not 
considere d a metastasis of the initial neoplasm.  All secondary malignancies will be reported as 
SAEs per the current Stanford SOP.  Three  options/examples are available to describe the 
event:   
• Leukemia secondary to oncology chemotherapy [eg, acute myeloid leukemi a (AML)]  
• Myelodysplastic syndrome  (MDS)  
• Treatment -related secondary malignancy  
By [CONTACT_108], secondary malignancies are serious and related adverse events, and require 
expedited reporting.  
7.4.2  Other Adverse Events of Special Considerations  
[IP_ADDRESS]    Adverse Event s of Special Interest (AESI)  
Specific adverse events, or groups of adverse events, will be followed as part of standard safety 
monitoring activities.  In addition to normal reporting, these events (regardless of seriousness) 
will be reported on the Serious  Adverse Event Report Form and sent via email or fax to 
Pharmacyclics Drug Safety , Pharmacovigilance & Epi[INVESTIGATOR_623] (DSP&E) , or designee within 
15 days of awareness . 
• Major Hemorrhage, as defined by [CONTACT_39132]:  
o Any treatment -emergent hemorrhagic a dverse events of Grade  3 or higher . *  
o Any treatment -emergent serious adverse events of bleeding of any grade.  
o Any treatment -emergent central nervous system hemorrhage/hematoma of any 
grade.  
* All hemorrhagic events requiring transfusion of red blood cells  should be reported as 
Grade  3 or higher AE per CTCAE  v4.03 .  
[IP_ADDRESS]    Eye-Related Adverse Events  
New or worsening eye -related symptoms that are Grade  [ADDRESS_235000] whose 
findings should be reported in the CRF .  
[IP_ADDRESS]    Pregnancy  
Before study enrollment, subjects must agree to take appropriate measures to avoid pregnancy.  
However, should a pregnancy occur in a female study subject, consent to provide follow -up 
informat ion regarding the outcome of the pregnancy and the health of the infant until [ADDRESS_235001] dose of study drug.  Any female subjects receiving study drug(s) who become 
IRB-[ADDRESS_235002]’s partner from the time of consent 
to [ADDRESS_235003] be reported to Pharmacyclics Drug Safety, or designee, per SAE reporting timelines.  All 
pregnancies will be followed for outcome, which is defined as elective termination of the 
pregnancy, mis carriage, or delivery of the fetus.  Pregnancies with an outcome of live birth, the 
newborn infant will be followed until 30  days old by [CONTACT_197775].  Any congenital anomaly/birth defect noted in the 
infant must be reported as a serious adverse event.  
7.5 Case Report Forms  (CRFs) for Adverse Event Reporting  
Both SAEs and non -serious AEs will be clearly described in source documentation and listed on 
study -specific Case Report Forms  (CRFs or eC RFs) .  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 65 of 111  23 June  2017  
 8 CORRELATIVE / SPECIA L STUDIES  
8.1 Pharmacokinetics Assessments: Collected at Stanford Cancer 
Institute Site ONLY  
Ibrutinib:  
Pharmacokinetic samples for ibrutinib will be collected pre -dose (window: 30  to 60 minutes 
before dose), then 1  hour (window: 45  to 75 minutes); 2  hours (window: 1.5  to 2.5 hours); 
4 hours (window: 3.5  to 4.5 hours); and 6  hours (window 5.5  to 6.5 hours) post -ibrutinib 
administration on the first day of ibrutinib dosing (Week  1 Day 1) and each day when dosed in 
combination with new ly-escalated dose of venetoclax in all  subjects enrolled in the study.   
Venetoclax:  
Pharmacokinetic samples for venetoclax will be collected at 0, 8, 24  hours with each 
dose -escalation of venetoclax.  
8.2 Biomarker Assessments  
Blood for CLL FISH  
Approximately 4 mL of blood will be collected by [CONTACT_112777] a heparin vacutainer from 
subjects at the following time point:  
• Screening or Week  1 Day 1 pre -dose  
Blood for Mutation Profiling  
Approximately 10 mL of blood will be collected by [CONTACT_197776]:  
• Week  1 Day 1 pre -dose  
• Final Visit/Time of Relapse  
Blood /Bone Marrow  for ClonoSEQ  Sequencing  
Approximately 10 mL of blood will be collected by [CONTACT_197777] s: 
Blood:  
• Week  1 Day 1 pre -dose  or anytime between screening and start of treatment  
• Within 1 month of completion of therapy  at Week 117  
Bone Marrow:  
• Week [ADDRESS_235004]'s legally acceptable representative  before any study -specific 
procedures are undertaken or before any prohibited medications are withheld from the subject 
to participate in this study.  After signing the informed consent form, screening and meeting 
inclusion/exclusion criteria for trial enr ollment, Stanford will assign subjects a unique 
consecutive subject number.  
9.1.[ADDRESS_235005] dose as possible.  
During the treatment and follow -up periods, AE and assessment will occur on an ongoing basis.  
Local labs will be used to guide all dosing -related decisions.  
Treatment will initiate on Week  1 Day 1 with ibrutinib 420  mg PO da ily.  For tumor lysis 
prophylaxis, all subjects will be classified into 3 risk categories based on the risk for developi[INVESTIGATOR_197732]  (ie, after 8  weeks of ibrutinib administration)  as detailed 
in Section  4.3.1.   
Subjects in lo w category and medium risk category with CrCl ≥  80 mL/min and low tumor 
burden will begin treatment with venetoclax in the outpatient setting with an initial dose of 20  mg 
venetoclax on Week  9 Day 1.  If no significant findings suggestive of clinical or la b TLS occur 
within 24  hours, the same dose will be continued until  Day 7 in the outpatient setting.  Subjects 
with no laboratory abnormalities suggestive of LTLS will escalate to a dose of 50  mg venetoclax 
on Week  10 Day 1 in the outpatient setting.  
Medium  risk subjects with CrCl <  80 mL/min and higher tumor burden may be admitted to the 
hospi[INVESTIGATOR_197733] [ADDRESS_235006] Cr Cl <  80 mL/min and 
higher tumor burden at the investigator's discretion.  Subjects with no laboratory abnormalities 
suggestive of LTLS will escalate to a dose of [ADDRESS_235007]'s risk status will be reassessed prior to subsequent dose increments to determine 
the need for hospi[INVESTIGATOR_059].  
If no significant findings occur within [ADDRESS_235008](s) at 
particularly high -risk for TLS.  
9.2 Study Procedures and Assessments  
All study procedures are discussed in detail in this section except for  adverse event information 
(discussed in Section  7).  Procedures  performed at Screening will serve as baseline unless 
repeated prior to dosing in which case the latest prior  to dosing will serve as baseline.  
9.2.1  Study Assessments  
Medical and Oncologic History  
Screening Visit  assessment will include:  
• Complete medical history, including documentation of any clinically significant medical 
condition  
• History of tobacco and alcohol use  
• Detailed oncology history including:  
o Histology  
o Cytogenetics  
o Date of CLL diagnosis  
o Stage at diagnosis  
o Any surgical procedures  
o Treatments administered (including dates, type of modality, response to 
treatment and reason for treatment discontinuation)  
• Detail ed prior and concomitant medication usage including dates of usage and dosing 
information for all medications and supplements taken  
Week  1 Day 1:  Any changes observed from the Screening assessments (prior to dosing) will be 
recorded in the subject's medic al history.  
Adverse Event and Concomitant Medication Assessment  
Medication (prescription or over -the-counter, including vitamins and herbal supplements) will be 
recorded beginning with the Screening Visit through the end of the study.  At each visit, 
including the Final Visit and the [ADDRESS_235009]'s medical history will 
be reviewed and any changes from baseline will be recorded.  
Vital Signs, Physical Examination, ECOG Performance Status  
Body temperature (oral or tympanic ), weigh t, blood pressure and heart rate, evaluation of 
ECOG performance status (see Appendix  B) as  well as a complete physical examination 
including evaluation of the head, eyes, ears, nose, throat, cardiovascular, dermatologic, 
musculoskeletal, respi[INVESTIGATOR_696], gast rointestinal and neurologic systems will be performed at 
screening, Week  [ADDRESS_235010] Calendars/Diaries  
Subject calendars/diaries will be provided.  Subjects will be instructed to bring their 
calendars/diaries for r eview at:  
• Week  1 Day 1 
• Week  5 Day 1 
• Week  9-14 Day 1 
• Week  18 Day 1 
• Week  22 Day 1 
• Week  26 Day 1 
• Week  30 Day 1  
• Week  [ADDRESS_235011] the date and time each dose of study drug is tak en, 
(indicating if any doses of study drug are missed) and the timing of each dose relative to the 
subject’s first meal of the day.  Subjects will also be instructed to record adverse events and 
concomitant medications.  
The calendars/diaries are to be revi ewed at each visit and relevant pages are to be photocopi[INVESTIGATOR_197734].  At the end of the subject's participation in the study, the calendars/diaries are to 
be returned to the site and appropriately filed with the subject's source documents for this s tudy.  
9.2.[ADDRESS_235012] scan of involved anatomic regions (or MRI if CT is 
medically contraindicated)  as well as b one mar row aspi[INVESTIGATOR_197735] .  
Subjects will be evaluated with documentation of response (CR/PR/SD/progressive disease) per 
2008 Modified IWCLL NCI -WG Criteria for Tumor Response (Appendix  D).  
• Week  9 Day 1 
• Week  14 Day 1, and every 4  weeks t hrough Week  30 Day 1 
• starting Week  [ADDRESS_235013] scans (or MRI) will be obtained  
• Week 9 Day 1  
• Week 38 Day 1  
• Week 62 Day 1  
• Within 1  month of completion of therapy  
Bone marrow aspi[INVESTIGATOR_197736] 62  and within 1  month of completion of 
therapy  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 69 of 111  23 June  2017  
 Minimal Residual Disease (MRD) Assessment  
Subjects will have MRD assessed in a bone marrow aspi[INVESTIGATOR_197737] . 
Survival Assessment(s)  
Survival information will not be collected . 
9.2.3  Study Diagnostics  / Procedures  
Clinical Laboratory Tests  
Pregnancy Test  
For female subjects of childbearing potential, pregnancy testing must be performed as follows:  
• Screening – quantitative beta -human chorionic gonadotropin (β -hCG) serum pregnancy 
test. 
• Week  1 Day 1:  Urine test, if it has been >  [ADDRESS_235014] ≥ 1 year. 
Hematology and Chemistry  
Chemistry and hematology samples will be collected at the following time points (refer to 
Table 5 for specific tests):  
• Screening  
• Week  1 Day 1 
• Week  5 Day 1 
• For Weeks 9 -13 refer to Section  4.3.1 Prophylaxis  and Management of Tumor Lysis 
Syndrome and Appendix  E Recommendations for Initial Management of Electrolyte 
Abnormalities and Prevention of Tum or Lysis Syndrome (TLS) for monitoring during 
intra-patient dose escalation of venetoclax  
• Week  14 Day 1 
• Week  18 Day 1 
• Week  22 Day 1 
• Week  26 Day 1 
• Week  30 Day 1 
• Week  38 Day 1and every 12  weeks thereafter  
• Final Visit  
• 30-Day Safety Follow -Up Visit  
• As needed t hroughout study  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 70 of 111  23 June  2017  
 Coagulation Panel  
PT/aPTT samples will be collected at the following time points:  
• Screening  
• Week  9 Day 1 
Note:  Coagulation panel may be collected within 72  hours prior to the scheduled visit.  
Urinalysis  
Urinalysis samples will be collected  at: 
• Screening  
Note:  Urinalysis may be collected within 72  hours prior to the scheduled visit.  
Viral Serologies  
A sample for viral serologies to identify Hepatitis  B (HBsAg, anti -HBs, total anti -HBc, IgM 
anti-HBc), Hepatitis  C (HCV) antibody or RNA, cytom egalovirus, varicella zoster virus, herpes 
simplex virus, and Epstein -Barr virus will be collected at the following time points:  
• Screening  
• As needed for suspi[INVESTIGATOR_197738] 5.  Clinical Laboratory Tests  
Hematology  
Hematocrit  
Hemoglobin  
Red Blood Cell (RBC) count  
White Blood Cell (WBC) count  
Neutrophils  
Bands  
Lymphocytes  
Monocytes  
Basophils  
Eosinophils  
Platelet count (estimate not acceptable)  
Mean platelet volume (MPV)  
Mean corpuscular hemoglobin (MCH)  
Mean corpuscular volume (MCV)  
Mean corp uscular hemoglobin concentration 
(MCHC)  Clinical Chemistry  
Blood Urea Nitrogen (BUN)  
Creatinine  
Total bilirubin  
Serum glutamic -pyruvic transaminase 
(SGPT/ALT)  
Serum glutamic -oxaloacetic transaminase 
(SGOT/AST)  
Alkaline phosphatase  
Sodium  
Potassium  
Calcium  
Inorganic phosphorus  
Uric acid  
Total protein  
Glucose  
Albumin  
Lactate dehydrogenase (LDH)  
Magnesium  
Chloride  
Bicarbonate  
G6PD assay (prior to rasburicase only)  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 71 of 111  23 June  2017  
 Urinalysis  
Specific gravity  
Ketones  
pH 
Protein  
Blood  
Glucose  Coagulation  
Prothrombin time (PT)  
Activated partial thromboplastin time (aPTT)  
Note for samples from patients treated with rasburicase:  rasburicase causes enzymatic degradation of the uric acid 
in blood/plasma/serum samples potentially resulting in spuriously low plasma uric acid assay re adings.  The following 
special sample handling procedure must be followed to avoid ex vivo uric acid degradation.  Uric acid must be 
analyzed in plasma.  Blood must be collected into pre -chilled tubes containing heparin anticoagulant.  Immediately 
immerse plasma samples for uric acid measurement in an ice water bath .  Plasma samples must be prepared 
by [CONTACT_26795] a pre -cooled centrifuge (4°C).  Finally, the plasma must be maintained in an ice water bath and 
analyzed for uric acid within four  hours of  collection.  
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)  
A CT scan with contrast (unless medically contraindicated) must be performed within [ADDRESS_235015] exhibits clinical signs of disease progression (increased lymphadenopathy, 
hepatosplenomegaly) without meeting laboratory criteria for progression, a CT scan will be 
performed within 2  weeks to confirm or rule out progressive disease  as described in Appendix  D 
according to the Modified IWCLL Criteria for Tumor Response . 
Bone Marrow Aspi[INVESTIGATOR_127843]  
A bone marrow aspi[INVESTIGATOR_197739] (within [ADDRESS_235016] 
dose of study drug).  The bone marrow aspi[INVESTIGATOR_197740], unless otherwise obtained through standard of care.  Bone 
marrow aspi[INVESTIGATOR_99193], immunohistoche mical analysis and cytogenetics performed as 
standard of care throughout the study should also be documented.  
If the subject meets clinical/laboratory criteria and a confirmatory CT scan meets criteria for a 
CR, a bone marrow aspi[INVESTIGATOR_197741].  
The order of collections from the bone marrow aspi[INVESTIGATOR_197742] 1) MRD 
assessment and 2) clinical assessment .  
12-Lead Electrocardiogram  
A 12-lead resting ECG will be obtained at the following:  
• Screening  
• As clinically indicated  
The EC G results will be used by [CONTACT_197778], including 
adverse event determination and management and termination of subjects from the study.  
- ECG results will be summarized as follows:  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
 Page 72 of 111  23 June  2017  
 - Normal ECG  
- Abnormal ECG – not clinically significant  
- Abnormal ECG – clinically significant  
- Unable to evaluate  
The QT interval measurement will be documented only if a "prolonged  QT" is observed.  
Correction by [CONTACT_182097] (QTcF) is preferred.  The original ECG tracing will be 
retained in the subject's records at the study site.   
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 73 of 111  
 9.3 Table of Assessments / Study Calendar  
Table 6:  Schedule of Assessments  
Study Visits  Screenin
g Phase  Treatment Phase  
Week 
[ADDRESS_235017]  ± 7 days  + 30 
days  
 Procedures  
Informed consent  X          
Medical history  X          
Confirm eligibility and enroll   X         
Cumulative Illness Rating Scale 
(CIRS)   X         
Concomitant medications  X X X X  X X X X  
Adverse events b X X X X  X X X X  
Study drug compliance review c   X X  X X X   
Height  X          
Physical exam, vital signs, weight, 
ECOG  X X X X  X X X X  
Disease assessment:            
CT/MRI scan  X j   X f   X f  X f   
Bone marrow biopsy/aspi[INVESTIGATOR_337] h X        X  
Disease -related symptoms i X X X X  X X X X  
Overall response assessment     X  X X X X  
Hematology  X X X X  X X X X  
Serum chemistry  X X X X X X X X X  
Creatinine clearance 
(Cockcroft -Gault)  X   X       
Cytogenetic, CLL FISH panel X          
Hepatitis serologies  X          
Coagulation panel  X   X l       
12-lead ECG k X  
Any new anticancer therapy           
IRB-[ADDRESS_235018] assessment m  X        X 
 
 
Study Visits  Screenin
g Phase  Treatment Phase     
Study Drug Administration and Dispensation 
 Venetoclax    Continuous daily dosing  
Dispensed weekly during dose ramp -up and every specified 
study visit thereafter throug h Week 117  
Intra-patient dose 
ramp -up  400 mg daily  
 Ibrutinib 420  mg PO   Continuous daily dosing  g 
Dispensed every 4  weeks from Week  1 through Week  30 and every 
specified study visit  thereafter through Week 117  
D = day; Term  = treatment terminat ion; d/c  = discontinuation; PD  = progressive disease; FU  = follow -up; (x)  = not all visits or all subjects  
a To be collected pre -dose  
b AEs are reported from the time the patient signs the Informed Consent Form until [ADDRESS_235019] -progression follow -up for overall survival.  
c Includes patient instruction and routine review of study drug diary and evaluation of contents of study drug containers from home administration  
d At SCI only:   Ibrutinib: Pre -dose  (window:  30  to 60 minutes before dose), then 1 hour (window:  45  to 75 minutes), 2  hours  (window:  1.5  to 2.5 hours ), 4 hours  
(window:  3.5  to 4.5 hours ), and 6  hours  (window:  5.5  to 6.5 hours ) post -dose on the first day of ibrutinib dose administration  (Week  1 Day 1) and each day when 
dosed in combination with new dose of venetoclax.  Venetoclax:  [ADDRESS_235020] -dose with each Day  1 dose increase  of venetoclax  
f Between Week  8 Day 1 and prior to Week  9 Day 1; Week  38 Day 1 +/- 7 days; Week  62 Day 1 +/- 7 days ; within 1  month after completion of therapy ; within 2  weeks 
of suspected disease progression  
g Day 1 dose of Cycle 1 and each PK day should be administered at the investigational site.  Subsequent daily doses may be self -admin istered at home.  
h Bone marrow biopsy and/or aspi[INVESTIGATOR_197743] [ADDRESS_235021] minimal residual di sease (MRD) assessed by [CONTACT_197779][INVESTIGATOR_337]  
i Disease -related symptoms include weight loss, fatigue, fever, night sweats, abdominal pain/discomfort due to splenomegaly including e arly satiety, and anorexia.  
j Baseline CT scan can b e performed within 28  days prior to study drug administration  
k ECG’s may be performed at the investigator’s discretion, particularly in subjects with arrhythmic symptoms (eg,  palpi[INVESTIGATOR_814], lightheadedness) or new onset dyspnea  
l Coagulation test to be don e Week 9, Day1 only  
IRB-[ADDRESS_235022] Agreement, the Investigator reserves the right to terminate the study at any time.  Should 
this be necessary, both  the Investigator will arrange discontinuation procedures in partnership with 
Pharmacyclics.  In terminating the study, the Investigator will assure that adequate consideration is 
given to the protection of the subjects’ interests.  Pharmacyclics may terminate the study for reasons 
including, but not limited to:  evidence that the PI [INVESTIGATOR_197744] (eg,  is listed on a debarment or ineligible investigator list); 
failure to meet timelines or achieve agreed upon milestones; a known or perceived risk to patient 
well-being is identified; or breach of contract.  Additional grounds for termination are outlined in the  IST 
Agreement.  
9.4.[ADDRESS_235023] Agreement, the Investigator is required to submit to Pharmacyclics a copy of a planned 
publication (abstract, poster, oral presentation or manuscript) prior to the submission thereof for 
publication or disclosure.  Pharmacyclics may provide scientific comments and suggestions 
understanding that the Investigator has sole editorial responsibility,and retains the authority to make the 
final determination on whether or not to incorporate Pharmacyclics com ments or requests for additional 
information.  
9.[ADDRESS_235024] (IRB) Approval of Protocol  
This clinical study was designed and will be implemented in accordance with the protocol, the ICH 
Harmonized Tripartite Guidelines for Good Clinical Practices, with applicable local r egulations 
(including US Code of Federal Regulations [CFR] Title 21 and European Directive 2001/20/EC), and 
with the ethical principles laid down in the Declaration of Helsinki.  This protocol; the proposed informed 
consent; and all forms of information re lated to the study that will be provided to the subjects (eg, 
questionnaires, handouts, written instructions, diaries, advertisements used to recruit participants, etc) 
will be submitted to and reviewed and approved by [CONTACT_197780]  (SRC).  Any changes made to the protocol will be submitted as a 
modification and will be approved by [CONTACT_14226].  The Protocol Director will 
disseminate the protocol amendment information to all pa rticipating investigators.  The IRB must 
comply with current [LOCATION_002] (US) regulations (§21 CFR 56) as well as country -specific national 
regulations and/or local laws.   
Per the IST Agreement, any amendments to the Protocol or Informed Consent Form mu st be sent to 
Pharmacyclics for review and approval prior to submission to the IRB.  Written verification of IRB 
approval will be obtained before any amendment is implemented.  The following documents must be 
provided to Pharmacyclics or its authorized rep resentative before entering subjects in this study:  
(1) a copy of the IRB letter that grants formal approval; and   (2) a copy of the IRB -approved ICF.   
10.[ADDRESS_235025](s) to trial subjects, or when the change(s) 
involves only logistical or administrative aspects of the trial [eg, change in study monitor(s), change of 
telephone number(s)], will be knowingly permitted without review and approval by [CONTACT_1201].  
10.2.[ADDRESS_235026] University HRPP Policy Guidance “Events and Information that Require Prompt Reporting 
to the IRB” GUI -P13 with be reported to the IRB within the defined timeframes.   
10.2.[ADDRESS_235027] as part of the informed consent process, either as 
part of the ICF or as a separate signed document (for example, in the US, a site -specific HIPAA 
consent may be used).  The Investigator or designee must explain to each subj ect that for the 
evaluation of study results, the subject’s protected health information obtained during the study may be 
shared with Pharmacyclics and its designees, regulatory a gencies, and IRBs .  As the study Sponsor, 
IRB-[ADDRESS_235028]’s protected health information or disclose it to a third  party 
without applicable subject authorization.  It is the Investigator’s or designee’s responsibility to obtain 
written permission to use protected health information from each subject.  If a su bject withdraws 
permission to use protected health information, it is the Investigator’s responsibility to obtain the 
withdrawal request in writing from the subject and to ensure that no further data will be collected from 
the subject.  Any data collected on the subject before withdrawal will be used in the analysis of study 
results.  During the review of source documents by [CONTACT_118106], the confidentiality of the 
subject will be respected with strict adherence to professional standards and reg ulations.  
10.[ADDRESS_235029] Cancer Institute Data and Safety Monitoring Committee  (DSMC) will be the monitoring 
entity for this study.  The DSMC will audit study -related activities to determine whether the study has 
been conducte d in accordance with the protocol, local standard operating procedures, FDA regulations, 
and Good Clinical Practice  (GCP).  This may include review of the following types of documents 
participating in the study:  regulatory binders; case report forms; elig ibility checklists; and source 
documents.  In addition, the DSMC will regularly review serious adverse events and protocol deviations 
associated with the research to ensure the protection of human subjects.  Results of the DSMC audit 
will be communicated t o the IRB and the appropriate regulatory authorities at the time of continuing 
review, or in an expedited fashion, as needed.  
10.3.[ADDRESS_235030] 
with all  required study data accurately recorded such that the information matches the data contained in 
medical records (eg,  physicians’ notes, nurses’ notes, clinic charts and other study -specific source 
documents).  Authorized study site personnel (ie,  listed o n the Delegation of Authority log) will complete 
CRFs designed for this study according to the completion guidelines that will be provided.  The 
Investigator will ensure that the CRFs are accurate, complete, legible, and completed within a 
reasonable time.   At all times, the Investigator has final responsibility for the accuracy and authenticity 
of all clinical data.  Study staff will be appropriately trained in the use of CRFs before the start of the 
study.  After database lock, the Investigator will recei ve a copy of the subject data (eg,  paper; CD;  or 
other appropriate media) for archiving at the study site.  
[IP_ADDRESS]  Record Retention  
The Investigator must keep a record that lists all subjects considered for enrollment (including those 
who did not undergo screening ) in the study.  For those subjects subsequently excluded from 
enrollment, the reason(s) for exclusion is to be recorded.  The Investigator/study staff must maintain 
adequate and accurate records to enable the conduct of the study to be fully documented an d the study 
data to be subsequently verified.   
Essential documentation includes, but is not limited to, the IB, signed protocols and amendments,  
IRB approv al letters (dated), signed Form  FDA 1572 and Financial Disclosures, signed ICFs (including 
subject c onfidentiality information), drug dispensing and accountability records, shippi[INVESTIGATOR_197745] -related materials, signed, dated and completed CRFs, and 
documentation of CRF corrections, SAE forms and notification of SAEs and  related reports, source 
documentation, normal laboratory values, curricula vitae for study staff, and all relevant 
correspondence and other documents pertaining to the conduct of the study.   
IRB-[ADDRESS_235031] notify Pharmacyclics and obtain written a pproval from Pharmacyclics before 
destroying any clinical study documents or images (eg,  scan, radiograph, ECG tracing) at any time.  
Should an Investigator wish to assign the study records to another party or move them to another 
location, advance written  notice will be given to Pharmacyclics.  Pharmacyclics will inform the 
Investigator of the date that study records may be destroyed or returned to Pharmacyclics.  
Pharmacyclics must be notified in advance of, and Pharmacyclics must provide express written 
approval of, any change in the maintenance of the foregoing documents if the Investigator wishes to 
move study records to another location or assign responsibility for record retention to another party.  If 
the Investigator cannot guarantee the archiving r equirements set forth herein at his or her study site for 
all such documents, special arrangements must be made between the Investigator and Pharmacyclics 
to store such documents in sealed containers away from the study site so that they can be returned 
sealed to the Investigator for audit purposes.  
10.[ADDRESS_235032] the study according to the 
current protocol; will read and und erstand the IB; will obtain IRB  approval to conduct the study; will 
obtain informed consent from each study participant; will maintain and supply to, auditors and 
regulatory agencies adequate and accurate records of study activity and drug accountability for 
study -related monitoring, audits, IRB reviews and regulatory inspections; will report SAEs to 
Pharm acyclics and IRB according to the specifics outlined in this protocol; will personally conduct or 
supervise the study; and will ensure that colleagues participating in the study are informed about their 
obligations in meeting the above commitments.  
10.[ADDRESS_235033] Agreement, the Investigator is required to submit to Pharmacyclics a copy of a planned 
publication (abstract, poster, oral presentation or manuscript) prior to the submission thereof for 
publication or disclosure.  Pharmacyclics may provide scientific comments and suggestions 
understanding that the Investigator has sole editorial responsibility, and retains the authority to make 
the final determination on whether or not to incorporate Pharmacy clics comments or requests for 
additional information.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 80 of 111  
 11 STATISTICAL CONSIDER ATIONS  
11.1 Statistical Design  
This study uses the FDA approved dose of ibrutinib 420  mg PO daily for CLL/SLL and intra -patient 
dose -escalation of venetoclax to establish the efficacy, safety, and tolerability of venetoclax when 
combined with ibrutinib in patients with relapsed and refractory CLL/SLL.  A description of the statistical 
methods to be used to analyze the efficacy and safety data is outlined below.   
11.1.1  Treatment Assignment  
Not applicable for this single -arm study.  
11.2 Endpoints  
All endpoints will be assessed during  treatment period only.   
11.2.1  Primary Endpoint  
Complete response rate  (CRR )  
[IP_ADDRESS]  Measurement Time Points  
The time  frame for assessment of the primary endpoint is 62 w eeks.  
11.2.2  Seconda ry Endpoint(s)  
Secondary Endpoints include:  
• Overall response rate (ORR)  
• Duration of response  (DOR)  
• Time -to-progression (TTP)  
• Progression -free survival (PFS)  
• Overall survival ( OS) 
• Rate of minimal residual disease (MRD) negativity in the bone marrow  
• Safety  
Efficacy analyses will be performed on the intent -to-treat population but will also detail the response 
rates for evaluable patients (those who receive at least one dose of venetoclax).  
[IP_ADDRESS].1  Assessment Methods  
Laboratory and clinical assessments gathered as dire cted in the Study Treatment Schedule (Section  9).  
[IP_ADDRESS]  Overall Response Rate  
The proportion of subjects with an overall response (per investigator assessment) will be calculated for 
all subjects based on IWCLL criteria.   
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 81 of 111  
 [IP_ADDRESS]  Duration of Response  
Duration of respo nse will be defined as the number of days from the date of first response per 
investigator assessment to the earliest recurrence or progressive disease per investigator assessment.  
If a subject is still responding then the subject's data will be censored at the date of the subject's last 
available clinical disease assessment.  For subjects who never experienced response, the subject's 
data will be censored on the date of enrollment.  
[IP_ADDRESS]  Time -to-progression  
Time -to-progression will be defined as the number of d ays from the date of first dose (date of 
enrollment if not dosed) to the date of earliest disease progression (per the investigator assessment).  
All disease progression will be included regardless whether the event occurred while the subject was 
taking st udy drug or had previously discontinued study drug.  If the subject does not experience 
disease progression, then the data will be censored at the date of the last available disease 
assessment.  
[IP_ADDRESS]  Progression -free Survival  (PFS)  
Progression -free Survival wil l be defined as the number of days from the date of first dose to the date of 
earliest disease progression (per the investigator assessment) or death.  All disease progression will be 
included regardless whether the event occurred while the subject was tak ing study drug or had 
previously discontinued study drug.  If the subject does not experience disease progression or death, 
then the data will be censored at the date of the last disease assessment.   
[IP_ADDRESS]  Overall Survival  (OS)  
Overall survival will be defined as the number of days from the date of first dose to the date of death for 
all dosed subjects.  For subjects who did not die, their data will be censored at the date of last study 
visit or the last known date to be alive, whichever is later.  
[IP_ADDRESS]  Rate of Minim al Residual Disease (MRD) Negativity in the Bone Marrow  
MRD negativity will be defined as less than one CLL cell per 10,000 leukocytes (or below 10 -4) on bone 
marrow -based flow cytometry.  Rate of MRD negativity will be defined as the proportion of subject s who 
achieve MRD negativity status.   
11.2.3  Exploratory Endpoint(s)  
Time to Next Anti -CLL Treatment (TTNT)  
Time to next anti -CLL treatment will be defined as the number of days from the date of the first dose of 
ibrutinib to the date of first dose of new non -protocol anti -leukemia therapy (NPT) or death from any 
cause.  For subjects who did not take NPT, the data will be censored at the last known date to be free 
of NPT.   
11.[ADDRESS_235034] accrual slot .  Accrual of 1 to 2 patients a month is anticipated .  The historical rate of complete 
response  (CR) in thi s setting is on the o rder of 7  to 8%.36 8% will be taken as a null hypothesis for an 
informal power calculation to describe the precision fu rnished by [CONTACT_15365].  With a minimum of 
20 patients evalua ble for CR, there is  80% power to reject a CR rate of 8% with a one -sided 
significance level of 5%, if the true CR rate is 32% or better .  
Efficacy Analysis  
Efficacy analysis will be performed on the intent -to-treat population but will also detail the response 
rates for evaluable patients (those who receive at least one dose of ve netoclax).  
Overall Response Rate  
A 95% confidence interval based on binomial distribution will be constructed for the calculated 
ORR.  
Duration of Response  
Duration of response will be analyzed by [CONTACT_5263] -Meier methodology using data for all enrolled 
subjec ts.  Median duration of response will be calculated and the corresponding 95% confidence 
interval will be presented.  
Time -to-progression  (TTP)  
TTP will be analyzed by [CONTACT_5263] -Meier methodology using data for all enrolled subjects.  Median 
time TTP will be calculated and 95% confidence interval for median time TTP will be presented.  
Progression -Free Survival  
PFS will be analyzed by [CONTACT_197760].  Median PFS 
time will be calculated and 95% confidence interval for median PFS time will be presented.  
Overall Survival  
OS will be analyzed by [CONTACT_5263] -Meier methodology using data from all dosed subjects.  Median 
time survival will be calculated and 95% confidence interval for the median time survival will be 
presented.  
Rate of Minimal Residual Disease (MRD) Negativity in the Bone Marrow  
Ninety -five percent (95%) confidence intervals based on the binomial distribution will be provided.  
Time -to-Next Anti -CLL Treatment (TTNT)  
TTNT will be analyzed by [CONTACT_5263] -Meier methodology u sing data for all dosed subjects.  Median 
TTNT time will be calculated.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 83 of 111  
 11.4.3  Accrual estimates  
It is anticipated that 1-2 patients a month will accrue .   
11.4.4  Safety Analysis  
Safety Endpoints:  
• Frequency, severity, and relatedness of AEs  
• Frequency, severity and mana gement of TLS  
• Frequency of AEs requiring discontinuation of study drug or dose reductions, or leading to death  
All patient safety information collected will be summarized using descriptive statistics (number of 
non-missing values, mean, median, standard de viation, minimum and maximum) for continuous 
variables and counts and percentages for categorical variables, where applicable.  All safety outcome 
information reported will be presented in data listings.  
11.4.5  Pharmacokinetic Analysis  
Values for the pharmacokine tic parameters for ibrutinib and venetoclax including the maximum 
observed plasma concentration (C max), the time to C max (peak time, T max), the area under the plasma 
concentration -time curve (AUC) from [ADDRESS_235035] measurable concentration (AU Ct) and 
AUC over a 24 -hour dose interval (AUC 0-24) will be determined using non -compartmental methods.  
Additional analyses may be performed if useful in the interpretation of the data.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 84 of 111  
 12 REFERENCES  
1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, L inet MS.  Lymphoma incidence 
patterns by [CONTACT_197781], 1992 –2001.  Blood .  2006; 107: 265 –76. 
2. Zwiebel JA, Cheson BD.  Chronic lymphocytic leukemia:  staging and prognostic factors.  
Semin  Oncol .  1998;25(1):42 -59. 
3. American Cancer Societ y:  Cancer  Facts  and Figures  2013 .  Atlanta, GA:  American Cancer 
Society, 2013.  
4. Sant M, Allemani C, Tereanu C, et al.  Incidence of hematologic malignancies in Europe by 
[CONTACT_130105]:  results of the HAEMACARE project.  Blood .  2010;116(19);3724 -34.  
Erratum in:  Blood.  2011;117(12):3477.  
5. Jemal A, Clegg LX, Ward E, et al.  Annual report to the nation on the status of cancer, 1975 -2001, 
with a special feature regarding survival.  Cancer .  2004;101(1):3 -27. 
6. Dighiero G, Maloum K, Desablens B, et al.  Chlorambucil in indolent chronic lymphocytic leukemia. 
French Cooperative Group on Chronic Lymphocytic Leukemia.  N Engl J Med.  1998;338:1506 -14. 
7. Rai KR, Peterson BL, Appelbaum FR, et al.  Fludarabine compared with chlorambucil as primary 
therapy for chro nic lymphocytic leukemia.  N Engl J Med.  2000;343:[ADDRESS_235036] JC, Rai K, Peterson BL, et al.  Addition of rituximab to fludarabine may prolong 
progression -free survival and overall survival in patients with previously untreated chronic 
lymphocytic leukem ia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 
9011.  Blood .  2005;105:49 -53. 
9. Tam CS, O'Brien S, Wierda W, et al. Long -term results of the fludarabine, cyclophosphamide, and 
rituximab regimen as initial therapy of chronic lymphoc ytic leukemia.  Blood .  2008;112:975 -80. 
10. Hallek M, Fischer K, Fingerle -Rowson G, et al.  Addition of rituximab to fludarabine and 
cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open -label, 
phase  3 trial.  Lancet .  2010;376:1 164-74. 
11. Bishop GA, Haxhinasto SA, Stunz LL, et al.  Antigen -specific B -lymphocyte activation.  
Crit Rev Immunol .  2003;23:165 –197.   
12. Shaffer AL, Rosenwald A, Staudt LM.  Lymphoid malignancies: The dark side of B -cell 
differentiation.  Nat Rev Immunol .  2002;2:920 –932.  
13. Afar DE, Park H, Howell BW, Rawlings DJ, Cooper J, Witte ON.   Regulation of BTK by [CONTACT_197782].  Mol Cell Biol.  1996;16:3465 -71. 
14. Cheng G, Ye ZS, Baltimore D.  Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a 
Src homology 3 domain -mediated interaction.  Proc Natl Acad  Sci [LOCATION_003].  1994;91:8152 -5. 
15. Humphries LA, Dangelmaier C, Sommer K, et al.  Tec kinases mediate sustained calcium influx via 
site-specific tyrosine phosphorylation of the phospholipase Cgamma Src hom ology 2 -Src homology 
3 linker.  J Biol Chem .  2004;279:[ZIP_CODE] -61. 
16. Kuppers R.   Mechanisms of B -cell lymphoma pathogenesis.  Nat Rev Cancer .  2005;5:251 -62. 
17. Meeker T, Lowder J, Cleary ML, et al.  Emergence of idiotype variants during treatment of B -cell 
lymph oma with anti -idiotype antibodies.  N Engl J Med.  1985;312:1658 -65. 
18. Gururajan M, Jennings CD, Bondada S.  Cutting edge: constitutive B cell receptor signaling is 
critical for basal growth of B lymphoma.  J Immunol .  2006;176:5715 -9. 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 85 of 111  
 19. Satterthwaite AB, Witt e ON.  The role of Bruton's tyrosine kinase in B cell development and 
function: a genetic perspective.   Immunol  Rev.  2000;175:[ADDRESS_235037].  J Cell Sci.  
2003;116(20):4053 -6. 
21. Cory S, Ad ams JM.  The Bcl -2 family:  regulators of the cellular life -or-death switch.  
Nature  Rev Cancer .  2002;2(9):647 -56. 
22. Borner C.  The Bcl -2 protein family:  sensors and checkpoints for life -or-death decisions.  
Mol Immunol .  2003;39(11):615 -47. 
23. Cory S, Huang DC, Adams JM.  The Bcl -2 family:  roles in cell survival and oncogenesis.  
Oncogene .  2003;22(53):8590 -607. 
24. Cimmino A, Calin GA, Fabbri M, et al.  miR -15 and miR -16 induce apoptosis by [CONTACT_129305]2.  
Proc Natl Acad  Sci [LOCATION_003].  2005;102(39):[ZIP_CODE] -9. 
25. Calin G A, Cimmino A, Fabbri M, et al.  MiR -15a and miR -16-1 cluster functions in human leukemia.  
Proc Natl Acad  Sci [LOCATION_003].  2008;105(13):5166 -71. 
26. Souers AJ, Leverson JD, Boghaert ER, et al.  Venetoclax, a potent and selective BCL -2 inhibitor, 
achieves antitumor ac tivity while sparing platelets.  Nat Med.  2013;19(2):202 -208. 
27. Smith TJ, Khatcheressian J, Lyman GH, et al.  2006 update of recommendations for the use of 
white blood cell growth factors:  an evidence -based clinical practice guideline.  J Clin Oncol .  
2006 ;24(19):3187 -205 
28. Yamamura K, Kamada S, Ito S, et al.  Accelerated disappearance of melanocytes in bcl -2-deficient 
mice.  Cancer  Res.  1996;56(15):3546 -50. 
29. Wilson H, O'Connor A, Czuczman S, et al.  Phase 1/2a study of navitoclax (ABT -263) in relapsed or 
refractory lymphoid malignancies.  Haematologica .  2010;[ADDRESS_235038] 2:[ADDRESS_235039] 0292.  
30. Yan W, Huang JX, Lax AS, et al.  Overexpression of Bcl -W in the testis disrupts spermatogenesis:  
revelation of a role of BCL -W in male germ cell cycle control.  Mol Endocrinol .  2003;17(9):1868 -79. 
31. Sugiyama N, Obinata M, Matsui Y.  Bcl -2 inhibits apoptosis of spermatogonia and growth of 
spermatogonial stem cells in a cell -intrinsic manner.  Mol Reprod  Dev.  2001;58(1):30 -8. 
32. Oldereid NB, Angelis PD, Wiger R, et al.  Expre ssion of Bcl -2 family proteins and spontaneous 
apoptosis in normal human testis.  Mol Hum  Reprod .  2001;7(5):403 -8. 
33. Seymour JF, Davids MS, Pagel JM, et al.  Bcl -2 inhibitor venetoclax (GDC -0199) monotherapy 
shows anti -tumor activity including complete remi ssions in high -risk relapsed/refractory (R/R) 
chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Presented at:  
55th annual ASH Meeting; December 7 -10, 2013; New Orleans, LA.  Abstract 872.  
34. Pan Z, Scheerens H, Li SJ, et al.  Discover y of selective irreversible inhibitors for Bruton's tyrosine 
kinase.  ChemMedChem .  2007;2:58 -61. 
35. Herman SE, Gordon AL, Hertlein E, et al.  Bruton tyrosine kinase represents a promising 
therapeutic target for treatment of chronic lymphocytic leukemia and i s effectively targeted by 
[CONTACT_9090]-[ZIP_CODE].   Blood .  2011;117:[ADDRESS_235040] JC, Furman RR, Coutre SE, et al.  Three -year follow -up of treatment -naïve and previously 
treated patients with CLL and SLL receiving single -agent ibrutinib.  Blood .  2015;125:[ADDRESS_235041] will be retained in the patient’s  study  file, and 
the study’s Regulatory  Binder.   
The Study  Coordinator, treating Physician and an Independent  Reviewer will verify that the participant’s 
eligibility is accurate, complete, and legible in source records.  A description of the eligibility v erification 
process will be included in the EPIC or other Electronic Medical Record progress note.  
I. Protocol Information  
Protocol Title:  An Open Label Phase  1-2 Trial of Venetoclax with Ibrutinib in Relapsed 
and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic 
Leukemia  
eProtocol Number:  IRB-[ZIP_CODE]  
Principal Investigator:  [CONTACT_1525]  E Coutre,  MD 
II. Subject Information  
Subject name / Study ID :   
Gender                     Male                         Female   
III. Study Information  
SRC -Approved   IRB-Approved   Contract signed   
IV. Inclusion / Exclusion Criteria  
Inclusion Criteria  
(From IRB -approved protocol  3.1) Yes No Supporting Documentation*  
1. Voluntarily sign and date an informed consent 
form (ICF) with authorization to use protected 
health information (in accordance with national and 
local subject privacy regulations) and approved by 
[CONTACT_4707]  (IRB) prior to 
initiation of any study specific procedures     
2. Diagnosis of chronic lymphocytic leukemia  CLL) or 
small lymphocytic leukemia  (SLL) meeting 
IWCLL/NCI -WG criteria, and relapsed  after or 
refractory  to at least 1  prior treatment     
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 87 of 111  
 Inclusion Criteria  
(From IRB -approved protocol  3.1) Yes No Supporting Documentation*  
3. Measurable nodal  disease by [CONTACT_33456]  (CT)    
4. Adequate hematologic function independent of 
transfusion and growth factor support for at least 
7 days prior to screening  [except for  pegylated 
G-CSF (pegfilgrastim) and darb epoetin which 
require at least 14  days prior to screening ] defined 
as the following.  
• Absolute neutrophil count >  750 cells/mm3 
(0.75  x 109/L) 
• Platelet count >  30,000 cells/mm3 (30 x 109/L) 
without transfusion support ; evidence of mucosal 
bleeding; a known bleeding epi[INVESTIGATOR_5319] 
3 months of screening; or a history of a 
bleeding  disorder  
• Hemoglobin >  8.0 g/dL  
If the bone marrow evaluation shows heavy 
infiltration with underlying disease, growth factor 
support may be a dministered after screening and 
prior to the first dose of therapy.     
5. Adequate hepatic and renal function defined as:  
• Serum aspartate transaminase (AST) or alanine 
transaminase (ALT) ≤  2.5 x upper limit of normal 
(ULN)  
• Estimated Creatinine Clearance ≥  30 mL/min 
(Cockcroft -Gault)  
• Bilirubin ≤  1.[ADDRESS_235042] (unless bilirubin rise is due 
to Gilbert’s syndrome or of non -hepatic or igin)    
6. PT/INR <  1.[ADDRESS_235043] and PTT (aPTT) <  1.[ADDRESS_235044]    
7. Men and women ≥  18 years of age     
8. Eastern Cooperative Oncology Group (ECOG) 
performanc e status of 0, 1, or 2     
9. Female subjects who are of non -reproductive 
potential (ie,  post-menopausal by [CONTACT_969] - no 
menses for ≥  1 year; OR history of hysterectomy; 
OR history of bilateral tubal ligation; OR history of  
bilateral oophorectomy).   
OR 
Female subjects of childbearing potential must 
have a negative serum pregnancy test upon study 
entry.     
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 88 of 111  
 Inclusion Criteria  
(From IRB -approved protocol  3.1) Yes No Supporting Documentation*  
10. Male and female subjects who agree to use highly 
effective methods of birth control  (eg, condoms, 
implants, injectables, combined oral contraceptives, 
some intrauterine devices [IUDs], sexual 
abstinence, or sterilized partner) during the period 
of therapy and for [ADDRESS_235045] dose of 
study drug.     
 
Exclusion Criteria  
(From IRB -approved protocol 3.2)  Yes No Supporting Documentation*  
1. Prior treatment with either venetoclax or ibrutinib.     
2. Vaccinated with live, attenuated vaccine(s) within 
[ADDRESS_235046] allogeneic transplant.     
4. Richter’s tra nsformation confirmed by [CONTACT_9256].     
5. Active uncontrolled autoimmune cytopenias     
6. Chemotherapy ≤  [ADDRESS_235047] 
administration of study treatment and/or 
monoclonal antibody ≤  [ADDRESS_235048] 
administration of study treatment.     
7. History of other malignancies, except:  
• Malignancy treated with curative intent and with 
no known active disease present for ≥  [ADDRESS_235049] dose o f study drug and felt to be 
at low risk for recurrence by [CONTACT_35425].  
• Adequately treated non -melanoma skin cancer or 
lentigo maligna without evidence of disease.  
• Adequately treated carcinoma in situ without 
evidence of disease.     
8. Concurrent systemic immunosuppressant therapy 
(eg, cyclosporine A, tacrolimus, etc, or chronic 
administration [>  14 days] of >  20 mg/day of 
prednisone) within [ADDRESS_235050] dose of study 
drug.     
9. Recent infection requiring systemic treatment that 
was completed ≤  [ADDRESS_235051] dose of 
study drug.     
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 89 of 111  
 Exclusion Criteria  
(From IRB -approved protocol 3.2)  Yes No Supporting Documentation*  
10. Unresolved toxicities from prior anti -cancer therapy, 
defined as having not resolved to Common 
Termi nology Criteria for Adverse Event (CTCAE, 
version  4.03), Grade  ≤ 1, or to the levels dictated in 
the inclusion/exclusion criteria except for  alopecia.     
11. Known bleeding disorders (eg,  von Willebrand’s 
disease) or hemoph ilia    
12. History of stroke or intracranial hemorrhage within 
[ADDRESS_235052] dose of study  drug.    
13. Known history of human immunodeficiency virus 
(HIV) or active with hepatiti s C virus (HCV) or 
hepatitis  B virus (HBV).  
Subjects who are positive for hepatitis  B core 
antibody or hepatitis  B surface antigen must have a 
negative polymerase chain reaction (PCR) result 
before enrollment.  Those who are PCR -positive 
will be excluded.     
14. Any uncontrolled active systemic infection.     
15. Major surgery within [ADDRESS_235053] dose of study 
drug    
16. Any life -threatening illness, medi cal condition, or 
organ system dysfunction that, in the investigator’s 
opi[INVESTIGATOR_1649], could compromise the subject’s safety or 
put the study outcomes at undue risk.     
17. Currently active, clinically significant cardiovascular 
disease, such as uncontrolled arrhythmia or Class 
3 or 4 congestive heart failure as defined by [CONTACT_197783]; or a history of myocardial infarction, 
unstable angina, or acute coronary syndrome 
within 6 months screening .    
18. Unable to swallow capsules ; malabsorption 
syndrome ;  disease significantly affecting 
gastrointestinal function ;  resection of the stomach 
or small bowel ;  symptomatic inflammatory bowel 
disease or ulcerative c olitis;  or partial or complete 
bowel obstruction     
19. Concomitant use of warfarin or other Vitamin K 
antagonists     
20. Received a strong cytochrome P450  (CYP)  3A 
inhibitor or inducer wit hin [ADDRESS_235054] 
dose of ibrutinib, OR subjects who require 
continuous treatment with a strong 
cytochrome  P450 CYP3A  inhibitor or inducer 
(see Appendix  C)     
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 90 of 111  
 Exclusion Criteria  
(From IRB -approved protocol 3.2)  Yes No Supporting Documentation*  
21. Lactating or pregnant.     
22. Unwilling or unable to participate in all required 
study evaluations and procedures.     
23. Unable to understand the purpose and risks of the 
study     
24. Subjects with chro nic liver disease with hepatic 
impairment Child -Pugh class  B or C    
* All subject files must include supporting documentation to confirm subject eligibility.  The method of 
confirmation can include, but is not limited to, laboratory test results, radiology test results, subject 
self-report, and medical record review.   
By [CONTACT_114052] I verify that this subject is:   eligible /  ineligible for participation in 
the s tudy.  This study is approved by [CONTACT_114053], the 
Stanford IR B, and has finalized financial and contractual agreements as required by [CONTACT_197784]’s Research Management Group.   
Treating Physicia n Signature:  [CONTACT_1782]:   
Printed name:  
 
[CONTACT_138690]:  Date:   
Printed name:  
 
[CONTACT_115211]:  Date:   
Printed name:  
[CONTACT_1744]-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 91 of 111  
 13.2 Appendix B.  ECOG Status Scores  
Status  Eastern Cooperative Oncology Group (ECOG) Performance Status**  
0 Fully  active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg,  light housework, office work.  
2 Ambulatory and ca pable of all self -care, but unable to carry out any work activities.  Up and 
about more than 50% of waking  hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking  hours.  
4 Completely disabled.  Cannot carry on a ny self -care.  Totally confined to bed or chair.  
5 Dead.  
**Oken,MM, Creech RH, Tormey DC, et al.  Toxicity And Response Criteria Of The Eastern Cooperative 
Oncology Group .  Am J Clin Oncol .  1982;5:649 -655. 
Available at:  http://www.ecog.org/general/perf_stat.html .  Accessed [ADDRESS_235055].  Further information can be found at the following websites: 
http://medicine.iupui.edu/clinpharm/ddis/main -table/ and   
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabe
ling/ucm080499.htm  
Refer to  Section  [IP_ADDRESS]  on instr uctions for concomitant use of CYP3A inhibitors and inducers with 
ibrutinib and venetoclax.  
 
CYP3A inhibitors:  
Strong  Moderate  Weak  
boceprevir  aprepi[INVESTIGATOR_197746]/ritonavir  cilostazol  
ketoconazole  dronedarone  cimetidine  
lopi[INVESTIGATOR_197747]-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 92 of 111  
 CYP3A inhibitors:  
Strong  Moderate  Weak  
nelfinav ir fosamprenavir  ginkgo  
posaconazole  imatinib  goldenseal  
ritonavir  verapamil  isoniazid  
saquinavir   nilotinib  
telaprevir   oral contraceptives  
telithromycin   pazopanib  
troleandomycin   ranitidine  
voriconazole*   ranolazine  
  suboxone  
  tipranavir/rito navir  
  ticagrelor  
  zileuton  
 
CYP3A inducers:  
Strong  Moderate  Weak  
avasimibe  bosentan  amprenavir  
carbamazepi[INVESTIGATOR_197748],  
phenobarbital  etravirine  armodafinil  
phenytoin  modafinil  clobazamechinacea  
rifabutin  nafcillin  glucocorticoids ( eg, prednisone)  
rifampin  oxcarbazepi[INVESTIGATOR_197749]’s  Wort  troglitazone  pi[INVESTIGATOR_197750] P -gp 
aliskiren  fexofenadine  saxagliptin  
ambrisentan  lapatinib  sirolimus  
colchicines  loperamide  sitagliptin  
dabigat ran etexilate  maraviroc  talinolol  
digoxin  nilotinib  tolvaptan  
everolimus  ranolazine  topotecan  
 
Inhibitors of P-gp (Venetoclax)  
amiodarone  cyclosporine  quinidine  
azithromycin  dronedarone  ranolazine  
captopril  felodipi[INVESTIGATOR_197751]-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 93 of 111  
 BCRP  (Venetoclax  only)  
Substrates  Inhibitors  
methotrexate  cyclosporine  
mitoxantrone geftinib  
irrinotecan   
lapatinib   
rosuvastatin   
sulfasalazine   
topotecan   
 
OATP1B1/B3 (Venetoclax  only)  
Substrates  Inhibitors  
atrasentan  gemfibrozil  
atorvastatin  eltrombopag  
ezetimibe  cyclosporine  
fluvastatin  tipranavir  
glyburide   
olmesartan   
rosuvastatin   
simvastatin acid   
pi[INVESTIGATOR_197752]   
* Allowed to dose with [ADDRESS_235056].  Further information can be found at the following websites:  
• http://medicine.iupui.edu/clinpharm/ddis/main -table/  and  
• http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentR esources/DrugInteractionsLabeling/ucm08 0499.htm.  
In addition to the medications listed in this table, subjects receiving venetoclax should not consume grapefruit, 
grapefruit products, Sevill e oranges (including marmalade containing Seville oranges) or starfruits.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 94 of 111  
 13.4 Appendix D.  Modified 2008 IWCLL Criteria for Tumor Response  
 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 95 of 111  
 
 
13.5 Appendi x E.  Recommendations for Initial Management of Electrolyte 
Abnormalities and Prevention of Tumor Lysis Syndrome  (TLS)  
Section  1:  First Dose of Venetoclax or Dose Escalation  
• Within the first [ADDRESS_235057] dose or dose escalation, if any laboratory criteria below 
are met, the patient should be hospi[INVESTIGATOR_197753].  No 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 96 of 111  
 additional venetoclax doses should be administered until resolution.  A rapi[INVESTIGATOR_197754] a medical emergency.  
• Nephrolog y (or other acute dialysis service) must be consulted/contact[INVESTIGATOR_530] (per institutional 
standards to ensure emergency dialysis is available) upon admission for any subject hospi[INVESTIGATOR_197755].  
• IV fluids (eg,  D5 1/2  normal saline) should be initiated at a rate of at least 1  mL/kg/hr rounded to the 
nearest 10  mL (target 150  to 200 mL/hr;   not <  50 mL/hr).  Modification of fluid rate should also be 
considered for individuals with specific medical needs.  
• Monitor for sym ptoms or signs of TLS (eg,  fever, chills, tachycardia, nausea, vomiting, diarrhea, 
diaphoresis, hypotension, muscle aches, weakness, paresthesias, mental status changes, 
confusion and seizures).  If any clinical features are observed, rech eck potassium, ph osphorus, 
uric acid, calcium and creatinine within 1  hour STAT.  
• Vital signs should be taken at time of all blood draws or any intervention.  
• The management recommendations below focus on the minimum initial responses required.  If a 
diagnosis of TLS is esta blished, ongoing intensive monitoring and multi -disciplinary management 
will be per institutional protocols.  
In addition to the recommendations below, for patients receiving the first dose of venetoclax:  
• For potassium increase ≥  0.5 mmol/L from baseline, or any value >  5.0 mmol/L, recheck potassium, 
phosphorus, uric acid, calcium and creatinine within [ADDRESS_235058] guideline.  
• For phosphorus increase of >  0.5 mg/dL AND >  4.5 mg/dL, administer  phosphate binder and 
recheck potassium, phosphorus, uric acid, calcium and creatinine within 1 hour STAT.  
If Potassium ≥  0.5 mmol/L increase from prior value (even if potassium within normal limits [WNL])  
Recheck potassium, phosphorus, uric acid, calcium and creatinine in 1 hour STAT.   
If further ≥  0.2 mmol/L increase in potassium, but still <  upper limit of normal (ULN), manage as per 
potassium ≥  ULN.   
Otherwise recheck in 1  hour.  Resume per protocol testing if change in potassium is <  0.2 mmol/L, 
and potassium <  ULN, and no other evidence of tumor lysis.   
At the discretion of the investigator, may recheck prior to hospi[INVESTIGATOR_059].  If stable or decreased, 
and still WNL, hospi[INVESTIGATOR_197756].  Potassium, phosphorus, 
uric acid, calcium and creatinine must be rechecked within 24 hours.  
If Potassium >  upper limit of normal  
Perform STAT ECG and commence telemetry.  
Nephrology (or other acute dialysis service) notification with consideration of initiating dialysis.  
Adminis ter Kayexalate 60 g (or Resonium A 60 g).  
Administer furosemide 20  mg IV  × 1. 
Administer calcium gluconate 100  to 200 mg/kg IV slowly if there is ECG/telemetry evidence of life 
threatening arrhythmias.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 97 of 111  
 Recheck potassium, phosphorus, uric acid, calcium and creatinine in 1 hour STAT.  
If potassium <  ULN 1 hour later, repeat potassium, phosphorus, uric acid, calcium and creati nine 
1, 2 and 4 hours, if no other evidence of tumor lysis.  
If Potassium ≥  6.0 mmol/L(6.0 mEq/L) and/or symptomatic (eg,  muscle cramps, weakness, 
paresthesias, nausea, vomiting, diarrhea)  
Perform STAT ECG and commence telemetry.  
Nephrology (or other acute dialysis service) assessment with consideration of initiatin g dialysis.  
Administer Kayexalate 60 g (or Resonium A 60 g).  
Administer furosemide 20  mg IV  × 1. 
Administer insulin 0.1 U/kg IV + D25 2  mL/kg IV.  
Administer sodium bicarbonate 1  to 2 mEq/kg IV push.  
If sodium bicarbonate is used, rasburicase should not be used as this may exacerbate calcium 
phosphate precipi[INVESTIGATOR_332].  
Administer calcium gluconate 100  to 200 mg/kg IV slowly if there is  
ECG/telemetry evidence of life threatening arrhythmias.  Do not administer in same IV line as 
sodium bicarbonate.  
Recheck potas sium, phosphorus, uric acid, calcium and creatinine every hour STAT.  
If Uric acid ≥  8.0 mg/dL (476 μmol/L)  
Consider rasburicase (dose based on local guidelines and/or institutional standards).  
If rasburicase is used, sodium bicarbonate should not be used a s this may exacerbate calcium 
phosphate precipi[INVESTIGATOR_332].  
Recheck potassium, phosphorus, uric acid, calcium and creatinine in 1 hour STAT.  
If Uric acid ≥  10 mg/dL (595 μmol/L) OR Uric acid ≥  8.0 mg/dL(476 μmol/L) with 25% increase and 
creatinine increase ≥  0.3 mg/dL (≥  0.027 mmol/L) from pre -dose level  
Administer rasburicase (dose based on local guidelines and/or institutional standards).  
When rasburicase is used, sodium bicarbonate should not be used as this may exacerbate calcium 
phosphate precipi[INVESTIGATOR_332].  
Notify nephrology (or other acute dialysis service).  
Recheck potassium, phosphorus, uric acid, calcium and creatinine in 1 hour STAT.  
If uric acid <  8.0 mg/dL 1 hour later, repeat potassium, phosphorus, uric acid, calcium and 
creatinine 2 and 4 hours, later, if no other evidence of tumor lysis.  
If Calcium ≤  7.0 mg/dL (1.75 mmol/L) AND Patient symptomatic  
(eg, muscle cramps, hypotension, tetany, cardiac arrhythmias)  
Administer calcium gluconate 50  to 100 mg/kg IV slowly with ECG monitoring.  
Telemetry.  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 98 of 111  
 Recheck potassium, phosphorus, uric acid, cal cium and creatinine in 1 hour STAT.  
If calcium normalized 1 hour later, repeat potassium, phosphorus, uric acid, calcium and creatinine 
2 and 4 hours, later, if no other evidence of tumor lysis.  
Calculate corrected calcium and check ionized calcium if albu min low.  
If Phosphorus ≥  5.0 mg/dL (1.615 mmol/L) with≥  0.5 mg/dL (0.16 mmol/L) increase  
Administer a phosphate binder (eg,  aluminum hydroxide, calcium carbonate, sevelamer hydroxide, 
or lanthanum carbonate).  
Nephrology (or other acute dialysis service) notificatio n (dialysis required for phosphorus 
≥ 10 mg/dL).  
Recheck potassium, phosphorus, uric acid, calcium and creatinine in 1 hour STAT.  
If phosphorus <  5.0 mg/dL 1 hour later, repeat potassium, phosphorus, uric acid, calcium and 
creatinine 2 and 4 hours, later, if no other evidence of tumor lysis.  
If Creatinine Increase ≥  25% from baseline  
Start or increase rate of IV fluids.  
Recheck potassium, phosphorus, uric acid, calcium and creatinine in 1  to 2 hours STAT.  
Section  2:  Ongoing Dosing of Venetoclax  
Management of electrolyte changes from last value at intervals >  [ADDRESS_235059] dose or 
dose escalation (eg,  48 or 72  hours) are as below.  
Note:  If the patient is hospi[INVESTIGATOR_057], no additional venetoclax doses should be administered until 
resolution.  
• For potassium, admit patient for any increase ≥  1.0 mmol/L (1.0  mEq/L), or any level >  upper limit of 
normal.  
o Refer to the management guidelines for electrolyte changes observed within the first [ADDRESS_235060] dose or dose escalation (see prior section).  
• If a smaller potassium increase is observed that does not meet the criteria for admission above, 
recheck potassium, phosphorus, uric acid, calcium and creatinine in 24 hours and confirm no 
evidence of tumor lysis prior to further venetoclax  dosing.  
• For uric acid, calcium, phosphorus and creatinine, refer to the management guidelines for 
electrolyte changes observed within the first [ADDRESS_235061] dose or dose escalation 
(see prior table).  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 99 of 111  
 13.6 Appendix F.  Clinical and Laboratory  Definition of Tumor Lysis 
Syndrome  
 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 100 of 111  
 13.7 Appendix G.  Template for Protocol Amendments  
Protocol Amendment < Arabic number>  to Stanford IRB -< number>   
< Date>   
Retain this template for your files .   
Please provide a list of changes from the previous IRB -approv ed version of the protocol.  The list shall 
identify by [CONTACT_197785] a protocol document with hyperlinks to the section in 
the protocol document.  All changes shall be described in a point -by-point format (ie, Page 3, section 
1.2, r eplace ‘xyz’ and insert ‘abc’).  When appropriate, a brief justification for the change should be 
included.  
 
Item Section  Page(s)  Change  
1.    
2.    
3.    
4.    
5.    
 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 101 of 111  
 13.8 Appendix H.  Drug Order Form for Venetoclax  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 102 of 111  
 
 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 103 of 111  
 13.9 Appendix I.  Drug Order Form for Ibr utinib  
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 104 of 111  
 
 
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 105 of 111  
 13.10  Appendix J.  Drug Diary for Ibrutinib  
PATIENT DRUG DIARY INSTRUCTIONS  
Instructions:    The bottles with the study drug, ibrutinib, should be stored at room temperature 
and should not be stored in the bathroom.  Please do not freeze or refrigerate t he study drug.  
You will take 420 mg of study drug (3 x 140 -mg capsules) by [CONTACT_31943] a day with 8 ounces 
(240 mL) of water ( do not take with grapefruit juice or Seville orange juice ).  The capsules 
should be swallowed intact.  Do not open capsules or dis solve them in water.   
Each dose ( all 3 capsules ) should be taken at least [ADDRESS_235062] be returned to the clinic or hospi[INVESTIGATOR_197757].   
Please complete the form attached when a dose is missed or reduced . The purpose of this 
form is to help you keep track and remember when/why a dose was missed or reduced.  For 
each day a dose i s missed or reduced, complete the date it was missed or reduced and 
specify the reason  for the missed or reduced  dose.  If you experience any abnormal 
symptoms while taking the study drug, you can also record them on the attached form.  It is 
mandatory tha t you return this form and your bottles of the study drug to the study staff at each 
visit to the clinic or hospi[INVESTIGATOR_307].   
IRB-[ZIP_CODE]    
Steven  E Coutre,  MD   Protocol [ZIP_CODE] dated 27 AUG   2020  
Page 106 of 111  
 PATIENT DRUG DIARY - IBRUTINIB  
Site #   Patient #:   
Date Dispensed   Date 
Returned   
PI [INVESTIGATOR_197758].                      
Initial here to confirm that no doses of the study drug were missed or reduced .  
Initial here to confirm that no extra doses of the study drug were taken by [CONTACT_86966].      
   
DIARY FOR MISSED OR REDUCED DOSES OF IBRUT INIB 
Date Dose is 
Missed or 
Reduced  Number of 
capsules taken if 
Missed or 
Reduced  Reason for Missed or 
Reduced Dose  Abnormal  Symptoms  
 (if applicable)  
Example: 10/1/2016  0 Not feeling well  Nauseous  
Example: 10/1/2016  2 Forgot to tak e all 3 capsules   
    
    
    
    
    
 
Patient’s Signature    [CONTACT_197787]-[ADDRESS_235063] Calendar/Diary Venetoclax  
Subject Number:  
Date Calendar dispensed:  
Week    Day [ADDRESS_235064] meal of the day.  
a. Drink 1 glass of water (approximately 8  oz or 240  mL) when you take your 
Study  Drug.  
b. Do NOT chew or crush the Study Drug tablets;  tablets must  be swallowed whole.  
c. Use all medication within a bottle before opening another bottle of the same dose 
strength.  Bottle may contain more tablets than are needed.  Return all bottles (including 
empty and partially full) to the clinic.  
2. Record the doses you  take in the Daily Calendar:  
a. Record dose information daily:  
1) Record Week of treatment.  
2) Record the Date (Month/Day/Year).  
3) Record your current dose.  
4) Record the time that you took your dose.  
5) Record whether your dose was taken within [ADDRESS_235065] meal of the day.  
Note :  Store study drug supplies as listed on the label.  Keep out of the reach of  children.  
IRB-[ADDRESS_235066] Number:  
 WEEK_____DOSING DETAILS  WEEK_____DOSING DETAILS  WEEK_____DOSING DETAILS   
 Date:___/___/_____  Dose:__ ____mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_ _____:_____   am   pm   
 Dose within [ADDRESS_235067] meal?   Yes   No  Dose within [ADDRESS_235068] m eal?   Yes   No  Dose within [ADDRESS_235069] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:___ __  am   pm   
 Dose within [ADDRESS_235070] meal?   Yes   No  Dose within [ADDRESS_235071] meal?   Yes   No  Dose within [ADDRESS_235072] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235073] meal?   Yes   No  Dose within [ADDRESS_235074] meal?   Yes   No  Dose within [ADDRESS_235075] meal?   Yes   No   
 Date:___/___/_ ____ Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235076] meal?   Yes   No  Dose within [ADDRESS_235077] meal?   Yes   No  Dose within [ADDRESS_235078] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dos e:_____:_____  am   pm   
 Dose within [ADDRESS_235079] meal?   Yes   No  Dose within [ADDRESS_235080] meal?   Yes   No  Dose within [ADDRESS_235081] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:__ ____mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235082] meal?   Yes   No  Dose within [ADDRESS_235083] meal?   Yes   No  Dose within [ADDRESS_235084] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235085] meal?   Yes   No  Dose wi thin [ADDRESS_235086] meal?   Yes   No  Dose within [ADDRESS_235087] meal?   Yes   No   
IRB-[ADDRESS_235088] Number:  
 WEEK_____DOSING DETAILS  WEEK_____DOSING DETAILS  WEEK_____DOSING DETAILS   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/ _____ Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_ _____:_____   am   pm   
 Dose within [ADDRESS_235089] meal?   Yes   No  Dose within [ADDRESS_235090] meal?   Yes   No  Dose within [ADDRESS_235091] meal?   Y es   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235092] meal?   Ye s   No Dose within [ADDRESS_235093] meal?   Yes   No  Dose within [ADDRESS_235094] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_ ____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235095] meal?   Yes   No  Dose within [ADDRESS_235096] meal?   Yes   No  Dose within [ADDRESS_235097] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235098] meal?   Yes   No  Dose within [ADDRESS_235099] meal?   Yes   No  Dose within 30 min of firs t meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235100]  meal?   Yes   No  Dose within [ADDRESS_235101] meal?   Yes   No  Dose within [ADDRESS_235102] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of d ose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235103] meal?   Yes   No  Dose within [ADDRESS_235104] meal?   Yes   No  Dose within [ADDRESS_235105] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose :______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235106] meal?   Yes   No  Dose within [ADDRESS_235107] meal?   Yes   No  Dose within [ADDRESS_235108] meal?   Yes   No   
IRB-[ADDRESS_235109] Number:  
 WEEK_____DOSING DETAILS  WEEK_____DOSING DETAILS  WEEK_____DOSING DETAILS   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm Time of dose:_____:_____  am   pm  Time of dose:_ _____:_____   am   pm   
 Dose within [ADDRESS_235110] meal?   Yes   No  Dose within [ADDRESS_235111] meal?   Yes   No  Dose within [ADDRESS_235112] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/ ___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235113] meal?   Yes   No  Dose within [ADDRESS_235114] meal?   Yes   No  Dose within [ADDRESS_235115] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235116] meal?   Yes   No  Dose within [ADDRESS_235117] meal?   Yes   No  Dose within [ADDRESS_235118] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____ :_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235119] meal?   Yes   No  Dose within [ADDRESS_235120] meal?   Yes   No  Dose within [ADDRESS_235121] meal?   Yes   No   
 Date:___/___/_____  Dose:______m g Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235122] meal?   Yes   No  Dose within [ADDRESS_235123] meal?   Yes   No  Dose within [ADDRESS_235124] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am    pm  
 Dose within [ADDRESS_235125] meal?   Yes   No  Dose within [ADDRESS_235126] meal?   Yes   No  Dose within [ADDRESS_235127] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of  dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235128] meal?   Yes   No  Dose within [ADDRESS_235129] meal?   Yes   No  Dose within [ADDRESS_235130] meal?   Yes   No   
IRB-[ADDRESS_235131] Number:  
 WEEK _____DOSING DETAILS  WEEK_____DOSING DETAILS  WEEK_____DOSING DETAILS   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_ _____:_____   am   pm   
 Dose within [ADDRESS_235132] meal?   Yes   No  Dose within [ADDRESS_235133] meal?   Yes   No  Dose within [ADDRESS_235134] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:_____ _mg  
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235135] meal?   Yes   No  Dose within [ADDRESS_235136] meal?   Yes   No  Dose within [ADDRESS_235137] meal?   Yes   No   
 Date:_ __/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235138] meal?   Yes   No  Dose withi n [ADDRESS_235139] meal?   Yes   No  Dose within [ADDRESS_235140] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235141] meal?   Yes   No  Dose within [ADDRESS_235142] meal?   Yes   No  Dose within [ADDRESS_235143] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235144] meal?   Yes   No  Dose within [ADDRESS_235145] meal?   Yes   No  Dose within [ADDRESS_235146] meal?   Yes   N o  
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235147] meal?   Yes   No  Dose within [ADDRESS_235148] meal?   Yes   No  Dose within [ADDRESS_235149] meal?   Yes   No   
 Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg  Date:___/___/_____  Dose:______mg   
 Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm  Time of dose:_____:_____  am   pm   
 Dose within [ADDRESS_235150] meal?   Yes   No  Dose within [ADDRESS_235151] meal?   Yes   No  Dose within [ADDRESS_235152] meal?   Yes   No   
 